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Abstract 
Investigating antibiotic resistance mechanisms in Neisseria 
gonorrhoeae using peptide probes 
 
The continuing evolution of antibiotic resistance strains of Neisseria gonorrhoeae coupled 
with the paucity of new antimicrobial agents makes the treatment of gonococcal 
infections challenging. A major cause of resistance is the expression of a multidrug efflux 
pump termed MtrCDE, which exports a wide range of antimicrobial agents. Efflux 
pumps are membrane-bound systems and consequently challenging to study and target 
with drugs. The transcriptional regulator (MtrR) of the efflux pump, however, is a 
soluble protein and therefore more amenable to study and drug target validation 
investigations. This thesis serves to investigate the hypothesis that substrates for the 
MtrCDE efflux pump are also ligands for the regulator MtrR.  
 
Isothermal titration calorimetry (ITC) was used to show that MtrR binds commercial 
antibiotics and antimicrobial peptides. -lactam antibiotics not only bind MtrR but are 
hydrolysed by the multidrug protein. Evidence for this novel enzymatic activity is 
provided by ITC, mass spectrometric and microbiological techniques. 
 
A series of peptides derived from LL-37 were synthesised and screened for binding to 
MtrR. A key region of LL-37 with a higher affinity to MtrR than the natural product was 
then identified. The peptide binding site in MtrR was elucidated via a photoactivated 
peptide binding study. Electrophoresis mobility shift assays indicated that the peptides 
do not induce derepression of the genes controlled by MtrR, although the peptide 
derivatives of LL-37 were shown to be substrates for the MtrCDE efflux pump.  
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[a] Specific rotation 
ABC ATP binding cassette 
ABPP Activity based protein profiling 
ACT Activotec 
ACVS Alanine cysteinyl valine synthetase 
AMP Antimicrobial peptide 
ATP Adenosine triphosphate 
bla -Lactamase (gene) 
BOP Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium  
hexafluorophosphate) 
t-Bu tert-butyl 
°C Degrees Celsius 
CAS Clavulanic acid synthase 
CCl4 Carbon tetrachloride 
CDCl3 Deuterated chloroform 
CID Collision induced dissociation 
Chemical shift in parts per million 
DBD DNA binding domain 
DCB Dichlorobenzoylchloride 
DCM Dichloromethane 
DIC Diisopropylcarbodiimide 
DIPEA Diisopropylethylamine 
DMAP 4-(N,N-dimethylamino)pyridine 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOACS Deacetylcephalosporin synthase 
DOPC Dioleoylphosphatidylcholine 
DPPC Dipalmitoylphosphatidylcholine 
DPPG Dipalmitoylphosphatidylglycerol 
DTT Dithiothreitol 
EB Ethidium bromide 
ECD Electron capture dissociation 
EDTA Ethylenediametetraceteic acid 
EGFR Epidermal growth factor receptor 
EMSA Electrophoresis mobility shift assay 
ESI Electrospray ionisation  
FDA Fluorescein diacetate 
Fmoc 9-fluorenylmethoxycarbonyl 
FT-ICR Fourier transform ion cyclotron resonance 
HATU 2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyluronium  
hexafluorophosphate 
HBTU O-Benzotriazole-N,N,N‟,N‟-tetramethyl-uronium- 
hexafluoro-phosphate 
hCAP18 Human cathelicidin antimicrobial protein-18 
HGT Horizontal gene transfer 
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HIV  Human immune deficiency virus 
HPLC High-performance liquid chromatorgraphy 
HRMS High-resolution mass spectrometry 
HTH Helix-turn-helix 
IM Inner membrane  
IPNS Isopenicillin synthase 
IPTG Isopropyl -D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
J Coupling constant (in NMR spectrometry) 
LB Luria broth 
LCA Lithocholic acid 
LPS Lipopolysaccharide 
LTA Lipoteichoic acid 
MALDI Matrix-assisted laser desorption ionisation 
MATE Multidrug and toxic compound extrusion 
MeOH Methanol 
MFS Major facilitator superfamily 
MHB Műller hinton broth 
MIC Minimum inhibitory concentration 
MSNT 1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole 
mtr Multiple transferable resistance 
NMR Nuclear magnetic resonance  
OD Optical density 
OM Outer membrane 
PBP Penicillin binding protein 
PC Phosphotidylcholine 
PI Propidium iodide 
PICC Proximity induced covalent capture 
PS Phosphotidylserine 
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
QRDR Quinolone resistance determinant region 
RND Resistance nodulation and division 
rRNA Ribosomal ribonucleic acid 
SDS-PAGE Sodium dodecylsulphate polyacrylamide gel electrophoresis 
SM Sphinogmyelin phopholipid 
SMR Small multidrug resistance 
SOC Super optimal broth with catabolite repression 
SPPS Solid phase peptide synthesis 
TEMED N,N,N‟,N‟-tetramethyl-1,2-ethylenediamine 
TFA Trifluoroacetic acid 
TFE Trifluoroethanol 
TLR Toll-like receptor 
TO Thiazole orange 
TOF / TOF Time of flight / time of flight 
tRNA Transfer Ribonucleic Acid 
WT Wild type 
v / v Volume per unit volume 
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 1 Introduction 
 
This thesis describes research carried out using a combination of peptide chemistry, 
biophysical and microbiological techniques, to investigate antimicrobial resistance 
mechanisms in Neisseria gonorrhoeae. More specifically, this research focuses on the 
transcription regulator protein MtrR, its ability to bind a range of synthetic peptides and 
commercial antibiotics and ultimately how these binding events regulate the expression 
of a multidrug efflux pump. 
The following chapter provides an overview of antibiotic resistance mechanisms in 
bacteria, highlights the importance of multidrug, membrane bound transport systems 
(efflux pumps), and discusses the role of the transcriptional regulator in the expression 
of efflux pumps. Chapter 2 describes the characterisation of a previously unknown 
secondary function of MtrR, namely a -lactamase function. Chapter 3 details the design, 
synthesis and evaluation of natural product-derived peptides to probe how MtrR 
responds to binding ligands. The use of a photoactivated peptide as a ligand for MtrR 
enables the first characterisation of the ligand binding domain of MtrR to be reported. 
Chapter 4 concludes the thesis and consider future work arising from this thesis. 
Chapter 5 provides experimental procedures. 
1.1 Antimicrobial resistance 
1.1.1 Overview of antibiotics and bacterial resistance 
The introduction of antimicrobial agents such as sulphanilamide (1) and benzyl 
penicillin (2) in the early 20th Century greatly improved patient survival rates (Figure 1).  
 
Figure 1 Structures of the first synthetic, commercial antibiotics sulphanilamide (1) and benzyl 
penicllin (2) 
The success of these antibiotics was curtailed by the rapid evolution of resistant bacteria, 
which is exemplified by the development of penicillin resistance in 
Staphylococcus aureus.1 In 1940 more than 85 % of S. aureus strains were susceptible to less 
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than 0.1 g / mL benzyl penicillin, whilst by 1947 susceptibility had decreased to 30 %. 
This considerable increase in resistant strains is a powerful example of how quickly 
antibiotic resistance can (and does) develop.  
The concept of „resistance‟ is a subjective notion with several definitions listed in the 
literature. The World Health Organisation defines resistance as when 5% of infections 
are not cured by treatment with the recommended antibiotic.2 Clinicians and infection 
control specialists define resistance on the basis of „breakpoint‟ concentrations, whereby 
a breakpoint is defined as “a discriminating concentration used in the interpretation of results 
of susceptibility testing to define isolates as susceptible, intermediate or resistant.”3 
Concentrations are determined by monitoring bacteria growth at different concentration, 
with a resistant organism showing no reduction in population size, even at high 
antibiotic concentrations. The concentration of an antibiotic required to prevent bacterial 
growth is termed the „minimum inhibitory concentration‟ (MIC) and levels of resistance 
in pathogenic bacteria are frequently quoted as n-fold increases compared to the 
susceptible strain. For example the MIC for ciprofloxacin against N. gonorrhoeae is 0.03 
mg / mL in susceptible strains and 0.06 mg / mL in resistant strains.3 This thesis adopts 
the conventional biochemical definition of resistance, namely as the observation of 
decreased susceptibility towards an antimicrobial agent due to the presence of a 
selective advantage.4 
In order to combat bacterial resistance, intensive research during the mid-twentieth 
century led to the development of several classes of antibiotic (Table 1). Despite the 
structural diversity of antimicrobial compounds bacteria have continued to respond 
through the evolution of resistant strains. For example the relatively new antibiotic 
linzolid (3) is no longer effective at inhibiting protein synthesis in all strains of S. aureus 
due to the emergence of strains with mutations in the antibiotic target site, the 23S 
subunit in RNA.5 
 
Figure 2 Linzolid (3) 
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Antibiotic Cellular target Bacterial resistance mechanism Representative organisms with 
resistance phenotype 
Ref 
Class Examples 
-lactam Benzylpenicillin 
Cephalosporin 
Cell wall biosynthesis 
(transpeptidase) 
-lactamase 
Mutations in PBP‟s 
Active efflux 
Staphylococcus aureus 
Neisseria gonorrhoeae 
 
6 
Cyclic peptide Vancomycin Cell wall biosynthesis 
(transglycosylation) 
Alterations in LPS / LTA 
Target site mutation 
Clostridium difficile. 
Staphylococcus aureus 
7 
Polymixin Outer membrane integrity Modification of LPS Pseudomonas aeruginosa 
Daptomycin Unknown MRSA 
Macrolide Erythromycin Protein synthesis (50S RNA subunit) Methylation of taget RNA 
Esterase  
Active efflux 
Staphylococcus aureus  
Esherischia coli 
41 
Tetracycline Tetracycline 
Tigecyline 
tRNA 30S subunit  
 
Oxidation of tectracyline 
Efflux 
Enterobacteriacea 8 
Aminogylcoside Gentamycin 
Kanamycin 
 
Protein synthesis (50S and 30S 
subunits) 
N-acetylation,  
O-phosphorylation  
N-nucleotidylation of drug 
Staphylococcus aureus  
Staphylococci, 
Staphylococcus aureus  
33 
Quinolones Nalidixic 
Ciprofloxacin 
DNA gyrase  
topoisomerase IV 
Mutations in target proteins 
Efflux 
Staphylococci, streptococci 
and enterococci 
9 
Oxazolidinone Linezolid Protein synthesis (23S subunit of 50S Mutation in 23S subunit of RNA Staphylococcus aureus  5 
Table 1 Summary of common clinically used antibiotics, bacterial targets, resistance mechanisms and species. 
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The predominance of resistant bacterial strains coupled to the paucity of new 
antimicrobial agents now severely compromises the treatment options for a wide range 
of infections including meningitis (Neisseria meningitidis)10, hospital-acquired infections 
(Clostridium dificle, Methilicilin resistant Staphylococcus areus),11 and sexually transmitted 
infections (STI). Recent figures for STI‟s highlight these problems, with resistance in 
N. gonorrhoeae to fluroquinolones currently between 10 and 27 % of isolates across 
Europe but more than 50 % in Australia and up to 98 % in China.12 The World Health 
Organisation (WHO) recommends that antimicrobial agents are no longer used to treat 
infections where resistance is seen in 5% of the community; consequently since 2009 
fluroquinolones are no longer recommended for the treatment of N. gonorrhoeae. Third 
generation cephalosporins are now recommended but, worryingly, resistant isolates 
have already been reported in Japan.13 This rapid increase in antibiotic resistance, 
coupled with the increasing number of cases and its frequent co-infection with HIV has 
driven research to understand antimicrobial resistance mechanisms in N. gonorrhoeae in 
the hope of developing new antimicrobial agents. 
 
1.1.2 Antimicrobial resistance mechanisms 
1.1.2.1 Genetic features of bacteria that contribute to resistance 
Important influences on the continued evolution of bacterial resistance are increased 
usage of antibiotics (in both a clinical setting and in the food chain) and greater mobility 
of people across the world.14 The presence of antibiotics in the environment increases the 
selective pressure on bacteria and the increased movement of people across the globe 
enhances the rate of transmission of resistance genes. Bacteria can accept resistance 
genes from other bacteria of the same strain, or a different strain via fundamental 
processes referred to as horizontal gene transfer (HGT, also known as horizontal 
evolution,  Figure 3).15,16  
Bacteria lacking a particular resistance feature (e.g. a -lactamase) can accept a plasmid 
from a species of bacteria that contains the desired resistance element (e.g. bla gene) in a 
process referred to as conjugation (A, Figure 2).11 The acquired plasmid is integrated into 
the bacterial genome causing the recipient bacteria to display the resistance phenotype 
(e.g. -lactamase). Furthermore, gene sharing by conjugation in bacteria  
17 
 
 
 Figure 3 Genetic mechanisms used by bacteria to enhance antibiotic resistance 
enables genes encoding a beneficial mutation to be transferred to other bacteria, 
accelerating bacterial evolution and species survival.17 In transduction, genes are 
transferred between bacteria through the use of bacteriophages (B, figure 3). The final 
method of transformation describes the ability of bacteria to incorporate DNA segments 
that have been released by other bacteria after cell lysis (C, figure 3). These genetic 
bacterial features underpin the mechanisms used by bacteria to decrease susceptibility to 
antimicrobial agents. 
In addition to horizontal evolution, there is a process called vertical evolution.18 This 
genetic feature refers to spontaneous mutations that occur in and confer increased 
resistance to antibiotics. Mutations are generally uncommon events, occurring at a 
frequency of 1 event per 107–1010 bacteria, but may result in the development of 
resistance during antimicrobial therapy in organisms that are initially susceptible, for 
example a mutation in the coding region of a protein. An example of this would be 
mutation in RNA at the binding site of fluoroquinolone antibiotics that abrogates drug 
binding, which will be discussed in more detail later.19 
As a result of these genetic features, five principle resistant phenotypes exist, viz. 
decreased cell permeability, inactivation of the drug compound, modification of the 
target site, up-regulation of resistance gene transcription and decreased cellular 
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concentration. Each mechanism will be discussed using examples from the literature, 
with specific reference to N. gonorrhoeae, the pathogen of interest in this thesis. 
1.1.2.2 Decreased cell permeability 
An innate resistance feature of bacteria is the cell membrane and associated structures 
(e.g. peptidoglycan), which provides a natural barrier to antimicrobial agents. N. 
gonorrhoeae possesses a double cell membrane and is classified as a Gram negative 
bacterium as it does not retain the crystal violet dye (Figure 4). Other Gram negative 
pathogenic organisms include E. coli, P. aeruginosa and V. Cholera. Between the inner 
membrane (IM) and the outer lipid bilayer (OM) is the periplasmic space and 
peptidoglycan, linked to the OM by lipoproteins. Lipopolysaccharides (LPS) are 
anchored to the surface of the outer membrane and play a key role in pathogenicity and 
resistance.20  
  
Figure 4 Structure of the Gram negative cell membrane (Image drawn in ChemDraw, adapted from 
Stryer, Biochemistry and Albert et al, The Molecular Biology of the Cell)  
Large cationic antibacterial agents such as antimicrobial peptides, aminoglycosides and 
macrolides bind to the negatively charged lipopolysaccharide on the outer surface of 
Gram negative bacteria and then enter the cell via diffusion through the lipid bilayer.21 
Decreasing the overall negative charge of the OM is a key strategy utilised by 
N. gonorrhoeae to resist cationic antimicrobial agents. The acylation (with 
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phophoethanolamine) of the phospho head group of lipid A in the gonoccocal OM 
decreases the anionic character and hydrophobicity of the membrane increasing cell 
survival in the presence of cationic host defence peptides and human serum.22,23 Further 
modification to the cell envelope in N. gonorrhoeae is achieved by O-acylation of 
peptidoglycan conferring resistance to host defence secreted lysozyme.24  
In contrast to Gram negative bacteria, Gram positive bacteria have a very thick layer of 
peptidoglycan, which does retain the crystal violet dye (Figure 5). A second major 
component of the Gram positive cell wall is lipoteichoic acids that are an important 
viruluence factor in infections.25 
 
Figure 5 Structure of the gram positive cell membrane 
The cell membrane also contains a number of protein channels called porins. Porins are 
non-selective mono or trimeric protein channels present in Gram negative and Gram 
positive bacteria, that enable nutrient molecules (often hydrophilic) to enter the cell.21 
Small antibiotics such as -lactams, tetracycline, fluroquinolines and chloramphenicol 
also enter bacteria through these protein channels. In order to lower cell permeability to 
antibiotics, bacteria can decrease production of porin proteins, but this compromises 
bacterial viability. A more selective evolutionary advantage comes from mutations in the 
primary structure of the porin, particularly in flexible loops at the entry to the protein 
channel. A typical example of this is the penB mutation of the porin IB in N. gonorrhoeae 
that encodes amino acid replacements GK alone or GD and AD in the entry loops 
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of the porin.26 The increased negative charge resulting from these point mutations 
decreases the translocation of benzyl penicillin into the cell, however, the increase in 
MIC as a result of penB are only seen in conjunction with a mutation in another 
resistance element, mtr. This will be discussed in more detail in section 1.1.4.27,28 
1.1.2.3 Inactivation of the drug compound  
If the antimicrobial agent passes through the membrane one mode of resistance used by 
bacteria is to detoxify the compound by chemical modification, in a process analogous to 
the phase I and phase II metabolisim in humans.7 -Lactam containing antibiotics are 
susceptible to enzymatic degradation (phase I process) by extended spectrum -
lactamases29, metallo- -lactamases30 and AmpC enzymes.31 A detailed review of -
lactamases can be found in Chapter 2. Other examples of phase I type metabolisim are 
hydrolases present in pathogenic organisms include erythromycin esterases in E. coli and 
S. aureus. Aminoglycosides are subject to enzymatic modification to give O-
phosphorylated, N-adenylated or N-acetylated compounds, for example N-acylated 
kanamycin (4, Figure 6). The modification of the antibiotic disrupts a crucial hydrogen 
bonding interaction necessary for the drug to locate in the binding site on the ribosome, 
thus conferring resistance to the antibiotic.32 Chloramphenicol and streptogramin are 
also prone to O- or N-acetylation.33 
The survival advantage that N-acetylation confers is exemplified by the acetylation of 
aminoglycosides in E. coli.34 N-acetyl-ciprofloxacin (5) has a four fold higher MIC than its 
unmodified parent drug.  
 
 
Figure 6 Deactivated antibiotics by bacterial enzymes: 6’N-acetyl kanamycin (4); N-acetyl ciprofloxacin (5) 
and N-nitroso norfloxacin (6). 
Furthermore fluoroquinoline detoxification enzymes have been observed in soil bacteria, 
and these are capable of N-nitrosation (6).35 Such transformations are not currently seen 
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in clinical strains but due to genetic transfer mechanisms between bacteria it is possible 
for such detoxification mechanisms to become more common. 
 
1.1.2.4 Mutation of active site residues  
A further means that bacteria have developed for preventing antibiotics binding to their 
target site, are point mutations in the amino acid sequence of the binding site, as 
highlighted earlier in Table 1. Fluroquinolones target DNA gyrase and specific 
mutations in the amino acid sequence in topoisomerase IV and in DNA gyrase (subunits 
GyrA and GyrB) decrease fluoroquinoline binding to the protein-DNA complex.36,37 The 
point mutations are species specific but are primarily localised to a region of the protein 
called the quinone resistance determinant region (QRDR) although there are more recent 
reports of mutations occurring outside this region.38 In N. gonorrhoeae, a charged amino 
acid (Asp 95) is replaced with a neutral asparagine, alanine or glycine in the QRNR, with 
the probable result being disruption of hydrogen bonding networks in the 
protein : DNA complex.39  
 
Figure 7 Cartoon representation of DNA gyrase. Fluoroquinolones bind at the interface of the A and B 
subunits inhibiting DNA repair. The amino acids highlighted in the red circle correspond to the 
quinolone resistant determinant region (QRDR) on the A subunit in N. gonorrhoeae, the region in which 
most amino acid mutations are found that abrogate drug binding.  
 
Macrolides target bacterial ribosomes and inhibit protein synthesis by blocking the 
elongation of peptide chains.40 Oral pathogenic species of N. gonorrhoae were isolated 
which contain an rRNA methylase that transfers a methyl group to adenine at position 
2142 on the 23S rRNA, consequently disrupting the binding of erythromycin (7, Figure 
8) to the ribosome subunit and thus conferring resistance to 7 and other macrolides. 41,42 
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A further RNA modification that disrupts macrolide binding is a C  T mutation at 
position 2605 in 23S rRNA.43  
 
 
Figure 8 Macrolide antibiotic erythromycin (7) and aminoglycoside antibiotic kasugamycin 
The precise structural effects of the base alteration in the gonoccocal ribosome is not 
known but based on related literature studies it can be hypothesised that the cytosine to 
thymidine substitution alters the conformation of peptidyltransferase loop 5, lowering 
the binding affinity of macrolide antibiotics to RNA.44 The 16S subunit has also been 
shown to contain nucleotide mutations that confer resistance to aminoglycoside 
kasugamycin (8, Figure 8) although the molecular basis for this decreased susceptibility 
is yet to be established.45,46 
Mutations are also seen in penicillin binding proteins (PBP), the cellular target of 
penicillin type antibiotics and by altering the amino acids at the antibiotic binding site, 
PBP‟s become resistant to penicillin. The X-ray crystal structure of PBP2 from 
N. gonorrhoeae has recently revealed that the insertion of an aspartic acid at position 345 
near the active site of the enzyme is not the sole mutation responsible for lowering the 
affinity of PBP2 for penicillin as previously thought.47 Four mutations at the C-terminal 
region of the enzyme decrease the acylation rate 4.9 fold compared to 5.2 fold for the 
345a insertion. The C-terminal mutations include P  S and P  A / G which alter the 
orientation of the helix they occupy modulating the position of amino acids in the 
hydrogen bonding network of the bound penicillin : enzyme complex. Such detailed 
analysis at the atomic level is crucial in order to understand the molecular changes that 
cause drug resistance and is a theme developed in the Result and Discussion chapters of 
this thesis. 
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1.1.2.5 Up-regulation of chromosomal resistance genes 
The mechanisms discussed so far principally involve the modification of drugs through 
enzymatic means or the mutation of resistance related proteins. In addition to these 
mechanisms, chromosomally encoded proteins may be up-regulated in order to negate 
the effects of the drug. Examples of this are the increase in penicillin binding proteins 
(PBP) and the increase in membrane bound transport proteins for the active efflux of the 
toxic agents. The multi-protein systems capable of recognising and removing diverse 
antimicrobial agents from inside the cell are termed multidrug efflux pumps and these 
are a major resistance feature in pathogenic bacteria. The structure, function and 
regulation of these efflux systems is discussed in more detail in the following section. 
1.2 Efflux pumps 
1.2.1 Introduction  
Efflux of antibiotics via a membrane bound, multi-protein transport system was first 
demonstrated for the export of tetracycline in E. coli.48 Efflux pump genes are 
predominantly found on the bacterial chromosome indicating that antibiotic efflux is an 
evolutionary capability arising from an enhanced intrinsic ability to extrude diverse 
structures, rather than an acquired function resulting from horizontal gene transfer of 
plasmid DNA encoding antibiotic specific transporters.49 A further indication of the 
origin of efflux pump genes is revealed by the high number of efflux pump genes 
present in non-pathogenic bacterial species where there is a lack of clinical antibiotics, 
and also the unusually broad specificity of multidrug transporter proteins that are 
encoded across not only bacterial species but also animals kingdoms.50, 51 
Analyses of the evolutionary origin, amino acid sequence and structure of efflux pump 
proteins has resulted in efflux pumps being grouped into one of 5 categories (Figure 9): 
ATP-binding cassette (ABC), major facilitator superfamily (MFS), resistance /nodulation 
/ cell division (RND), small multidrug resistance (SMR) or multidrug and toxic 
compound extrusion (MATE).52  
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Figure 9 Bacterial efflux pumps and energy sources 
Further classification of the multidrug transporters arises from the energy source for 
drug translocation. The RND, MFS and SMR families are proton driven pumps.53 The 
ABC system links ATP hydrolysis to drug translocation and the MATE class is a 
Na+ / H+ antiporter system.54 A detailed study of each class of efflux pump is outside the 
scope of this thesis, but will focus on the RND class to which the gonoccal system 
belongs. The RND designation applies to the transport protein of the efflux pump and 
proteins of this class have 12 transmembrane spanning (TMS) regions, with two large 
loops between TMS 1 and 2 and 7 and 8. Examples of this class include AcrB from 
E. coli,55 MexB and MexD from P. aeruginosa56 and MtrD from N. gonorrhoeae.57 To achieve 
efflux of the antibiotic across the cell envelope, the transport protein associates with an 
outer membrane protein and the complex is held together by a membrane fusion 
protein.58  
The best studied example of an RND transport system is AcrA TolC from E. coli, 
where AcrA is the membrane fusion protein, AcrB is the transporter protein and TolC is 
the outer membrane protein.55 It is proposed that AcrB is in constant contact with the 
membrane fusion protein AcrA, but the outer membrane protein TolC is only recruited 
when a ligand is bound to the inner membrane protein. The presence of „vestibule‟ areas  
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Figure 10 Schematic representation of active efflux through the AcrA TolC system  
in the periplasmic region of enable hydrophilic drugs such as carbenicillin to be collected 
in the periplasm and exported (Figure 10). The precise mechanism of translocation is still 
a matter for debate, however, Asp407, Asp408, Lys940, and Arg971 are proposed to form 
ion pairs and are deprotonated in the unliganded resting state. On binding of a ligand 
and remote proton binding, the ion pairs become charged causing a conformational 
change in the protein complex opening the pore to the outermembrane protein thus 
allowing export of the ligand. The structure and function of the AcrA TolC system 
serves as a model system for the less well studied gonoccoal efflux systems. 
1.2.2 Overview of efflux pumps in N. gonorrhoeae 
Three efflux pump systems have so far been identified in N. gonorrhoeae conferring high 
levels of antimicrobial resistance to a range of antimicrobial agents. Antibacterial fatty 
acids are exported through the FarAB efflux pump and macrolides are transported 
through the MacAB system.59,60 Both FarAB and MacAB are composed of an inner 
membrane (transport) protein (FarA and MacA respectively) and a membrane fusion 
protein (FarB and MacB respectively) and require an outer membrane protein for export 
of the drug out of the cell. The outer membrane protein used is MtrE, from the MtrCDE 
efflux pump that recognises numerous toxic compounds of different structures.61,62 The 
MtrCDE and FarAB efflux pumps are both regulated by the regulator protein MtrR. The 
products of the multiple transferable resistance (mtr) locus, in particular MtrR, are the 
main focus of this thesis and are introduced in more detail below. 
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1.2.3 The MtrCDE efflux pump from N. gonorrhoeae 
MtrCDE is a tripartite protein pump composed of the RND family protein MtrD, an 
inner membrane protein (IMP) with 43 % identity to AcrB from E. coli.57 MtrC, a 
membrane fusion protein (MFP) has 45 % identity to AcrA. The outer membrane protein 
(OMP) MtrE is 22% homologous to TolC.63,64 MtrC is located in the periplasm and acts as 
the connection between MtrD and MtrE, as in the related AcrA TolC system. A further 
IMP, MtrF, has been linked to efflux of antimicrobials in N. gonorrhoeae and may function 
in conjunction with MtrCDE in conferring high level resistance.65  
As yet, there are no crystal structures of the constituent proteins in the MtrCDE efflux 
pump. Insights into the structure of the gonococcal multidrug transporter have recently 
been revealed by solution state characterisation of the multidrug complex.66 The 44 kDa 
lipoprotein MtrC was shown by mass spectrometry to exist as a stable hexamer, where 
as the OMP MtrE formed trimers indicating that MtrC interacts with MtrE in a 6 : 3 ratio. 
This finding is supported by analysis of Isothermal Titration Calorimetry (ITC) data that 
indicates MtrC interacts with MtrE, viz. two MtrC units interact per MtrE unit. No 
interaction was seen between MtrD and MtrE, and only a weak interaction was detected 
by pull down assays between the IMP and OMP, compared to a strong interaction 
between the MFP and IMP and MFP and OMP. 
A wide range of antimicrobial agents are substrates for the gonoccocal efflux pump. 
Large cyclic compounds such as azithromycin (9) and spectinomycin (10), planar 
aromatics such as tetracycline (11) and detergents (10) are all substrates.66 The human  
 
Figure 11 MtrCDE efflux pump substrates; azythromycin (9), spectinomycin (10), Tetracycline 
(11), human cathelicidin antimicrobial peptide (12) Triton X-100 (13) 
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antimicrobial peptide LL-37 (12) is also a substrate, which makes the specificity of the 
MtrCDE pump unusually broad. The ability the MtrCDE efflux pump to recognise 
peptide substrates is discussed further in Chapter 3.67 Studying membrane proteins, and 
multi-protein membrane systems is very demanding due to protein insolubility in 
aqueous solutions (without detergents). Consequently protein efflux pumps themselves 
represent challenging drug targets and not easily amenable to (bio-) chemical 
investigation. Efflux pump genes are tightly regulated by transcriptional regulators, that 
are also proposed to be multidrug recognition proteins. Transcriptional regulators are 
soluble proteins and thus present themselves as tractable drug targets. Understanding 
the molecular basis of efflux pump regulation would enable the development of new 
classes of antimicrobial agents. To this end, the concept of transcriptional regulators is 
introduced in the next section, with particular attention devoted to the MtrR protein that 
controls the expression of the MtrCDE efflux pump. 
1.3  Transcriptional regulation of efflux pumps 
1.3.1 Introduction  
Transcriptional control of efflux pump genes can be maintained by either a two-
component or single component system. In the former system a cell-surface bound 
kinase undergoes autophosphorylation (at a specific histidine residue) in response to a 
specific stimulus.68 The phosphoryl group is then transferred to an aspartate residue of 
the cognate response regulator that will be activated, for example in E. coli the MdtABC 
RND pump is regulated by BaeSR, a two component system (Figure 12). 69 This system is 
an example of positive regulation, that is the regulator when bound to DNA recruits 
other activating proteins ultimately enabling the RN polymerase to bind. 
In a single component system, the efflux pump genes are under the control of a regulator 
that responds to stimulus by an intracellular ligand, as exemplified by the TetR system 
(Figure 13). With regard to the regulation of bacterial export systems, two protein 
families (AraC and MerR, Figure 14 A and B) function as activators of gene transcription 
and a further two classes (MarR and TetR, Figure 14 C and D) function as repressors.49 
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Figure 12 Schematic representation for the regulation of efflux pump genes by a two component system. 
The efflux pump encoded by mdtABC genes are under the control of the BaeSR regulator. The cell 
surface receptor responds to a specific stimulus and is autophosphorylated. The phosphoryl group is 
transferred to BaeSR, which is then activates the gene for transcription.  
 
Figure 13 Schematic representation of single component regulation. The TetA transporter is under 
control of the TetR transcription regulator. TetR is divegently transcribed from tetA and the regulator 
protein occupies the operator DNA of the tetA gene, blocking transcription. On binding tetracyline 
(represented as a cross), TetR dissociates from the DNA allowing RNA polymerase to bind and transcribe 
the gene 
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Figure 14 HTH containing bacterial regulator proteins 
Regulator proteins often function as part of a complex regulatory pathway that is 
interdependent on several other activator and regulator proteins.70 For example, 
regulation of the the AcrA TolC system by AcrR (a TetR family protein) is classed as a 
single component system but the expression of AcrR is governed by activator proteins 
MarA / SoxS / Rob (AraC class).71 These activators are themselves negatively repressed 
by the transcriptional regulator MarR (an example of the MarR class), generating a 
complex regulator pathway.72,73 
Each of the four classes (AraC, MerR, MarR and TetR) utilise a Helix-Turn-Helix (HTH) 
domain located at either the N- or C-terminus of the regulator protein to bind the major 
groove of DNA (Figure 14). The (HTH) motif is seen in 95% of transcriptional regulatory 
proteins in prokaryotes characterised to date.74 The four groups are named after the first 
protein characterised and subsequent proteins are placed in the relevant group by 
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homology. AraC type proteins are classed by the homology to a 99 amino acid segment 
of AraC protein.75 This is a large class of proteins with more than 100 members and two 
subgroups have been identified, namely proteins that function as dimers (regulators of 
sugar catabolism) or monomers (bacterial stress / antibiotic response regulators). 
Monomeric regulators possess two HTH domains within one protein unit to enable the 
regulator to bind DNA next to the promoter region, recruiting operator DNA and 
activator induces a 35° bend in the DNA (Figure 14A). Examples of the latter class 
include MarA from E. coli and MtrA from N. gonorrhoeae. The function of MtrA will be 
discussed further in conjunction with MrtR, a TetR type transcriptional regulator in 
N. gonorrhoae and the subject of this thesis.  
As mentioned above, the AraC activators are under the control of the negative regulator 
MarR. MarR family proteins contain one „winged‟ HTH domain and bind DNA as 
dimers (Figure 14B).76 It is postulated that binding of a ligand to the regulator causes a 
conformational change, enlarging the distance between the two HTH motifs so that the 
dimer is no longer able to bind DNA, thus freeing the DNA for transcription.77 
MerR proteins are found in Gram negative and Gram postitive bacteria and act as metal 
sensing proteins.78 Binding of this regulator to the operator DNA induces a bend in the 
DNA preventing transcription of the gene, as can be seen in (Figure 14C). When a metal 
binds the MerR : DNA complex, a change in the conformation of MerR causes a 
flattening of the DNA enabling transcription to take place.79  
The final family of proteins discussed here is TetR, which also functions as a dimer. TetR 
transcriptional regulators are found in numerous species of bacteria including E. coli, M. 
tuberculosis and P. aeruginosa. The key protein of this thesis, MtrR, is an example of a 
TetR protein and this class of protein is discussed in greater detail below.  
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1.3.2 The TetR family of transcriptional regulators 
 
1.3.2.1 Structural studies on TetR family proteins 
The TetR family derives its name from the eponymous protein that has been most fully 
characterised genetically and biochemically.49 All TetR proteins possess a high degree of 
sequence homology in the N-terminal HTH motif but a low homology, typically less 
than 20% in the ligand binding domain. The numbering of the helices starts at the N-
terminus and to differentiate between protein units in the dimer, designations are 
followed by an apostrophe for the second unit Figure 15.  
There is a high degree of similarity in the type of amino acid present. Helix 2 and 3 
contain predominantly hydrophobic residues with the latter helix exhibiting a 
preference for F, Y, L or W. The only conserved charged residues in the HTH motif of 
TetR proteins are located at position 43 (predominantly R or K). As previously 
mentioned, there is little sequence similarity in the C-terminal ligand binding domain 
but a number of crystal structures have elucidated features common to all TetR proteins. 
One such feature is a highly flexible ligand binding domain, which is important for the 
recognition of a wide range of substrates.  
  
Figure 15 Dimeric structure of TetR protein in complex with its palindromic operator sequence80 (PDB 
Code 1QPI downloaded and annotated in Powerpoint)  
 
 Ligand binding domain 
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The dimerisation domain predominantly involves helices 8, 9 and 10. It has been 
demonstrated that helicies 4, 5, 6 and 7 make key contacts with ligands, and in response 
to binding a substrate the aforementioned helices alter their conformation. This 
alteration causes a reordering of hydrogen bonding and salt bridges that is transmitted 
throughout the protein, ultimately causing the distance between helix a3 and a3‟ to 
increase above 39Å. When the distance between the two HTH motifs is greater than 
39 Å, the protein can no longer bind in the major groove of DNA and hence the DNA 
protein complex dissociates. 
Crystallographic studies revealed that TetR binds DNA as a dimer and the HTH makes 
contact with the DNA perpendicular to the longitudinal DNA axis, as summarised in 
Figure 16.80 Conserved residues in 42 aligned TetR proteins suggested key residues that 
are involved in direct contact with DNA.81 These are position 22 on helix 2, position 33-
35 and 37-39 on helix 3 and 43 on helix 4 (positions are mirrored in the second subunit). 
Despite the similarities in the contact points between TetR type proteins and DNA, there 
are large differences in the exact mode of DN recognition. For example, QacR from S. 
aureus, introduces a 3° bend in DNA, whereas TetR induces a 17° bend. Also, 2 dimers of 
QacR binds one promoter DNA sequence, a ratio observed for SmeT from 
Stenotraphomonas maltophilia, AcrR from E. coli and TtgR from Pseudomonas putida.  
 
Figure 16 Schematic representation of the TetR dimer bound to the operator DNA. Monomer A binds the 
-4 to -7 region on the main strand of DNA, and makes contact with the +4 to +2 positions on the 
complimentary strand. The symmetric dimer binds the main strand from +2 to +7 and the complimentary 
from -4 to –7. 88 
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1.3.2.2. Functional studies of TetR proteins: Electrophoretic mobility shift assays 
Crystallographic studies only give a snap shot of the molecular mechanism involved in 
gene regulation and so other techniques have been employed to show that ligand 
binding induces protein dissociation from promoter DNA. For TtgR,82 ActR,83 TetR and 
SmeT,84 polyacrylamide gel electrophoteric mobility shift assays (EMSA) have been 
undertaken. The principle of the experiment is that oligonucleotides complexed to 
protein migrate slower than uncomplexed oligonucleotide in a non-denaturing 
polyacylamide gel. In the experiment, the oligonucleotides are labelled with either 32P (to 
enable detection by scintillation) or biotin (colourmetric detection via a streptavidin-
horse radish peroxidase conjugate) and the DNA protein complex is run in the presence 
and absence of ligand.  
EMSA has been used by several groups to determine the length of operator DNA 
recognised by TetR proteins.85 The effect of ligands on the protein : DNA complex for 
TetR type proteins has also been studied using this method and interesting results were 
obtained in a ligand screen for the biofilm repressor IacR, from Staphylococcus 
epidermidis. Previous reports in the literature had indicated that aminoglycosides are able 
to induce biofilm formation, implying they release IacR from its operator DNA. EMSA 
studies with aminogylcosides showed that only gentamycin was able to completely 
release the regulator from its DNA, whereas spectomycin lead to approximately 50% of 
the DNA being released and kanamycin failed to exert any effect. This result shows that 
despite TetR type proteins possessing large drug binding 
 
 
Figure 17 Principle of EMSA; lane 1 DNA only, lane 2 protein and DNA, lane 3 ligand inducer + protein 
and DNA. Only the DNA is visualised in the experiment so if the movement of the DNA is retarded in 
the gel, it is assumed that the DNA is in complex with protein. 
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pockets, highly specific interactions are necessary to induce the conformational change 
necessary to release the protein from DNA. A similar analysis of effector molecules on 
the TtgR : DNA complex showed that a wide range of flavones effect derepression, but 
the isoquinoline alkaloid berberine did not, highlighting the structural specifity of ligand 
binding in TtgR. EMSA studies with MtrR will be discussed in section 3.5.6. 
1.3.2.3. Functional studies of TetR proteins: Isothermal Titration Calorimetry 
EMSA only provides an „on‟ or „off‟ picture for protein : DNA binding and the effects of 
ligands on protein : DNA complexes. In order to gain biophysical information such as 
binding affinities, enthalpy and entropy changes other techniques have been used. One 
such technique is ITC that has the advantage of providing full thermodynamic 
parameters (ΔH, ΔS, Kd, N) from one binding experiment in solution, without the need 
of labels. Disadvantages to using microcalorimetry to investigate protein ligand binding 
are: i) it is a labour intensive technique and ii) relatively large volumes of protein are 
required. Despite these drawbacks ITC has been used to investigate protein : DNA and 
protein : ligand interactions in TetR proteins.  A brief overview of these studies are 
provided and results using ITC to characterise MtrR : DNA and MtrR : ligand 
interactions are detailed in subsequent chapters of this thesis.  
The length of oligonucleotide recognised by TetR type proteins and the ratio of protein : 
DNA binding has been investigated by ITC. Calormetric analysis revealed TetR binds its 
operator as a dimer and interacts with a 16 bp palindrome with a short central spacer, 
whereas both QacR and IacR binds 28 bp operator regions and TtgR binds a 40 bp 
nucleotide sequence. In each case binding to DNA is endothermic and in the micro 
molar range, and TtgR, IacR and QacR bind as a pair of dimers.86  
Several research groups have applied ITC to characterise ligand binding and specificity. 
TtgR is the regulator of the TtgABC efflux pump from Pseudomonas putida DOT-TIE soil 
organism that recognises a range of plant secondary metabolites (Figure 18). Increasing 
the number of hydroxy groups increases the affinity by more than a factor of 2 (15 
compared to 16). Furthermore the double bond in the B ring appears to increase ligand 
binding as this is absent in 14, which binds with much lower affinity than 15. These 
experiments highlight how ITC analysis gives insights into the structural characteristics 
of a ligand that are required for high affinity binding. 87 
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Figure 18 Ligands for TtgR identified by ITC; Naringenin (14), Apigenin (15) and luteolin (16) 
 
Ligand binding studies with BmrR, the regulator of a lipophilic transporter system 
encoded by the bmr locus in Bacillus subtilis, revealed that not only does the regulator 
recognise diverse ligands but also that charge in the ligand binding domain is 
important.88 Typically LBD‟s in TetR type proteins are characterised by hydrophobic 
interior surfaces with buried charged residues to stabilise ligand binding. ITC analysis of 
the binding of berberine and rhodamine revealed that a glutamic acid residue in the 
ligand binding domain is benifical to rhodamine but not berberine binding. Berberine is 
a natural product and more likely to be a natural substrate than rhodamine but the 
ability for the protein to recognise structures represented by rhodamine is indicative of 
the evolutionary capability for multidrug binding proteins to recognise diverse 
substrates. Similar investigations describe structurally related divalent cations as 
substrates for the QacR protein from Staphylococcus aureus.89  
 
Figure 19 Substrates for BmrR; berberine (17) and rhodamine (18) 
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The results with TetR proteins support the hypothesis that efflux pump repressors 
recognise substrates for the cognate efflux pump. The structural and biochemical 
insights are extremely useful when studying the function of homologous TetR proteins 
that do not yet have a solved three dimensional structure, for example MtrR from N. 
gonorrhoeae. The available literature on MtrR shall now be discussed. 
1.4 MtrR from N. gonorrhoeae 
1.4.1 Genetic origin and structure of the mature protein 
 
The multiple transferable resistance regulator (MtrR) is the product of the mtrR gene, 
located 250 bp upstream from the genes for the mtrCDE efflux pump and divergently 
transcribed from the efflux pump operon.90 The mature regulator protein binds a 22 – 27 
base pair region upstream of the mtrC gene as a dimer of dimers, consistent with other 
TetR proteins, as discussed above, protecting the efflux gene from being transcribed.91 
MtrR contains 210 amino acids that shows 30 % identity to TetR, 34% to AcrR and TtgR 
and 27% to CmeR. Despite the low sequence homology, there is considerable similarity 
in the ternary structures of TetR proteins, as highlighted in the overlay  diagram of TetR 
 
Figure 20 Overlay of -traces of MtrR homology model (red) with AcrR (green), CmeR (blue) 
and TtgR (pink). Image produced using MOE.  
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proteins (only monomers are shown, Figure 20). Homology modelling using AcrR as a 
template, produced a model for MtrR that provides visual support for the similarity 
between MtrR and TetR proteins of known 3D structure.  
 
1.4.2 Effect of oligonucleotide mutations on MtrR function 
The „normal‟ resting state for the MtrR protein is on the promoter region (meaning it is 
bound to DNA) for the mtrCDE operon, however, in clinical isolates of N. gonorrhoeae 
that exhibit elevated levels of resistance to antimicrobial agents several mutations in 
both the coding region and the promoter region for MtrR are observed. Four mutations 
in the MtrR gene lead to four amino acid substitutions in the mature protein: E202G, 
H105Y, A39T, G35D.92 Substitution of glutamic acid at position 202 for glycine is 
postulated to disrupt dimerisation of MtrR monomers, whilst the presence of tyrosine 
instead of histidine at the 105th position was isolated from penicillin resistant strains of 
N. gonorrhoeae but no molecular effect of this substitution is reported in the literature.93 
The effect of the H105Y mutation will be discussed in more detail in Chapter 2. 
Mutations in the N-terminal HTH region (A39T, G35D) disrupt DNA binding by 
replacing hydrophobic amino acids with polar amino acids. Amino acid mutations in  
  
Figure 21 Location of the MtrR binding site upstream of the mtrCDE operon and the location of 
alterations in the promoter sequence that lead to high level antimicrobial resistance. The diagram is not 
to scale. 
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the primary sequence of MtrR cause modest (< 10 fold) increases in resistance to 
antimicrobial agents and detergents whereas mutations in the promoter sites for mtrR 
and mtrC and in the MtrR DNA binding region provides > 1000 resistance towards the 
detergent TritonX-100 (13).94 The extremely high level of resistance seen is due to 
unregulated expression of the MtrCDE efflux pump because the mutation in the 
promoter region permanently abrogates protein binding. Mutations observed in clinical 
isolates are deletion of thymidine base or a single mutation (A→G) in the MtrR promoter 
region or an A  G mutation between the mtrR and mtrC start codons, which greatly 
increase antimicrobial resistance. 
1.4.3 MtrR regulatory network 
Although the best characterised role of MtrR in the gonococcus is transcription control of 
mtrCDE, there are an increasing number of reports in the literature that reveal a much 
more global regulatory capacity for MtrR. 95 Whole genome micro-array RNA analysis 
from N. gonorrhoeae showed MtrR to directly repress 47 and activate 22 genes.90 Five of 
the gene cassettes implicated in the transcription analysis have been characterised in 
detail and the pathways listed in the literature are summarised in Figure 22.  
 
 
Figure 22 Schematic representation of genes that have been shown by whole genome microarray analysis 
to be directly regulated by MtrR.  
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MtrR regulates its own expression, as well as negatively regulating expression of 
mtrCDE, rpoH (a stress response factor),90 pilM (part of the pilMNOPQ secretion 
system),96 the transport protein MtrF,97 and FarR, the regulator of the FarAB efflux 
pump.98 MtrR has also been shown to positively regulate the expression of ponA that 
encodes for penicillin binding protein-1. Each gene regulated by MtrR is implicated in 
antimicrobial resistance in N. gonorrhoeae and the majority of genes are negatively 
repressed, that is the regulator must leave the operator DNA in order for transcription to 
take place implying MtrR operates by a conserved mechanism.  
It is clear from genome analysis in N. gonorrhoeae that MtrR has multiple functions in the 
gonococcus. MtrR belongs to the TetR family of transcriptional regulators and is known 
to repress expression of the multidrug efflux pump MtrCDE. The ability for MtrR to 
interact with different genes leads to the hypothesis that MtrR acts as a protein sensor 
for a wide range of exogenous chemicals that are toxic to the bacterium. It is 
hypothesised that in response to binding the antimicrobial agent, MtrR dissociates from 
the operator / promoter upstream of the resistance gene, enabling gene transcription to 
take place. 
1.5  Project hypothesis and aims 
The molecular mechanisms underlying the function of MtrR have not yet been 
addressed in the literature and this thesis aims to answer the following key questions: 
1. Does MtrR bind substrates (small molecule antibiotics and antimicrobial 
peptides) of the MtrCDE efflux pump? 
2. Does binding of a ligand cause dissociation of MtrR from its operator DNA? 
The ability for small molecule antibiotics tetracycline, spectinomycin and penicillin G to 
bind MtrR is reported in Chapter 2, with particular emphasis on how penicillin G 
interacts with MtrR. 
Chapter 3 focuses on the interactions between MtrR and the human antimicrobial 
peptide LL-37. The structure of LL-37 is divided into small peptides to probe how the 
length and structure of the peptide effects binding to MtrR. The ligand binding domain 
of MtrR is characterised by use of a photoactivated peptide probe. The effect of ligand 
binding on the MtrR : DNA is investigated using EMSA. 
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Conclusions from the studies are drawn in Chapter 4. Suggestions for the development 
of the work are also made, together with a summary of other studies conducted during 
the course of this research project.  
Chapter 5 provides experimental detail for the thesis. 
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2 MtrR interaction with peptide antibiotics 
2.1.1 Introduction 
The mtr locus encodes the multidrug efflux pump MtrCDE and its cognate repressor 
MtrR, that are necessary for high level antibiotic resistance in N. gonorrhoeae. The 
transcriptional regulator MtrR has also been implicated in the regulation of specific 
resistance determinants necessary for high level penicillin resistance as highlighted in 
Figure 22 in Chapter 1.99 Herein, we propose that MtrR binds diverse antibiotics, causing 
activation of the resistance genes controlled by MtrR. During the course of investigations 
to establish evidence for this hypothesis, an unexpected enzymatic activity of MtrR was 
discovered, and the characterisation of this new activity is reported in this chapter. 
An overview of recent literature relating to -lactam antibiotics and -lactamases is also 
provided, in particular focussing on the characterisation of novel -lactamases. The 
results of a biophysical study on how MtrR binds -lactam antibiotics using isothermal 
titration calorimetry (ITC) and mass spectrometry are reported and discussed.  
2.1.2 -Lactam antibiotics 
The serendipitous discovery of penicillin by Fleming and the subsequent large scale 
preparation by Florey and Chain heralded the beginning of the modern antibiotic age.100 
The term antibiotic was proposed by Waksman to describe “a substance derived from 
microorganisms which has the capacity of inhibiting growth and even destroying other 
microorganisms.”101 In this thesis, the Waksman definition is adopted with the proviso 
that “derived” includes synthetic compounds as well as antibiotics of sole 
microbiological origin.   
Benzyl penicillin (2) represented the first antibiotic of the -lactam class and more than 
40 structurally diverse -lactam antibiotics are marketed today, the core ring structure of 
which is the product of non-ribosomal peptide synthesis pathways in fungi and soil 
bacteria (Scheme 1).102 Key chemical characteristics of these compounds are non-
proteinogenic amino acids (e.g. L-aminoadiapic acid 19), D-amino acids (D-valine), 
methylated nitrogen (NMe) and small heterocyclic rings.  
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Scheme 1 Biosynthetic origin of penicillins (6) and cephalosporins (34) 
Assembly of the isopenicillin N core structure of penicillin and cephalosporin antibiotics 
highlights many of the unique features of the non-ribosomal peptide synthesis (NRPS) 
pathway. ACV synthase catalyses the formation of a tripeptide 22 (L- aminoadipyl-L-
cysteinyl-D-valine) from three L amino acid, valine, cysteine and aminoadipidic acid. 
The 4,5-fused ring system is then formed in one step by isopenicillin–N-synthase (IPNS), 
a non-haem, Fe(II), dioxygen dependent enzyme. The core ring system is then subject to 
further enzymatic modification to give clinically useful secondary metabolites. The ring 
system can undergo oxidative ring expansion by an Fe(II) dependent enzyme 
deacetylcephalosporin synthase (DAOCS) to give the cephalosporin class of antibiotic, or 
the peptidyl side chain is modified by aminohydrolase / acetyl transferase to give 
penicillin derivatives.103 
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Early investigations into the biosynthesis of benzyl penicillin (2) led to the discovery of 
6-aminopenicillanic acid, the core structure that was then elaborated through chemical 
synthesis to give semi-synthetic penicillins, e.g. Penicillin V (29) Carbencillin (30) 
andNafcillin (33) (Table 2). These semi-synthetic drugs had better bioavailability and 
were more resistant to -lactamases.104 
Further screening of microorganisms was undertaken to find novel entities to act as anti-
infectives and these efforts led to the discovery of clavulanic acid (36) from Streptomyces 
clavuligerus.105,106 Clavulanic acid (37) had very low antibacterial effects but was shown to 
be a potent inhibitor of -lactamases. The first -lactam containing secondary metabolite 
identified from a natural source that contained an oxazolidine ring rather than a 
thiazolidine or dihydrothiazine ring was 37.107 Other interesting structural features of 
this inhibitor are the lack of acylamino substitution at C-6 and a -hydroxyethylidene 
function at C-2. The -lactam ring of clavulanic acid is formed by  -lactamase synthase 
enzyme, that unlike IPNS is an ATP / Mg2+ dependent enzyme (Scheme 2).108 An 
analogous enzyme catalyses the formation of the -lactam ring in carbapenems. As with 
the formation of the 5 and 6-membered heterocycles of penicillin and cephalosporins, 
the oxazolidine ring is constructed by an oxidative cyclisation Fe2+-dependent 
dioxygenase called clavulanic acid synthase (CAS).109,110 
 
Scheme 2 Biosynthetic origin of the -lactam ring in clavulanic acid 
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Table 2 summarises the -lactams referred to in this thesis. Compounds 29 to 33 are 
semi-synthetic derivatives of benzyl penicillin. The introduction of amino, alcohol or 
carboxy functionality improves bioavailibilty and stability in acidic media. The bulky 
naphthalene moiety renders the antibiotic too large for the -lactamase active site and so 
is -lactamase resistant. Developments to the cephalosporin class have also been made in 
attempts to overcome resistance mechanisms that are discussed in the following section. 
Antibiotics 37 and 38 are compounds that exhibit low antibacterial activities but are 
potent inhibitors of -lactamases. The mode of action of these antibiotics and the 
resistance developed by bacteria are discussed in the following section.  
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Table 2 -lactam antibiotics used in this study 
Class Core structure Subgroup R1 R2 Name 
Penicillin 
 
 
 
 
 
 
 
Extended 
spectrum 
 
---- 
Penicillin G 
(2) 
 
---- 
Penicillin V  
(29) 
 
---- 
Carbenicillin 
(30) 
-lactamase 
sensitive 
 
---- 
Ampicillin 
(31) 
 
---- 
Amoxicillin  
(32) 
-lactamase 
resistant 
 
---- Nafcillin (33) 
Cephalosporin 
 
 
3rd generation 
 
 
 Cefixime (34) 
Chromogenic 
substrate 
 
 
CENTA (35) 
Carbapenem 
 
-lactamase 
resistant 
  
Imipenem 
(36) 
Clavam  
 
-lactamase 
inhibitor 
--- ---- 
Clavulanic  
acid (37) 
Penicillin 
sulfone 
 
 
---- ---- 
Tazobactam 
(38) 
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2.1.3 Cellular target and bacterial resistance to -lactams 
-Lactam antibiotics target the enzymes that catalyse the final peptidyl-cross linking step 
in the synthesis of peptidoglycan (Scheme 3).4 The targeted enzymes are transpeptidases 
(also termed DD-peptidases or penicillin binding proteins) and contain a nucleophilic 
active site serine. The active site serine attacks the penultimate D-Ala amino acid of the 
stem peptide (39), which releases the last amino acid from the donor peptide and forms 
a covalent acyl-enzyme complex (40). In transpeptidases, the carbonyl of the D-Ala 
amino acid is linked via an ester linkage with the active site serine, then undergoes 
attack from a primary amine of the third amino acid of a second stem peptide (41). The 
resultant peptide bond is formed between the two stem peptides, forming a link 
between the glycan strands (42).111
 
Scheme 3 Mechanism of transpetidase 
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Figure 23 Schematic representation of a) inactivation of transpeptidase (green) by penicillin; b) 
hydrolysis of penicillin by -lactamase (blue). 
 
-lactams mimic the acyl-D-Ala D-Ala peptide in acting as covalent inhibitors of 
transpeptidases thus inhibiting cell wall synthesis.112 The -lacatam localises in the 
binding pocket by attractive electrostatic interaction involving hydrogen bonding from 
the backbone amide protons of the protein to the -lactam carbonyl, consequently 
activating the carbonyl to nucleophilic attack and this protein-substrate complex 
stabilizes the incipient tetrahedral species so as to enable general base catalysis for serine 
addition to the -lactam (44, Figure 23). The tetrahedral intermediate formed by the ring 
opening of -lactam (45) closely resembles that of the natural substrate and penicillin 
remains in the active site. The rate of deacylation of the intermediate is low because 
PBPs lack amino acids near the active site that can act as a general base to activate the 
nucleophilic water molecule.113  
The mechanism of -lactam hydrolysis by serine -lactamases is closely related to the 
mechanisms of transpeptidase inhibition. The acyl-intermediate 48 can be hydrolysed by 
an activated water molecule. The identity of the activating amino acid (identified by X in 
Figure 23) is different in each class of -lactamases and is still a matter of debate in the 
literature, as discussed below. The rate of hydrolysis is fast compared to PBP‟s and the 
ring-opened -lactam product 49 is ineffective as a PBP inhibitor thus no longer poses a 
threat to bacterial viability. -lactamases are proposed to have developed in bacteria as a 
response to environmental challenges, originally in nature but now in also in respsonse 
to man-made -lactam antibiotics used in human and veterinary medicine. The common 
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ancestral root of these two families of enzyme is suggested on the basis of the substrates 
catalysed, the tertiary structure of the protein and the composition of the active site 
residues.114 The different classes of -lactamases will now be discussed. 
 
2.1.4 Classification of -lactamases
There are currently more than 470 -lactamases known and they can be broadly 
divided into three categories; metal ion dependent enzymes, serine hydrolases and those 
of unknown catalytic site.6 The final group only contains a few members but is 
particularly relevant to this thesis and will be discussed in more detail in section 2.1.5  
Both PBP and -lactamases are present in the periplasmic space of Gram-negative 
bacteria. In Gram-positive organisms (which lack the outer membrane) the PBP are 
located on the outer surface of the cytoplasmic membrane and the -lactamases are 
either excreted or bound to the cytoplasmic membrane.114 
The metal and serine dependent enzymes are further classified in terms of the sequence 
homology, substrates hydrolysed, the inhibitors of the enzyme and the mechanism of 
action.115 The prevailing molecular classification system developed by Bush contains 
four families, A, B, C and D. 116 Class A, C and D contain active site serine residues in the 
hydrolysis mechanism, while class B contain zinc dependent enzymes.117 Class B 
enzymes are not discussed further in this thesis as they are not relevant to the discussion 
of MtrR. 
Serine -lactamases contain two groupings of amino acids, the active site and the 
recognition domain. The former contains a minimum of five amino acids: the serine, the 
general base for the serine, the oxyanion hole (two amino acids), and the cationic 
recognition site for the carboxylate. The latter domain contains amino acids that aid 
binding of the -lactam antibiotic by favourable hydrophobic and hydrophilic 
interactions. 
Class A enzymes hydrolyse penicillin but not cephalosporins, and are inhibited by 
clavulanic acid (37). The key catalytic motif is Ser 70-Lys 73-Lys 234-Ser 130-Glu 166 
where Ser 70 is the nucleophilic residue. NMR studies have revealed that Glu 166 is 
widely accepted as a general base in the deacylation step and Lys 73 provides 
stabilisation of the intermediate.118 
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Class C -lactamases are resistant to clavulanic acid and are capable of hydrolysing 
cephalosporins, including the clinically relevant third generation cephalosporins. A 
flexible loop (termed the  loop) in the enzyme is responsible for the ability to turn-over 
sterically demanding cephalosporins, such as 34.119,120 Tyr 150 has been shown to be the 
activating amino acid in the acylation and deacylation steps.121 
Class D are also known to be oxacillinases due to their ability to degrade 5-methyl-3-
phenylisoxazole-4-carboxy side chain penicillin class, exemplified by oxacillin and 
cloxacillin. Mechanistic investigations of class D proteins have revealed structural 
differences compared to other serine hydrolases, notably a short  loop and no 
similarity to previously identified activating amino acids outside the catalytic triad. 
Crystallographic studies revealed that the active site lysine is carboxylated and the 
resulting carbamic acid takes part in the acylation / deacylation steps as a general 
base.122 
 
2.1.4 Mechanism determination by mass spectrometry 
The mechanism of action for the inhibition of class A -lactamases by clavulanic acid 
and tazobactam has been studied in depth by several research groups.104 Rizwi et al 
observed an intermediate with an enamine chromaphore in the inhibition of S. aureus -
lactamase and this supported by the work of Charnas, who used 14C-radiolabelling 
experiments to determine the mechanism of clavulanate inhibition.123 It had also been 
suggested that a lysine residue was involved in cross linking to the enzyme bound 
clavulanate. Subsequent X-ray crystallography124 provided proof of the acylation of the 
enzyme by clavulanate but no lysine residue was determined to be spacially close 
enough to facilitate cross linking, leading Ser  130 to be implicated instead. Furthermore, 
the resolution of the structure determination was not sufficient to distinguish between 51 
and 52.125  
A subsequent mass spectroscopic study by Brown et al enabled the full mechanism to be 
determined.126 The successful approach utilised intact protein ESI MS to determine the 
adducts formed when S. aureus -lactamase reacted with clavulanic acid, and digestion 
of the modified protein using Endopeptidase C and trypsin followed by HPLC ESI MS 
analysis of the proteolytic peptides enabled the location of the acylation to be 
determined (Scheme 4).127   
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Scheme 4 Degredation pathway for clavulanic acid 
The acyl-enzyme intermediate 50, is the first product in the clavulanate reaction 
pathway, followed by decomposition of the oxazolidine to give imine 51. This can be 
decarboxylated to give intermediate 53. Imine 53 can degrade via a number of different 
pathways. Firstly imine 53 that can either be cross linked by a spatially near serine to 
give a vinyl ether 57 or it is converted to a hemiacetal 55 and then to aldehyde 56 by 
hydrolysis. The cross linked vinyl ether 57 can be hydrolysed to give either 
dehydroalanine and a hemiacetal (59) or the ester linkage is hydrolysed to give (58). 
Raman spectroscopic study of the intermediate 52 formed from hydrolysis of clavulanic 
acid by wild-type class A -lactamase SHV-1 showed a mixture of 52, 53 and 54, whereas 
a SHV-1 mutant that contains E166A exists predominantly as the trans-enamine 52. As 
discussed earlier E166 contributes to the inhibition of -lactamase. This highlights the 
importance of secondary sphere amino acids in active site labelling.  
51 
 
The mechanism proposed by Brown et al is supported by the results of other groups. 
Sulton and co workers identified that the same pathway occurred in the inhibiton of a 
class A -lactamase from E. coli. In enzymes that contain a S130G mutation, however, the 
enzyme is still acylated but only one adduct is seen in the intact protein mass spectrum 
at + 70 Da, arising from hydrolysis of enamine 56. A further adduct with m/z 136 was 
observed in the inhibition of -lactamase from M. tuberculosis. This fragment most likely 
arises from dehydration of 55.128
HPLC ESI MS experiments with tazobactam have revealed a similar degradation 
pathway to that of clavulanic acid, with common protein adducts at +70 and +88 Da.129 
 
2.1.5 Non-classical -lactamases 
There are examples of β-lactamases in the literature that fall outside the groupings 
discussed above.104 Recently mitochondrial Glyoxalase 2-1 from Arabidopsis thaliana was 
shown to hydrolyse nitrocefin, cefotaxime and imipenem with kcat = 1.20 ± 0.04 s-1, 0.20 ± 
0.01 s-1 and 0.20 ± 0.01 s-1 respectively, 10 – 100 times lower than most reported metallo-
-lactamases.130 The Glx 2-1 contains the conserved HXHXD metal binding domain, 
typical of metallo- -lactamases but the nearest homologue is the L1 metallo- -lactamase 
from Stenotrophomonas maltophiliaonly, with which it shares only 10% sequence identity. 
The role of penicillin in plant cells is unknown and the cellular localisation of Glx 2-1 
poses interesting evolutionary questions as to how the protein evolved -lactamase 
function. One theory is that the -lactamase function of Glx2-1 is a result of gene 
duplication and diversification and as a result is a redundant by-product of genetic 
evolution. 
Penicillin binding proteins (PBPs) are the cellular target of penicillin type antibiotics and 
do not display -lactamase function, instead they catalyze transpeptidation, or exhibit 
carboxypeptidase and endopeptidase function.131 The Tp47 PBP from Treponema pallidum 
exhibits -lactamase activity (for benzylpenicillin Kcat = 271 ± 6 s-1) but detailed 
mechanistic studies have revealed the enzyme activity does not correspond to a known 
mode of action. PBPs contain three conserved motifs namely SVTK, TEN and KTG as 
revealed through structural investigations.132 Site directed mutagenesis of the Ser in the 
SVTK motif, and Lys in the KTG motif did not affect -lactamase activity. The crystal 
structure of the enzyme revealed a four domain structure, with a mixture of -helical 
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and -sheet structure. Further investigation of the same enzyme by a different research 
group who used a series of stopped-flow experiments, lead to the conclusion that the 
hydrolysed -lactam product penicilloic acid acts as an inhibitor for the active site of the 
enzyme. The observation that the hydrolysed antibiotic blocks the enzymatic function of 
the PBP accounts for the clinical observation that T. pallidum is still susceptible to 
penicillin. The active site of the enzyme remains unknown.133  
Helicobacter cysteine-rich protein A (HcpA) is another protein reported as having 
-lactamase function yet despite crystallographic data, no active site or mode of action 
has been postulated. 134,135 This novel -lactamase adopts a modular structure consisting 
of four / -motifs, unique amongst reported penicillinase enzymes. Kcat is low, less than 
1.06 min-1 for both penicillin and cephalosporin type antibiotics, but Km for ampicillin 
(31) and amoxicillin (32) is 145 M and 155 M respectively indicating that the substrate 
is a good fit for the enzyme active site. The extra presence of OH and NH functionality 
on 31 and 32 may account for the higher Km compared to benzylpenicillin (2, 
Km = 48 M), suggesting hydrogen bonding stabilises the substrate : enzyme complex. 
2.2 Results and discussion 
2.2.1 Introduction 
N. gonorrhoeae exhibits high level resistance to -lactam antibiotics by a combination of 
the resistance mechanisms discussed above, namely i) the production of -lactamases, ii) 
decreased influx due to mutations in porin and PilQ proteins, iii) decreased affinity for 
penicillin in PBP proteins, iv) increased efflux of -lactam antibiotics by the MtrCDE 
efflux pump. 
The regulation of resistance mechanisms ii-iv are under the control of the transcriptional 
regulator MtrR. MtrR is a member of the TetR family of transcriptional regulators and as 
such contains a flexible ligand binding domain. It is hypothesised that in order for MtrR 
to activate the described resistance determinants, the regulator must be able to bind 
lactam antibiotics. The following chapter describes research into how MtrR interacts 
with -lactam type antibiotics.  
2.2.2. Origin, overexpression and purification of MtrR.  
All ligand binding studies performed in the course of this research used recombinant 
MtrR. Initial protein overexpression in BL21-AI cells used a pET21a plasmid carrying the 
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gene for MtrR, sourced from a stock of cells previously prepared in the group. The 
protein was expressed with an N-terminal His-TAG and purified by affinity 
chromatography using a 1 mL or 5 mL HITRAP column (Figure 24). Further purification 
was carried out by anion exchange chromatography and gel filtration. The identity and 
purity of the recombinant protein were assessed by SDS-PAGE (Figure 27) and mass 
spectrometry (Figure 26). A MASCOT (Matrix Science protein database) search using the 
data from trypsin digest of MtrR revealed that only tryptic peptides corresponding to 
MtrR were present and this result confirms that no other proteins were co-purified with 
MtrR. In order to ensure that any activity observed between MtrR and various -lactam 
antibiotics was solely due to MtrR and not any co-purified lactamase, the gene for 
mtrR was digested from the pET21a plasmid and inserted into a pET28a plasmid. The 
later plasmid carried a kanamycin resistance marker and there is no bla gene present 
eliminating the possibility of co-purifying a -lactamase. 
 
Figure 24 UV trace showing the absorption profile HIS-tag purification of MtrR. 40 mL crude MtrR lysate 
(20 mM Tris, 300 mM NaCl, 10 % glycerol, pH 8.2) was loaded onto 5 mL HITRAP column. HIS-Tagged 
protein was eluted using an imidazole gradient 0-100 % B over 20 minutes (Buffer A: Tris 20 mM, NaCl 
300 mM, 10 mM imidazole, pH 8.2; Buffer B Tris 20 mM, NaCl 300 mM, 1 M imidazole, pH 8.2). 
Purification carried out at 5 mL buffer / minute. 
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Figure 25 Gel filtration of MtrR. 5 mL MtrR loaded onto 16 / 40 sephadex column and eluted with 1.5 
column volumes buffer (Tris 20 mM, NaCl 300 mM, pH 8.2). MtrR eluted between 58 and 64 minutes. 
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Figure 26 Deconvoluted ES+ mass spectrum of MtrR 
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Figure 27 SDS-PAGE (12% acrylamide) analysis of MtrR purification. Lane 1 – crude overexpressed MtrR, 
Lane 2 - post HisTAG purifcation, Lane 3 - post Gel purification 
 
Despite MtrR being a soluble protein it is considerably unstable on storage at 4 °C in 
aqueous buffer for more than 2 days and if stored at -20 °C in aqueous buffer containing 
10 % glycerol, a considerable amount of protein precipitates on thawing. These 
observations are supported by the literature.136 Consequently, binding studies were 
carried out on the same day that the protein was dialysed into the final analysis buffer, 
and to ensure enough protein was available for binding studies, the protein was 
frequently produced. 
 2.2.2. MtrR and antibiotics ITC binding study 
The MtrCDE efflux pump has been shown to confer resistance to gonococci in the 
presence of tetracycline (11), benzyl penicillin (2) and spectinomycin (10).137 In order to 
find evidence that substrates for the MtrCDE efflux pump also bind MtrR the antibiotics 
were used as ligands in ITC binding studies with the regulator protein. 
In this investigation, 11, 2 and 10 (1 mM) were injected into a MtrR solution (70 M) 
using a VP-ITC (Microcal®). For each antibiotic control experiments involving the 
injection of antibiotic into buffer only were also carried out. The data from the control 
was subtracted from the experiment containing MtrR to remove any background effects. 
The observed data for tetracycline and spectinomycin could be fitted to a standard one 
site model using Origin® software (Figure 28), the calculated thermodynamic parameters 
of which are summarised in   
Table 3. Both antibiotics interact with MtrR but appear to do  
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Figure 28 ITC data for (A) tetracycline (1mM) and (B) spectinomycin injected into MtrR (70 M). Upper 
panel displays raw data, lower panel shows the data fitted to a Onesite model.  
Table 3 Thermodynamic parameters calculated from the raw ITC data by fitting to standard Onesite 
model. 
Antibiotic N ΔH /  kJ mol-1 ΔS / kJ mol-1. K Kd / M 
Tetracycline 0.4 ± 0.1 -9.5 ± 3 17 4 ± 0.1 
Spectinomycin 1.65 ± 0.02 -36 ± 9 3 0.09 ± 0.001 
 
so via different mechanisms. The ratio of 0.4 for 11 binding to MtrR suggests that one 
ligand binds to one MtrR dimer (1 : 2). MtrR appears capable of binding more than one 
spectinomycin (10) molecule as N >1.  
In contrast to the results obtained by injection of tetracycline (11) and spectinomycin (10) 
into MtrR, injection of penicillin G (2) gave an intriguing result (Figure 29 A). The steady 
reduction in baseline is indicative of an enzymatic reaction whereas the decreasing  
 
Figure 29. (A) Raw ITC data for the injection of penicillin G (1 mM) into a solution of MtrR (70 mM) in 
Tris buffer; (B) phosphate buffer (C) Data fitted to a Michealis-Menton model. 
A B C 
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power output is representative of a binding event. To further investigate the interaction 
between MtrR and 2 further, the experiment was repeated but phosphate buffer was 
used instead. Sodium phosphate buffer has a much lower heat of ionisation ( H = 3 kJ 
mol-1) than Tris buffer ( H = 45 kJ mol-1) causing buffer effects to be minimised with the 
former reagent. Despite the high heat of ionisation for Tris buffer, it is the preferred 
buffer for MtrR as Tris buffer confers stability during dialysis, preventing the loss of 
protein during buffer exchange.138,143 The raw data for the reaction in phosphate buffer 
gave a profile indicative of an enzymatic event (Figure 29 B) and the data could be fitted 
using the standard Michealis-Menton model supplied with the calorimeter‟s Origin data 
analysis software (Figure 29 C). The calculated kinetic constants are Km = 106 ± 0.002 M 
and kcat= 0.02 ± 1.3 x 10-4 s-1. The calculated parameters are low but comparable to other 
enzymes with unexpected -lactamase activity, e.g. HcpB from Helicobacter pylori 
exhibits a Kcat = 0.74 min-1 (section 2.1.6).139 
The results from the ITC binding study confirm that 11 and 10 are ligands for MtrR. The 
result of the penicillin binding study was unexpected and in order to find further 
evidence to support this, the ITC reaction was repeated and the solution from the ITC 
cell was analysed by ESI mass spectrometry.  
Analysis by ES+ mass spectrometry of the MtrR / penicillin from the ITC cell provided 
evidence for the presence of the penicillanoic acid m/z = 353 and the complete 
destruction of all the starting penicillin G, m/z = 335 (Figure 30). Identical analysis of a 
control sample, in which penicillin G was added to a buffer solution not containing 
MtrR, showed a considerable amount of unchanged 2 (Rt = 18.4 min) and only a limited 
amount of the penicilloic acid (62, Rt = 17.8 min) in contrast to the ITC solution where 
two peaks of approximately equal intensity are seen at 17.8 and 18.6 minutes. The peak 
at 15.36 minutes is for MtrR. The identity of penicillin (2) and penicilloic (62) acid were 
confirmed by accurate mass measurements.140 
The mass spectrometry results along with the ITC findings provide evidence to support 
the hypothesis that MtrR acts as a -lactamase. Having established this, attention turned 
to investigating the specificity of the MtrR activity.  
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Figure 30 ES+ ion chromatogram a) Control: Penicillin G in phosphate buffer, 2 hours b) MtrR and 
Penicillin solution post ITC 
2.2.3 Specificity of ligand binding 
As discussed in section 2.1.2 a range of penicillin type antibiotics have been developed to 
counter resistant strains. The modified side chains in semi-synthetic antibiotics not only 
improve the pharmacokinetics but also provide the antibiotic with different modes for 
protein binding, for example the introduction of alcohol, and amine functionality in 
amoxicillin enhances protein binding due to favourable hydrogen bonds while the 
presence of the large naphthyl group in nafcillin (33) has the effect of making the drug 
too large to fit into the active site of the protein.  
Using a range of -lactams it was postulated that insights into the type of active site of 
the enzyme could be gained. The semi-synthetic penicillins ampicillin (31), amoxillicin 
(32) and penicillin V (29) were all substrates for MtrR exhibiting kinetic parameters 
similar to benzyl penicillin (2) (Figure 31). As expected 33 was not hydrolysed by MtrR, 
showing instead weak binding to MtrR, as determined by a standard ligand binding ITC 
experiment. This ability of MtrR to promote the turnover of PenG, PenV and ampicillin 
to the corresponding penicillanoic acid but not nafcillin led to the suggestion that it has 
acquired a -lactamase function. The cephalosporin 35 is turned over at a much slower 
rate, which indicates that MtrR operates more as a Class A rather than a Class C -
lactamase. 
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Figure 31 (A) to (D) fitted using michelis-menton model (A) Penicillin V kcat = 0.03 s-1, Km = 101 M (B) 
Ampicillin kcat = 0.04 s-1, Km = 64 M; (C) CENTA kcat =  2 x10-4 s-1, Km = 44 M; (D) Amoxicillin 
kcat = 0.02 s-1, Km = 96 M  
 
 
Figure 32 Injection of nafcillin (1 mM) into MtrR (70 M) 
 
CENTA is a chromogenic reagent in that, on cleavage of the -lactam ring the aryl 
thiolate chromophore (65) is released, thus allowing the hydrolysis of the substrate to be 
monitored using UV spectroscopy at 407 nm (Scheme 5).141 CENTA is considerably more 
stable than nitrocefin (67), the previously commercially available 
chromogenic -lactamase substrate. No hydrolysis was detected after incubation at pH 8 
A B 
C D 
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in 10 mM 300 mM Tris buffer or 50 mM phosphate buffer whereas nitrocefin had a half-
life of 380 min. A further favourable characteristic of CENTA over nitrocefin is the 
aqueous solubility of CENTA, up to 60 mg / mL at pH 7 in sodium phosphate buffer.50 
 
 
Scheme 5 Expulsion of chromophore on ring opening of -lactam ring in CENTA 
 
Figure 33 Nitrocefin, a chromogenic -lactamase substrate 
The effect of the addition of a 200 mol solution of CENTA to MtrR (70 M) was 
monitored in a UV-spectrophotometer over a period of 700 min and compared to a 
negative control, with no MtrR present (Figure 34). The release of the nitro thiolate is 
clearly seen in the increase in absorbance at 407 nm. It is clear that this is due to action 
by MtrR, in that no considerable change is seen the control sample. 
 
Figure 34 Monitoring of the cleavage of CENTA (0.2 mmol) by MtrR (70 M) (dark grey diamonds) at 407 
nm. A control sample of CENTA only (light grey) showed very little change over the period of 
monitoring. 
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The ITC, mass spectrometry and UV analysis provide evidence that MtrR can act as a 
-lactamase. In order to gain insights into the mechanism of hydrolysis a mass 
spectrometric study was designed, using the -lactamase inhibitors clavulanic acid and 
tazobactam, as covalent probes.  
2.2.4 Mechanism investigations 
Firstly, ITC analysis of clavulanic acid injected into MtrR demonstrated that an 
exothermic binding event takes place (ΔH = -80 ± 1 kJ mol-1, N = 0.7 ± 0.02). Moreover, 
subsequent addition of 2 to this mixture showed no evidence for further binding or 
penicillin hydrolysis, consistent with an inactivated enzyme (Figure 35). Analysis of the 
resultant solutions by MALDI-MS revealed that the peak for MtrR had shifted from m/z 
= 25251 for the purified protein to m/z = 25327 for the product. The mass difference of 70 
Da is consistent with the acylation of protein by clavulanic acid in the mechanism 
proposed by Brown et al (scheme 5). 
 
Figure 35 (A) Acylation of MtrR by clavulanic acid to MtrR ΔH = -80 ± 1 kJ mol-1, Kd = 30 M, N = 0.7 ± 
0.02 (B) no interaction on injection of penicillin G into MtrR 
 
Figure 36 (A) native MtrR, m/z 25257 (B) MtrR after incubation with clavulanic acid, m/z 25327 (Δ = 70 
Da). The [M+H]2+ ion can be observed in both spectra ~ 12000 
 
A B 
A B 
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In an attempt to resolve the modified proteins by SDS-PAGE, a 15 l aliquot of each 
inhibitor – protein sample was loaded onto a 12 % polyacrylamide gel. The samples 
were denatured by heating to 90 °C for 5 minutes prior to loading onto the gel and it was 
hypothesised that this may have hydrolysed the covalent adducts, resulting in only 
native protein being present. The SDS-PAGE was repeated without heating at 90 °C but, 
no difference in mass between labelled and unlabelled protein was observed. If only the 
lower mass adducts are stable to the electrophoresis conditions, a mass difference of 
only 50 units may not be observed. With MALDI MS evidence for a new protein species, 
attention turned to localising the site of addition in MtrR. It was envisaged that 
subjecting the inhibitor – protein complex to proteolytic digestion followed by mass 
spectrometric analysis of the resultant peptides would facilitate the identification of the 
residues of MtrR that are labelled by the inhibitors.  
Clavulanic acid (1 mM) was mixed with MtrR (70 M) and incubated at either room 
temperature (approx. 22 °C) or at 37 °C for a minimum of one hour. The resulting 
solutions were then directly loaded onto a reverse phase HPLC column coupled to an 
FT-ICR mass spectrometer operating in ES+ mode. Following deconvolution, a series of 
peaks corresponding to covalently labelled adducts of MtrR could be identified (Figure 
37). Repitition using the sulfone inhibitor tazobactam (38) gave similar results (Figure 
38) Significantly these showed increases in mass consistent with reports in the literature, 
as discussed above, for labelling with tazobactam and clavulanic acid. Addition of 52 Da 
corresponds to cross linked protein (57). An increase of 70 Da indicated addition of 
C3H3O (56, 68 or 59) and 88 Da corresponds to hemiacetal 55. The observation of a + 155 
Da adduct in the clavulanic acid containing sample indicates that 51 is unstable and 
rapidly undergoes decarboxylation. The +136 Da adduct arises from dehydration of 53 
and this adduct is proposed to be stable and responsible for inhibition of the enzyme.142 
The adduct at 113 cannot be explained by chemical fragmentation of clavulanic acid but 
the same adduct has been observed in the literature.143 Table 4 summarises the observed 
adducts and peaks marked with an asterisk in Figure 37 could not be identified. The 
evidence provided by the mass spectrometric study shows that MtrR is covalently  
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Figure 37 Representative mass spectrum for MtrR incubated with clavulanic acid with proposed 
identities where possible, asterisk denotes unknown addition 
 
Figure 38 Representative mass spectrum for the incubation of Tazobactam with MtrR 
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modified by clavulanic acid and tazobactam and attention next turned to localising the 
site of modification. 
2.2.5 Localisation of modified residues using trypsin digests and mass spectrometry 
Having demonstrated that the -lactamase activity of MtrR could be inhibited by 
clavulanic acid and that this inhibition led to covalent labelling of the enzyme it was of 
interest to determine the location of this modification. Amino acids modified by covalent 
labelling can be determined by mass spectrometric analysis of peptides produced as a 
result of proteolytic cleavage of the modified protein of interest. The modified protein 
can be digested using trypsin or endoproteinase Glu-C (endo GluC).144 Trypsin cleaves 
peptide bonds C-terminal to lysine and arginine, whereas endoproteinase Glu-C cleaves 
only after glutamic acid residues. The lower frequency of proteolysis by endo GluC can 
produce less complex tryptic peptide maps but due to experience with trypsin digests 
within the group trypsin was chosen as the enzyme of choice for this work. The digest 
can be performed on protein extracted from an SDS-PAGE gel or soluble protein, or 
precipitated from buffer by acetone. 
An initial control experiment using unlabeled MtrR and trypsin was conducted to check 
the sequence coverage of the digest. MALDI MS analysis of tryptic peptides generated 
by incubation of MtrR with trypsin (~ 1:30) for 12 hours at 37 °C, showed high sequence 
coverage with the only missing peptide being 116-124, which does not contain any serine 
or threonine residues and so trypsin was an ideal choice for analysis in this project. To 
ensure that the MtrR used in these assays was not contaminated by any lactamase, the 
peak list generated by MALDI analysis of the tryptic peptides was exported to the 
MASCOT database. The search did not identify any peptides belonging to E. coli and one 
can therefore conclude that the sample of MtrR used was 100% pure.  
Two methods for the trypsin digest were attempted. Firstly, protein was extracted from 
an SDS-PAGE gel and digested overnight with trypsin. Mass spectrometric analysis did 
not indicate the presence of modified protein. In a second attempt, the protein was 
precipitated in acetone and re-suspended in trypsin solution. Following digestion, 
overnight at 37 °C, and freeze-drying, the resultant peptides were dissolved in 0.01% 
(v/v) aq HCO2H and analysed by MALDI MS (Figure 39). 
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In order to determine whether any modified peptides were present, the data set was 
compared a control digest of MtrR only and to an in silico digest of clavulanate labelled 
MtrR generated using SequenceEditor (Bruker Daltonik GmbH) software. The known 
inhibitor adducts (+52, +70, +88, +136, +155) were optionally added to all serine / 
threonine residues and two partial cleavages were allowed to enable all possible 
modifications to be predicted. The theoretical digest data set and the observed data set 
were manually compared and three modified peptides were identified (starred peaks 
Figure 39). The modified peaks are absent in the control sample of MtrR that was not 
treated with clavulanic acid prior to proteolysis with trypsin (Figure 40). 
To confirm that these peaks were modified and were not artefacts of MALDI analysis, 
the trypsin digest was repeated and the tryptic peptides analysed by ESI MS (Aruna 
Prakash). The same peptides were identified using both mass spectrometric techniques 
thus it can be concluded that the observed modified peptides are real and reproducible.  
 
 
Figure 39 MALDI spectrum of trypsin digest of MtrR labelled with clavulanic acid. * = modified tryptic 
peptide of MtrR 
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Figure 40 Mass spectrum for the trypsin digest of native MtrR. 
 
Table 4 Summary of trypsin digest data acquired using MADLI and ES+ techniques 
MALDI  Accurate 
mass 
ESI (ΔObs-Theo / ppm) Modified MtrR 
peptide 
Modification 
Clavulanic 
acid (37) 
Tazobactam 
(38) 
1269 1269.63748 0.257 -0.231 HTLLHFFER +70 
1695 1695.81189 1.429 0.202 CEHTEQNAAVIAAR +70 
2020 2020.00996 -2.624 Not 
observed 
TKEHLMLAALETFYR +70 
 
In order to further characterise the peptides, mass spectrometric sequencing was 
attempted on the modified peptides. The peptide at m/z = 1269 was isolated in the ion 
trap on a MALDI spectrometer and fragmented using enhanced laser power (Figure 41). 
A more detailed account of MALDI MS/MS techniques is given in section 3.2.3.2. The 
abundance of ions in the low mass range (0 – 400 m/z) together with the observation of 
several dipeptide ions (LL-28, LH-28, HF-28) and the observation of a tripeptide carrying 
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the modified threonine residue (T*LL, m/z = 369) enables the proposed peptide 
sequence to be suggested with confidence. Attempts to sequence the other modified 
peptides were unsuccessful. Furthermore, sequencing experiments using electrospray 
mass spectrometry in electron capture dissociation mode have so far been unsuccessful.  
The observed results indicate that MtrR is labelled on three threonine residues. This 
result is fascinating as it was also expected for the labelling to occur at serine, as in 
classic -lactmases. Two of the labelled threonine residues (Thr 91 and Thr 127) are in 
the ligand binding domain of MtrR whereas Thr11 is at the N-terminal DNA binding 
domain. In order to understand the spatial arrangement of the modifications a 
homology model of MtrR was built using the protein modelling programme MOE 
(Chemical Computing group). 
 
Figure 41 LIFT data for HT*LLHFFER, where T* is the modified residue. Detailed MS /MS data is shown 
in appendix 7.1 
 
2.2.6 Visualisation of results using a homology model of MtrR 
In order to construct the homology model, MtrR was aligned against TetR family 
proteins of similar sequence. The highest similarity is to AcrR from E. coli (overall 
68 
 
homology 34 %). A ten membered database of conformers is produced and the lowest 
energy conformer is the predicted structure for MtrR (Figure 42 A). The accuracy of a 
homology model can be determined by a Ramachandran plot, and the plot of phi vs psi 
angles in MtrR reveals no outliers, with all angles within predicted limits (Figure 42 B).  
Using the homology model it is clear that Thr 11 is at the N-terminus of the protein on 
helix1, Thr91 is on helix 5 and Thr 119 resides in helix 6. There are 15 threonine residues 
in MtrR and with only 3 labelled, it is suggested that this is due to specific interactions. It 
would be expected that serine to be labelled in preference to threonine due to the large 
number of serine -lactamases that are known. The methyl group  to the nucleophilic 
oxygen of threonine may hinder the access of the water nucleophile in the deacylation  
 
Figure 42 A: Homology model of MtrR (monomer) with labelled threonine residues represented in ball 
and stick format; B Ramachandran plot for the MtrR homology model showing no outliers indicating the 
model is biological feasible 
step. This steric hindrance could therefore account for the low Kcat observed and the 
addition of inhibitors at Thr and not Ser. 145 The labelling of threonines and not serines 
indicates a novel mechanism of action for hydrolysis of -lactams. Despite threonine 
occurring only 1.1% less often than serine in proteins, the occurrence of active site 
containing hydrolases and proteases is much less common (based on current 
understanding gained through x-ray crystal structures and functional protein 
characterisation).146 Examples of active site threonine enzymes are Ntn hydrolases, for 
example gammaglutamyl transferase, penicillinase acylase, and glutaminase-
asparaginase (PGA). 147 Crystal structures of bacterial L-asparaginases have also revealed 
threonines in the active site.148  
TetR family proteins exist as homodimers and it has been shown for TetR proteins that 
bind two ligands per dimer (one ligand per subunit), the binding site in each subunit are 
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slightly different. The crystal structure of phloretin bound to TtgR shows that the 
contacts between the ligand and the protein are not identical in both subunits of the 
dimer. One can therefore speculate that labelling of Thr127 and Thr 91 is due to different 
orientations of clavulanic acid in the ligand binding domain of MtrR. Despite Thr11 
being located on the N-terminal helix of MtrR, the homology model predicts that Thr11 
is within hydrogen bonding distance (< 15Å) of H105, and Thr 91 is also close to H105 
(Figure 43). This distance is interesting as a naturally occurring H105Y mutation has 
been reported in the literature in clinical isolates of N. gonorrhoeae that exhibit high level 
penicillin resistance. It was therefore postulated that a H105Y mutant protein would 
exhibit a higher kcat than the parent H105 protein (the protein used thus far in this 
project). Furthermore, there are reports of tyrosine participating in catalytic triads of 
class C lactamases and in threonine proteases such as L-asparaginase supporting the 
case for the preparation of mutant H105Y protein for use in catalytic studies. 
 
 
Figure 43 Possible active sites containing labelled threonine residues in MtrR. LEFT : Thr11, His 105,Asp 
56; RIGHT: Thr 91, His 105, Glu 70 
 
2.2.7 Site directed mutagenesis studies 
The mutant MtrR proteins prepared were H105A, H105F and H105Y. The construction 
of the mutant plasmids was carried out by Bing Zang, a collaborator in the School of 
Biological and Biomedical Sciences, Durham University. The mutant proteins were 
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overexpressed and purified using standard techniques and mass spectrometry 
confirmed the correct mutation was present. 
ITC analysis of the mutant proteins with MtrR unfortunately did not yield positive 
results. There was no discernable pattern in Kcat or KM of the mutant proteins, as 
summarised in Table 5. The highest Kcat was observed in H105F mutant and the lowest 
in H105Y, a result which contradicts the literature reports that H105Y increases 
resistance to penicillin. 
The results from the site directed mutagenesis study were confusing as they do not 
support the hypothesis that the H105Y mutation is necessary of high penicillinase 
activity. Other reports in the literature have suggested that the introduction of tyrosine 
at 105 disrupts dimer formation in MtrR, however, this is not the case as residue 105 is in 
the ligand binding domain and not in the protein dimerisation domain (helices 8 -10). 
The physiological role of the H105Y mutation, is therefore still a matter for investigation. 
 
105th Amino acid Drug Kcat /s-1 Km / mM 
H  
Penicillin G (2) 
0.0191 0.167 
Y 0.00666 0.075 
F 0.0567 0.00963 
A 0.0175 0.0067 
 
Table 5 Effect of mutatation at 105th position of MtrR. 
 
2.2.9 In vivo analysis of -lactamase action of MtrR 
Undeterred by the lack of conclusive data to localise the active site, attention was turned 
to examining the ability of MtrR to confer resistance to penicillin in vivo. With no access 
to clinical stocks of N. gonorrhoeae, a model system was sought that could enable the 
survival benefit (if any) incurred by expression of MtrR in the presence of benzyl 
penicillin to be determined. 
Mazzariol et al showed that deletion of acrB transport in a strain of K12 E. coli, resulted in 
a two fold reduction in MIC towards 2.149 The resultant strain was termed KAM3 and 
this type of cell has been used to assess the effects of specific proteins on the survival 
characteristics of bacteria.150 KAM3 cells are capable of low level production of AmpC -
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lactamase but a double knockout mutant (ΔacrBampC) displayed the same MIC as the 
single acrB mutant implying the background expression of AmpC does not effect the 
resistance profile of E.coli.151 The KAM3 system is therefore suitable for assessing the 
effect of MtrR as a -lactamase expression on cell survival. The strategy employed 
involved transformation of „empty‟ (no plasmid) cells with a plasmid encoding MtrR, 
inducing production of MtrR followed by dosing the cells with 2 and monitoring growth 
using UV-Vis spectroscopy and single cell analysis using flow cytometry. 
KAM3 E. coli were transformed with a pET28 plasmid containing the insert for mtrR. 
Expression of MtrR was induced by IPTG for 2 hours, while a control sample was not 
induced. Cell cultures were centrifuged, washed and resuspended in fresh LB broth for 
growth curve analysis to ensure that no IPTG remained. Susceptibility of the E. coli 
strain to penicillin G was followed by the monitoring of bacterial growth for 16 hours in 
a 96-well plate format using a UV-vis plate reader. Whilst low concentrations of MtrR, as 
regulated by IPTG (1 mM), afforded minimal benefit, enhanced MtrR (10 mM IPTG) 
expression led to superior survival rates (Figure 44). 
 
Figure 44 Survival curve for KAM3 E. coli + / - MtrR 
40% of cells expressing MtrR survived compared to MtrR negative or cells induced with  
1 mM IPTG. The observation that increased survival is related to increased IPTG implies 
that there is a link between the amount of MtrR produced and the resistance of the cell to 
penicillin (2). 
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2.2.10 Flow cytometry 
The use of growth curve monitoring to determine the antimicrobial effects of a 
compound, as described above, is a standard microbiological technique but this method 
only describes the whole population. In order to assess cell viability at the level of the 
single cell, a complimentary technique such as flow cytometry is required. The following 
section provides a brief overview of the literature on cell viability assays by flow 
cytometry. This summary is followed by a description of the experiments carried out 
using this technique in this thesis, and a discussion of the results.  
Since the first flow cytometric susceptibility tests (FCST) in the 1980‟s flow cytometry 
has developed as an important tool for investigating bacterial susceptibility to 
antimicrobial agents.152,153 The principle of the experiment is that the cells are stained 
with two dyes, each with a distinctive fluorescence emission profile and membrane 
permeabilities. The degree of membrane permeability is determined by the different 
levels of fluorescence from each dye. Numerous dyes exist but they can be classified by 
membrane permeability and the mechanism responsible for switching on the 
fluorescence. Phenanthridium nucleic acid, cell impermanent dyes such as propidium 
iodide (PI), ethidium brodimide (EB) and ethidium homodimer 1 are typically used to 
assess plasma membrane integrity as these dyes can only enter membrane permeabilised 
cells. Inside the cell these compounds bind to DNA resulting in enhanced fluorescence. 
Thiazole orange is a nucleic acid stain that is able to enter cells with intact plasma 
membranes, whereas fluorescein diacetate (FDA) is able to cross intact membranes and 
is a probe for functional esterase enzymes in a cell.  
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Figure 45 Viability stains for flow cytometry; ethidium bromide (67), propidium iodide (68), fluorescein 
diacetate (69), thiazole orange (70) 
 
The membrane permeabilities for the dye compounds are indicated by the ClogP values, 
whereby the more negative the ClogP value, the less able the compound is to traverse 
the membrane. Interrogating each cell with a laser and monitoring the emitted 
fluorescence enables the extent of staining in each cell to be determined and thus allows 
for the viability of the cell to be ascertained.154  
Enzyme based probes that translocate across „healthy,‟ intact membranes are also useful 
probes to ascertain cell viability. Fluoroscein diacetate (FDA) can cross cell membranes 
and then the acetate groups are cleaved by non-specific esterases to yield the green 
fluorescent probe, detected spectroscopically by measuring the emission at 520 nm 
( ex = 488 nm). An FDA viability assay was used by Wanandy et al for the flow 
cytometric determination of MIC‟s of various antibiotics for E. coli, S. aureus and P. 
aeruginosa.155  
Flow cytometric viability assays do not always result in a clear live vs dead result, as 
often the bacterial population contains mixed populations resulting in intermediates 
often described as being in an „unknown‟ metabolic state. A detailed study by Berney 
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and co-workers concluded that different uptake of the SYTO9® nucleic acid stain is due 
to changes in the composition of the outer membrane in response to UV radiation or 
treatment with EDTA.156 Likewise, uptake of SYBR green® nucleic acid stain is higher in 
exponentially growing bacteria than in stationary phase bacteria. We could use the 
differences in membrane permeability to our advantage to determine, in detail, the effect 
of MtrR expression on penicillin resistance.  
At the end of the growth curve monitoring experiment, each microwell culture was 
divided into three aliquots and stained with either 70 or 68 or both (final concentrations 
of 100 g /mL) Three discrete populations could be observed, reflecting dead (68), 
membrane compromised (68 +70), and membrane intact live cells (70). Consistent with a 
protective effect, populations expressing MtrR have a significantly higher proportion of 
undamaged cells with an intact membrane (Figure 46). 
 
Figure 46 Cell viability as determined by flow cytometric assay.Black bars represent cells expressing 
MtrR, white bars represent control (MtrR negative) cells 
 
2.2.11 Subcellular localisation of MtrR 
In order to achieve a protective effect against a -lactam antiobiotic it would be 
necessary for MtrR to be present at the site of -lactam action. This occurs in the 
periplasm and thus requires MtrR to be able to pass through the inner membrane. To 
investigate whether MtrR exists in the periplasm and the cytoplasm, localisation 
experiments were conducted and are described below. 
Methods for extracting periplasmic protein include treatment of cells with lysozyme-
EDTA,157 or chloroform158 and osmotic shock.159 Recent literature shows that the osmotic 
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shock is reliable for the specific extraction of periplasmic protein without damaging the 
cytoplasmic membrane.160,161 This technique involves suspending cells in a hypertonic 
solution containing 20 % sucrose and 1 mM EDTA at 4 oC or room temperature, 
followed by suspension in a hypotonic, aqueous buffer. The induced osmotic pressure 
disrupts the outer membrane causing release of solutes from the periplasmic space. 
Despite the gentle sucrose buffer method, it is possible that during such a procedure the 
cytoplasmic membrane is also damaged causing release of cytoplasmic components. 162 If 
the cytoplasmic membrane is damaged then a cytoplasmic protein such as GroEL could 
be detected by a specific antibody in the sucrose extract fraction and subsequent washes. 
Another source of error during an osmotic shock experiment is the forced translocation 
of protein through mechanosenitive protein channels.163,164 Gentle pipetting and addition 
of Gd3+ salts have been shown to block MscL channels in E. coli.68  
In order to investigate the cellular localisation of MtrR, pET28a KAM3 cells expressing 
MtrR were cultured and the periplasmic protein extracted by suspending the cells in ice 
cold 20 % sucrose solution, in the presence or absence of Gd3+. Following Western 
blotting using an MtrR antibody (Gift from W. M. Shafer, Emory University School of 
Medicine, Atlanta, USA) bands clearly showing the presence of MtrR could be observed 
in the periplasmic extracts. Addition of Gd3+ a known inhibitor of the MscCl channel (a 
mechanosensitive protein translocation mechanism across the inner membrane of E. coli) 
had no effect, indicating that the presence of MtrR in the periplasm is not triggered by 
the stresses arising from mechanical actions during the experiment such as pipetting and  
    
Figure 47 (A) MtrR antibody: Lane 1 Sonicated cells; Lane 2 Osmotic shock + Gd3+; Lane 3 Osmotic shock 
+ Gd3+; Lane 4 Wash + Gd3+; Lane 5 blank; lane 6 MW markers (B) GroEL antibody: Lane 1: Osmotic 
shock + Gd3+; Lane 2 Osmotic shock + Gd3+; Lane 3 Wash + Gd3+; Lane 4 sonicated cells. 
A B 
MtrR 
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centrifugation. Moreover, a second control experiment using an antibody to the 
cytoplasmic GroEL protein failed to reveal any protein in the periplasmic extract 
confirming that the inner membrane remained intact during the sucrose treatment. A 
second control using an antibody for maltose binding protein failed to detect any protein 
in any fraction of the osmotic shock experiment. 
2.3 Summary 
The investigation into how small molecule antibiotics interact with MtrR can be 
summarised as follows: 
1. ITC analysis confirms that tetracycline (11) and spectinomycin (10) are ligands for 
MtrR. 
2. An unexpected binding isotherm was observed for the injection of penicillin G (2) into 
MtrR. 
3. Subsequent analysis of the interaction between MtrR and 2 revealed a catalytic 
process, with kcat = 0.02 s-1 and Km = 107 M. 
3. MtrR is capable of turning over -lactamases with small side chains (ampicillin 31, 
amoxicillin 32, penicillin V 29) but not bulky side chains (nafcillin 33) and very slowly 
with cephalosporins (CENTA). 
4. Labelling studies with clavulanic acid identified three threonine residues, that were 
identified using MALDI and ES+ mass spectroscopic techniques. 
5. Modelling studies showed that the amino acids near the labelled threonines could 
form an active site and were spatially near to H105. Site directed mutatgenesis to 
prepare a H105Y mutant did not reveal any conclusive results. 
6. MtrR was shown to confer a survival advantage to hypersusceptible E. coli cells and 
flow cytometric analysis of the E. coli cells +/- MtrR showed that ~ 60 % of the MtrR 
positive cells had intact membranes, compared to ~ 5 % of the MtrR negative cells 
7. Subcellular localisation studies showed that MtrR could locate in the periplasm 
2.4 Conclusions 
The experiments presented here confirm that MtrR can recognise substrates of the 
MtrCDE efflux pump. The ability of MtrR to act as a -lactamase was a surprising result 
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but ITC, mass spectroscopic and microbiological assays confirmed this secondary 
function. The penicillinase activity may be due to an evolutionary process or a shadow 
of a previous function of MtrR. Further work to investigate this role are detailed in the 
further work section. 
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3 Peptide probes for MtrR  
3.1 Introduction 
This chapter details the work undertaken to identify peptide ligands for MtrR and to 
explore whether ligand binding can induce MtrR to dissociate from the operator region 
DNA for the MtrCDE efflux pump. The peptides synthesised are derived from human 
antimicrobial peptide LL-37, and a summary of the literature on LL-37 is provided first, 
followed by the results of the synthesis of the peptide probes used in this project. Results 
are also presented from the assays designed to investigate the bioactivities of the 
peptides.  
3.2 Antimicrobial peptides as substrates for microbial efflux pumps 
The hypothesis of this thesis is that the transcriptional regulator MtrR recognises 
substrates for the multidrug efflux pump, MtrCDE, and ligand binding to MtrR leads to 
the initiation of pump synthesis. Consequently if the function of MtrR could be 
modulated such that efflux pump synthesis can be permanently turned off or 
permanently tuned on (both states would fatally compromise the viability of the 
gonococcus) then a novel class of antimicrobial compound could be developed. To 
facilitate this long term aim, it is necessary to construct a detailed understanding of how 
MtrR binds substrates for the efflux pump.  
The multidrug efflux pump MtrCDE from N. gonorrhoeae recognises a wide range of 
substrates including antimicrobial peptides (AMPs), as shown in Figure 11.165 AMPs are 
produced by higher level organisms in response to bacterial challenge and are discussed 
in greater detail in section 3.3. Despite forming an ancient defence mechanism, not all 
bacteria have evolved efflux pumps that can extrude AMPs. For example deletion of the 
transport proteins AcrB or MexB from the AcrA TolC (E. coli) or the MexA OprM 
(P. aeruginosa) efflux pump systems respectively has no effect on the MIC value 
indicating that the efflux pumps do not confer a survival advantage to antimicrobial 
peptides. This is in contrast to N. gonorrhoeae, where deletion of the mtrD from the gene 
cassette causes a substantial reduction in MIC for three peptides tested.  
The ability of the MtrCDE efflux pump to export large peptides makes the gonoccocal 
pump unique amongst RND transporters. Assuming that substrates for the efflux pump 
are also substrates for the transcriptional regulator, MtrR, that controls efflux pump 
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synthesis then the translocated peptides should also bind MtrR and the following 
sections discuss research that explores this proposal. 
Table 6 Gram negative efflux pump specificity for antimicrobial peptides from different pathogenic 
organisms.  
Organism Strain MIC Peptide g /mL Reference 
LL-37 (12) PG-1 (71) PC-8 (72) 
E. coli WT 8 ND ND 166 
ΔacrB 8 ND ND 
P. aeruginosa WT 16 ND ND 
ΔoprM 16 ND ND 
N. gonorrhoeae WT 6.25 2.5 100 165 
ΔmtrD 0.75 0.3 25 
 The sequences of the peptides used in Table 7: 
LL-37: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES; PC-8: RGGRLARYARRRFAVAVGR, 
PG-1:  
 Understanding how MtrR binds such large and diverse compounds will expand the 
current level of knowledge regarding substrate binding in TetR type proteins. This 
chapter introduces the concept of antimicrobial peptides and focuses on the human 
cathelicidin LL-37; an important host defence agent against gonococcal infection but also 
a substrate for the MtrCDE system in N. gonorrhoae.  
In the results and discussion sections, evidence will be presented that supports the 
hypothesis that MtrR binds LL-37. Understanding how LL-37 binds the regulator protein 
is gained by adopting a chemical approach: peptide fragments of LL-37 are synthesised 
and tested for protein binding capabilities. Bioactivities of the synthesised peptides are 
determined and peptide fragments with antimicrobial effects are also substrates for the 
MtrCDE pump. The peptide binding site in MtrR is explored by using a photoactivated 
activity based protein profiling technique. Electrophoretic mobility shift assays (EMSA) 
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with LL-37 and derivatives indicate that the peptides do not activate MtrR, raising 
questions concerning the physiological outcome of peptide binding to MtrR.  
 
3.3 Antimicrobial peptides167 
3.3.1 Introduction 
Antimicrobial peptides are host defence peptides that have been detected in a wide 
range of species including amphibians, mammals, bacteria and fungi.168 There are 
currently more than 1300 antimicrobial peptides known169 and these host defence 
peptides are generally cationic, with between 12-100 amino acids and possess a wide 
range of structural motifs.170 Linked to structure is the function of the AMP and an 
equally wide range of bioactivities have been reported, including antibacterial, antiviral 
and antifungal properties. In addition there are an increasing number of reports of the 
immunomodulatory properties of AMP.171 Humans produce two classes of AMP, 
defensins172 and cathelicidins. Whilst humans secrete several peptides from the defensin 
class, only one example of a cathelicidin peptide is produced. This human cathelicidin, 
LL-37, is an important peptide as it not only exerts antimicrobial properties but also 
modulates the immune system and as reported above, the gonococcal efflux pump 
confers resistance to the peptide.  
3.3.2 Cathelicidins 
Cathelicidins are a large family of antimicrobial and immunostimulatory peptides. 173 
Whilst most commonly found in mammalian species recent evidence indicates that these 
proteins are of much older origins with a suggestion that they have evolved from the 
cystatins, ancient cysteine protease inhibitors.174 Cathelicidin peptides are characterised 
not by the structure of the antimicrobial peptide but rather by the form in which they are 
produced and stored within the cell. All members of this family are synthesised as a 
preproprotein, Figure 48, comprising a signal peptide, a highly conserved N-terminal 
prosequence termed the cathelin domain and a highly variable C-terminal peptide 
domain in which the antimicrobial activity is found. This last component, the 
cathelicidin peptide, ranges in size from 12-80 amino acids.175 Mirroring this lack of 
primary structure homology, diverse secondary structures have been found. These can 
be broadly grouped into three classes. The most common are the linear antimicrobial 
peptides with an -helical amphipathic structure, the other groups being i) peptides rich 
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in amino acids such as arginine, tryptophan and proline, and ii) peptides that have  
sheet structures stabilised by disulfide bonds , exemplified by PG-1, a porcine defence 
peptide.176 PG-1 is a 18 residue peptide, rich in arginine, amidated at the C-terminus and 
with disulphide bonds between Cys 6 and Cys 15, and Cys 8 and Cys 13. The disulphide 
linkages hold the natural product in a strict -hairpin shape and NMR studies in 
membrane-like environments have shown that PG-1 monomers dimerise in a head to tail 
fashion leading to the formation of ion conducting pores in membranes that are 
responsible for the antimicrobial action of the peptide.177 PG-1 is considered in more 
detail in Chapter 4. The remainder of this introduction focuses on the human 
cathelicidin LL-37, providing a foundation for the subsequent experimental results. 
 
Figure 48. Sequence of the CAMP gene product Signal peptide (red), Cathelin domain (blue); 
Antimicrobial Peptide LL-37 (green). 
 
Figure 49 A: PG-1; B: LL-37 
 
3.3.3 Human antimicrobial peptide LL-37  
The antibacterial and immunomodulatory properties of LL-37 have been widely studied 
and reviewed elsewhere.178 Rather than provide an exhaustive catalogue of all the 
bioactivities of LL-37, the primary aim of this review is to focus on developments in the 
understanding of how LL-37 acts at a molecular level. The human cathelicidin LL-37 is 
generated from the proprotein form hCAP18 encoded by the CAMP gene.179 Following 
excision of the signal peptide, this proprotein is stored in neutrophil granules and 
epithelial cells until activated through cleavage by the serine protease, proteinase 3.186 
The actual release of LL-37 is proposed to occur at the cell surface as, on stimulation of 
A B 
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the neutrophil, hCAP-18 locates to the plasma membrane potentially through an 
interaction with an hCAP-18 specific receptor.180 In addition to that stored in 
neutrophils, significant quantities of hCAP-18 are found in human plasma as a complex 
with lipoproteins.181 Interestingly, Zaiou has shown that, after cleavage of LL-37, the 
cathelin domain has antimicrobial properties highlighting how evolution has maximised 
the antimicrobial function of hCAP18.182  
As suggested by the name, LL-37 is a 37 residue peptide of sequence, 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES, that adopts an -helical structure 
in lipid membranes, micelles, and ions such as hydrocarbonate, sulphate and to a lesser 
extent chloride, but is a random coil in pure water.183 Although LL-37 is described as the 
sole human cathelicidin, other cleavage sites exist leading to different mature peptides. 
Greatest similarity is seen in ALL-38 found in seminal plasma which contains an 
additional N-terminal alanine residue arising through cleavage from hCAP18 by 
gastricsin at the adjacent site to that used to liberate LL-37.184 Similarly, patients with 
rosacea, a condition associated with an upregulated immune response, have been shown 
to possess high levels of FA29, an N terminal fragment of LL-37, as a result of hCAP18 
being processed by Stratum corneum tryptic enzyme.185 Conversely, a number of shorter 
peptides, derived from LL-37 including 102, 114, 120 and 121 are found in human sweat 
and skin cells.186 These arise through processing of either hCAP18 or LL-37 by serine 
proteases in the skin and provide enhanced antimicrobial activity when compared with 
full length LL-37. This enhanced ability to provide a protective barrier against bacteria 
etc is accompanied by a reduced immunological function and suggests that this post-
translational processing is part of the innate regulation of the multiple functions of 
LL-37. 
3.3.4 Bioactivity 
LL-37 has been shown to have a multitude of roles in the body. Originally identified for 
its antibacterial effects LL-37 also has other antimicrobial properties including antifungal 
and antiviral activities and the inhibition of biofilm formation.187 It has also been 
associated with modulation of the expression profiles of elements of the immune system, 
regulation of the inflammatory response, stimulation of wound healing, chemotaxis, 
apoptosis, angiogenesis and cancer tumourgenesis.188,198 Many of these 
immunomodulatory functions appear to occur at concentrations below the levels 
required for antimicrobial activities suggesting that the immune response may arise 
83 
 
from interactions with more specific receptor proteins and have led to LL-37 being 
labelled an “alarmin”.189 Reflecting this spectrum of activity, hCAP18 is constitutively 
expressed in range of inflammatory and epithelial cells particularly in parts of the body 
exposed to the outside environment, including the airway, gut and urinary tract and also 
in the circulatory system.190,191 There is tight regulation of in vivo levels of LL-37 through 
a complex network of signalling pathways. This is important because failure to produce 
microcidal concentrations of the antimicrobial peptide can result in increased 
susceptibility to pathogens,192,193 whereas over-production of LL-37 can lead to 
inflammatory disorders such as the skin diseases of psoriasis and atopic dermatitis.194A 
large number of external stimuli of LL-37 expression or release have been reported, for 
example, the presence of bacterial metabolites butyrate and lithocholic acid (LCA) leads 
to enhanced gene expression. Butyrate enhances histone acylation at the cathelicidin 
promoter site thus enabling AP.1 (activator protein 1) to bind to the cathelicidin 
promoter augmenting gene expression,195 whereas LCA binds nuclear receptors that 
causing recruitment of the transcriptional factor PU.1, which is key to CAMP gene 
transcription.196 Similarly, the yeast strain Malassezia sympodialis and bacterial products 
such as LPS and LTA also enhance LL-37 levels.197 However, this is primarily due to the 
foreign lipids activating TLR-like receptors on macrophages, monocytes, and 
neutrophils, which then release prototypic proinflammatory cytokines, e.g., IL-1, IL-6 
and TNF   that trigger release of LL-37 to the extracellular milleu.198 Conversely, levels 
of LL-37 can be lowered either through the simple action of bacterial proteases or 
through more complex, and as yet not well understood, interference in the expression of 
hCAP-18 expression including a self-regulation pathway.199 Importantly, proteolytic 
degradation appears to be one way in which the physiological role of LL-37 is regulated 
in a location-specific fashion. Notably there are a number of truncated forms of LL-37 
found in the skin samples which exhibit reduced immunomodulatory function but 
retain an antimicrobial effect. Interestingly, both LL-37 and 184, an LL-37 fragment, 
isolated from psoriatic skin, induce IL-8 release and hence a pro-inflammatory response, 
suggesting that, in homeostasis, proteases are utilised to prevent an erroneous immune 
response to enhanced secretion of LL-37.200 
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Figure 50 Helical wheel diagram for LL-37 showing the region 12-29 as an amphipathic helix (constructed 
using http://www-nmr.cabm.rutgers.edu/bioinformatics/Proteomic_tools/Helical_wheel.) N- (residues 1-
11) and C- (residues 30-37) termini residues are unstructured. 
3.3.5 Structure  
As can be seen from a classical helical projection, Figure 2 LL-37, is a classical 
amphiphilic -helical peptide. Whilst, at low concentrations (< 10-5 M) it is a largely 
unfolded monomeric peptide, at higher concentrations it adopts an -helical oligomeric 
structure. This switch can simply be attributed to the hydrophobic effect involving 
shielding of the hydrophobic face from the bulk medium. The enhanced -helical 
content observed for LL-37 in salt media, particularly that correlating to physiological 
conditions, is a further reflection of this phenomenon.182 Reflecting the diverse and 
important functions of LL-37, there has been considerable effort to understand how 
these functions are related to peptide sequence and structures. One challenge to this has 
been to access sufficient quantities of the peptide. Historically these have been obtained 
from clinical isolates or through chemical synthesis. Recently, various ingenious 
biotechnological solutions have been developed.201 Whilst most of these recombinant 
proteins are produced bearing residual residues derived from the cleavage domain, 
Ramamoorthy has described a GST fusion construct that affords the unmodified peptide 
albeit with relatively low levels of cleavage efficiency. 
At the simplest level, the structure of LL-37 can be divided into three portions with each 
section having specific characteristics. The N-terminal unit is a relatively disordered 
non-polar / hydrophobic section; the central bulk of the peptide is -helical, stabilised 
by a set of ion-pairs spaced n /n+3, whilst the C-terminal end is best described as a short 
hydrophilic tail unit. Recent NMR studies of LL-37 in micelles support this view but 
reveal that there is some flexibility within this central helical core according to the nature 
of the membrane. In DPC a helix-break-helix motif was found, whereas in SDS and 
D8PG the structure is better described as a bent helix.202,203 Significantly this „bend‟ 
region of discontinuity corresponds to area of high glycine content in related primate 
orthologs.204 This increased flexibility may relate to the change in role between relatively 
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unstructured (in solution) congeners which are primarily antimicrobial in activity to the 
more constrained and aggregated LL-37 in humans which has enhanced 
immunomodulatory function.205 
The multifunctional roles of LL-37 in vivo has led to intense research into understanding 
the function of the peptide in terms of physio-chemical properties, for example 
helicity, charge, hydrophobicity and hydrophilicity. Attempts to modulate these 
properties in order to separate and modulate the antimicrobial and immunomodulatory 
/ inflammatory responses have led to the generation of a large number of truncated 
sequences involving both native as well as modified sequences. These peptide 
derivatives of LL-37 are summarised in Table 7. The correlation between helicity and 
antimicrobial activity has been reinforced by a number of studies. For example, N- 
terminal peptide 98, which has a low calculated-helicity of 0.57, has little or no 
antibacterial activity, whereas the LL-37 central 100 and C-terminal fragment 96, which 
have helicity values of 8.32 and 5.51 respectively, retains significant antimicrobial 
activity. Significantly only fragments 119 and 120, which most closely resemble LL-37, 
showed consistently high activity against a range of micro-organisms and retain this 
activity at high salt concentrations or in the presence of human serum.206 The designed 
LL-37 analogue 148 has a calculated helicity eight times greater than that of the natural 
product (148 = 44.4; 12 = 5.08) and also exhibits a potent bioactive profile. However, this 
correlation is not universal as peptides 111 and 112 that have helicities of 0.96 and 0.83 
respectively, are more antibacterial than LL-37 towards E. coli and MRSA. The high 
activity is likely to be due to the charge of the peptides (+6 for 111 and +7 for 112). The 
presence of the two phenylalanine residues exposed at the N-terminus of 111 accounts 
for the 2 fold increase in anti-E.coli activity relative to 112 as aromatic amino acids are 
known to aid peptide insertion into the bilayer.207,208 
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ID Sequence Ha %b +c C d Rel. Bioactivitye Ref 
      LPSf AMg CYTh  
12 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.6 54 6 5.08 1 1 1 221 
73     LLGDFFRKSKEKIGKEFKRIVQ 0.7 55 4 0.99 < 0.1 NDj ND 221 
74       LGDFFRKSKEKIGKEFKRIVQR 0.9 59 5 1.01 < 0.1 ND ND 221 
75          GDFFRKSKEKIGKEFKRIVQRI 0.9 59 5 0.8 < 0.1 ND ND 221 
76             DFFRKSKEKIGKEFKRIVQRIK 1 64 6 0.8 < 0.1 ND ND 221 
77                FFRKSKEKIGKEFKRIVQRIKD 1 64 6 1.23 < 0.1 ND ND 221 
78                  FRKSKEKIGKEFKRIVQRIKDF 1 64 6 1.91 < 0.1 ND ND 221 
79                    RKSKEKIGKEFKRIVQRIKDFL 1 64 6 2.9 < 0.1 ND ND 221 
80                       KSKEKIGKEFKRIVQRIKDFLR 1 64 6 3.81 < 0.1 ND ND 221 
81     SKEKIGKEFKRIVQRIKDFLRN 0.9 64 5 5.6 <0.1 ND ND 221 
82         KEKIGKEFKRIVQRIKDFLRNL 0.8 59 5 7.98 < 0.1 ND ND 221 
83            EKIGKEFKRIVQRIKDFLRNV 0.6 55 4 8.01 < 0.1 ND ND 221 
84                 KIGKEFKRIVQRIKDFLRNVP 0.5 50 5 11.37 0.25 ND ND 221 
85                     IGKEFKRIVQRIKDFLRNVPR 0.5 50 5 10.99 0.2  ND ND 221 
86                        GKEFKRIVQRIKDFLRNVPRT 0.5 50 5 7.44 0.16 ND ND 221 
87                             KEFKRIVQRIKDFLRNVPRTE 0.7 55 4 5.37 0.2 ND ND 221 
88                                  EFKRIVQRIKDFLRNVPRTES 0.6 55 3 3.89 < 0.1 ND ND 221 
89                        KIGKEFKRIVQRIKDFLRNLVPRTE 0.6 52 5 7.45 0.5 ND ND 221 
90                       KIGKEFKRIVQRIKDFLRNLVPRT 0.5 50 6 7.57 0.37 ND ND 221 
91                            IGKEFKRIVQRIKDFLRNLVPRTE 0.5 50 4  0.6 ND ND 221 
92                      KIGKEFKRIVQRIKDFLRNLVPR 0.6 52 6 7.58 0.34 ND ND 221 
93                           IGKEFKRIVQRIKDFLRNLVPRT 0.4 48 5 7.26 0.37 ND ND 221 
94                               GKEFKRIVQRIKDFLRNLVPRTE 0.6 52 4 5.41 0.41 ND ND 206 
95       LLGDFFRKSKEKIGKEFKRIV 0.7 52 5 0.94 ND 0.75  209 
96                            GKEFKRIVQRIKDFLRNLVPR 0.6 52 6 5.51 ND 1.5  210 
97                                           FKRIVQRIKDFLRNLVPRTES 0.4 52 5 3.37 ND 1  210 
98       LLGDFFRKSKEK 0.8 58 2 0.57 NEk NE NE 210 
99                                   IGKEFKRIVQRIKDFLRNLVPRTES 0.5 52 4 6.96 ND 0.5 NS 210 
100                                   FKRIVQRIKDFLRNLV† 0.2 50 5 8.32 ND 2  210 
101                           FKRIVQRIKDFLR† 0.5 54 5 4.29 ND 1  210 
102       LLGDFFRKSKEKIGKEFKRIVQR 0.8 57 6  ND < 0.1  212 
103                                             KRIVQRIKDFLRNLVPRTES 0.6 55 4 3.14 ND < 0.1   212 
104    SKEKIGKEFKRIVQRIKDFLR 0.9 62 5 2.75 ND 0.1   212 
105                         KRIVQRIKDFLR 0.7 58 4 0.79 ND < 0.1   212 
106                          KEFKRIVQRIKDFLRNLV 0.5 56 5 3.11 ND 1.2l NS 214 
107        GDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.8 57 6 6.08 2.86 0.3  214 
108      LLGDFFRKSKEKIGKEFKRIVQRIK                                  0.7 56 6 1.3 ND 4 NSm 214 
109      LLGDFFRKSKEKIGKEFKRI                         0.8 55 4 0.98 ND NE NS 207 
110      LLGDFFRKSKEKIGKE 0.9 56 2 1.01 ND NE NS 207 
111           GDFFRKSKEKIGKEFKRIVQRIK 1 61 6 0.96 ND 4 NS 207 
112               RKSKEKIGKEFKRIVQRIK 1.3 68 7 0.84 ND 2 NS 207 
113                        EKIGKEFKRIVQRIKDFLRN 0.8 60 4 3.67 ND 2 NS 207 
114                                      KRIVQRIKDFLRNLVPRTES 0.6 55 4 3.14 ND NE NS 207 
115                                            VQRIKDFLRNLVPRTES 0.4 53 2 0.52 ND NE NS 207 
116                            EKIGKEFKRIVQRIK 1 60 4 0.79 ND > 2 NS 207 
117          GKEFKRIVQRIKDFLRN 0.7 59 4 2.57 ND 2 NS 207 
118               EFKRIVQRIKDFLRN 0.6 60 3 1.65 ND  > 2 NS 207 
119               RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.9 61 7 6.61 ND 8   207 
120                 KSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.9 60 6 6.79 ND 8 NS 207 
121                                   EFKRIVQRIKDFLRNLV 0.4 53 3 2.62 ND < 0.1  211 
122            FRKSKEKIGKEFKRIVQRIKDFLRNLV 0.7 59 7 4.67 ND ND NS 211 
123                        KIGKEFKRIVQRIKDFLRNLVPRTES 0.6 54 5 7.28 ND ND NS 211 
124 LLGDFFRKSKEKIGKEFKRIVQRIKDFL 0.6 54 5 2.27 1 ND ND 212 
125 LLGDFFRKSKEKIGKEFKRIVQRIK 0.7 56 6 1.3 1 ND ND 212 
126 LLGDFFRKSKEKIGKEFKR 0.9 58 4 1.00 4.5 ND ND 212 
127          RKSKEKIGKEFKRIVQRIKDFLRNL 1 64 7 4.75 1 ND ND 212 
128          RKSKEKIGKEFKRIVQRIK 1.3 68 7 0.84 3.5 ND ND 212 
129                          IGKEFKRIVQRIKDFLRNLVPRTES 0.5 52 4 6.96 0.9 ND ND 212 
130                          IGKEFKRIVQRIKDFLRNL 0.5 53 4 5.18 1 ND ND 212 
131                          IGKEFKRIVQRIK 0.7 54 4 0.82 4 ND ND 212 
132                                        RIVQRIKDFLRNLVPRTES 0.5 53 3 2.39 ND ND ND 212 
133 NLVPRTES 0.4 50 0 0 ND NS ND 212 
134 KRIVQRIKDFL 0.5 50 1 0 ND <0.1 ND 185 
135 IVQRIKDFLR 0.3 50 2 0.34 ND NS ND 185 
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136 LLGDRRF 0.4 43 1 0.01 ND NS ND 185 
137 NLVPR 0 40 1 0 ND NS ND 185 
138 RKSKEKIGKEF 1 40 0 0.11 ND NS ND 185 
139 KRIVQRIKDF 0.8 60 3 0.31 ND <0.1 ND 185 
140 RIVQRIKDFL 0.3 50 2 NCn ND <0.1 ND 185 
141 LLGDFFRKSKEKIGKEF 0.8 3 60 0.99 ND NS ND 185 
142 LLGDFF -0.9 -1 17 0 ND NS ND 185 
143 LRNLVPRTES 0.4 1 50 0 ND NS ND 185 
144 LLGDF -0.6 -1 20 0 ND NS ND 185 
145 IGKEFKRIVQRIKDFLRNLVRPLR 0.5 50 6 10.55 0.27 ND ND  221 
146 IGKEFERIVQRIKDFLRNLVPRTE 0.5 50 2 6.49 0.16 ND ND 221 
147 IGKEFKRIVERIKDFLRNLVRPLR 0.6 50 3   0.27 ND ND 221 
148 IGKEFKRIVERIKRFLRELVRPLR 0.7 50 6 44.49 0.52 1.5 ND 221 
149 IGKEFKRIVERIKRFLRELVPRTES 0.8 50 4 43.23 0.17 ND ND 221 
150 IGKLFKRIVQRIKDFLRNLVPRTES 0.3 48 5 2.7 0.2 ND ND 221 
151 IGKEFKRIVQLIKDFLRNLVPRTES 0.3 48 3 8.07 0.22 ND ND 221 
152  IGKLFKRIVQLIKDFLRNLVPRTES 0.1 44 4 5.08 0.35 ND ND 221 
153 IGKEFKRIVERIKDFLRELVPRTES 0.8 52 2 20.23 0.15 ND ND 221 
154 LLGDFKRIVQRIKDF 0.3 47 3 0.37 0.16 0.25 NE 210 
155                                 GFKRIVQRIKDFLRNLV  ND ND ND ND ND 2 NE 210 
156 FKRIVQRIKDFLRNLV 0.2 50 5  ND 1  210 
157                                      RLFDKIRQVIRKF 0.5 54 4 2.08 ND <0.1 ND 211 
158                                      KRIVQRIKDFLR 0.7 58 4 0.79 ND <0.1 ND 211 
159                                 GFKRIVQRIKDFLRNLV 0.2 47 4 2.85 ND 0.5o  210 
160                                 GFKRIVQRIKDFLRNLV 0.2 47 4  ND ND NE o  210 
161                                 GFKRIVQRIKDFLRNLV 0.2 47 4  ND ND NE o  210 
162                            GIKEFKRIVQRIKDFLRNLV 0.4 50 4 5.16 ND 0.75 o  210 
163                            GIKEXKRIVQRIKDFLRNLV  ND  ND  ND ND ND NE o  210 
164                           GIKEWKRIVQRIKDFLRNLV 0.3 50 4 6.63 ND 0.2 o  210 
165                           GIKQFKRIVQRIKDFLRNLV 0.2 50 5 3.18 ND 0.56 o  210 
166                           GIKEFKREFQRIKDFLRNLV 0.6 55 3 6.26 ND 1 o  210 
167                               KLFKRIVQRILDFLRNLV 0 44 5 7.74 ND 0.75  217 
168                               KEFKRIVKRIKKFLRKLV 0.8 56 9 1.13 ND 2 NS 217 
169                                KLFKRIVKRILKFLRKLV 0.3 44 8 3.77  0.5  217 
170 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES  NC NC NC ND ND ND ND 212 
171            FRKSKEKIGKLFKRIVQRILDFLRNLV 0.4 52 7 10 ND ND  211 
172            FRKSKEKIGKFFKRIVQRIFDFLRNLV 0.3 52 7 1.22 ND ND NS 211 
173 LLGNFFRKSKQKIGKQFKRIVQRIKNFLRNLVPRTQS 0.2 54 11 2.9 ND 2.3p ND 218 
174 RKKW KRIVQRIKDFLRNLVPRTES 0.7 58 7 3.79 ND 2.5q ND 219 
175 RKTPFWKRIVQRIKDFLRNLVPRTES 0.4 50 6 6.64 ND 2.5q ND 219 
176 GSLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.6 54 6 5.7 ND 1 ND  
177 PLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.6 53 6 5.6 ND 1 ND  
178 ALLGDFFKSKEKIGKEFRIVQRIKDFLRNLVPRTES 0.6 53 6 5.7 ND 1 ND  
179 EFRIVQRIKDFLRNLV NC NC NC NC ND < 0.1  220 
180 EWRWVQRWKDWLRNLV 0.1 53 3 NC ND 0.25 NS 220 
181 Ac- EFRIVQRIKDFLRNLV 0.5 52 2 ND ND 0.25  220 
182 Ac- EFRIVQRIKDFLRNLV NC NC NC NC ND < 0.1  220 
183 Ac- EWRWVQRWKDWLRNLV 0.2 53 2 NC ND 0.25  220 
184 FALLGDFFKSKEKIGKEFRIVQRIKDF 0.4 48 3 1.11  ND ND ND 186 
185 DISCDKDNKRFALLGDFFRKSKEKIGK 0.9 59 3 2.08 ND ND ND 186 
186 DISCDKDNKRFALLGDFFRKSKEKIGKE 1 61 2 2.11 ND ND ND 186 
187 ALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTE 0.6 51 6 5.85 ND ND ND 228 
188 LLGDFFRKSKEKIGKEFKRIVQRIKDWLRNLVPRTES 0.6 54 6 ND ND NS ND 228 
 
Table 7: LL-37 analogues and derivatives. Bold and underlined indicate non-native amino acids, bold 
italic indicates D-amino acid, a = hydrophilicity, b = % hydrophobic, + = charge, C  = calculated -
helicity, rel. Bioactivity = activity of peptide relative to LL-37 
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The overall structure of the peptide is a key contributing factor to the bioactive profile of 
LL-37 and its derivatives. By using NMR techniques to identify disordered regions on 
binding of peptides to micelles it is possible to show that the predominance of 
hydrophobic residues in the N-terminal region and the hydrophilic amino acids at the C-
terminus make terminal sections of LL-37 unstructured in lipid micelles and therefore 
not essential for antibacterial activity.213,214 Wang was able to use this approach to 
identify a „core‟ antibacterial peptide from LL-37, 100. This showed MIC values against 
E.coli K12 of 20 M (cf 12 40 M). This highly active is found in many of the degradation 
products of LL-37 (e.g. 119, 120, 109) notably those detected in human skin and excreted 
in sweat, that show higher antimicrobial activity than LL-37 but with lower immuno-
stimulatory properties suggesting that this is one way in which the activity of LL-37 may 
be regulated in vivo.215  
Further reduction in size of this „core‟ region led to the smallest -helical fragment of LL-
37, 105 to retain antimicrobial effects (40 M vs E.coli K12). Curiously, whilst 105 has 
reduced host cell toxicity when compared with the one residue longer „analogue‟ 101, 
further reduction in size to 133, 134 and 138 lead to almost complete loss of antimicrobial 
activity.205 As suggested by these observations, the location and specific nature of the 
amino acids in the central region of LL-37 appears crucial for the function of the peptide. 
For example, whilst fragment 100 has increased antimicrobial activity compared to LL-
37, it also has significant cytoxicity compared to 101. This is rationalised by the presence 
of hydrophobic residues at the C-terminus that enable the peptide to insert more easily 
into membranes than analogue 101.216 Nagoaka has demonstrated that incorporating Leu 
at positions 16 and 25 gives the peptide 167 maximum amphiphacity (average 
hydrophilicity = 0).217 Further modification to the core sequence to give peptide 169, 
incorporating Lys in place of Asp-26, Gln-22 and Asn-30 increased the cationicity and 
hydrophilicity whilst maintaining the ratio of hydrophilic: hydrophobic residues. These 
alterations led to an even more effective antimicrobial peptide that killed 100% of MRSA 
at 0.1 µM. For comparison, at the same concentration, peptide 106 and LL-37 1 achieved 
50% and 30% cell-death respectively.217 The antibacterial effects of analogue 173, where 
acidic side chain are replaced by amides, is not reduced by the presence of plasma 
protein apolipoprotein I indicating that charge, as well as the previously discussed 
hydrophilic effects, are important in minimising inhibition of the natural product. 218 
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Other reports have described peptides that combine elements of the core region with 
designed peptide motifs. Whilst a combination of the core region with a short LL-37 N 
terminal sequence led to an inactive peptide coupling of a synthetic antifungal 
hexapeptide with the C terminal fragment of LL-37 (148) provided a conjugate with 
activity greater than the equivalent length LL-37 fragment 91. Although the greater 
degree of helicity induced by this modified N-terminus could be responsible for the 
increase in activity, a better correlation was observed for net charge and 
hydrophobicity.219 
In addition to the cell lytic activity, LL-37 has proven to be effective in binding to and 
thus neutralising LPS and consequently has considerable potential in the treatment of 
endotoxic shock and sepsis associated with bacterial infections. In order to seek a viable 
therapeutic agent, there have been a number of attempts to dissect this activity from 
both the immuno-stimulatory role and general host cell toxicity of LL-37. 220 A common 
strategy involves initial removal of the N-terminal sequence, which is believed to 
contribute most to the immuno-regulatory function, and then a selective modification of 
the central core. Consistent with such a suggestion, Nell and co-workers found that the 
N-terminal region (1-12) was not essential for LPS binding, as demonstrated by peptide 
91, whereas removing C-terminal residues (30-37) significantly decreased LPS binding, 
for example peptides 73 to 83. Further analysis reveals that a hydrophilicity value of 0.5 
and minimum charge of +4 favours LPS binding (peptides 89, 91, 94).221  
Incorporation of D-amino acids in the peptide can also impact on the function of the 
natural product. Whilst the enantiomeric peptide 170 retains much of the activity of 
L-LL-37 in stimulating the immune system, suggesting that overall shape, if not helical 
sense, is important to activity,209 the selective incorporation of D amino acids into the 
sequence drastically reduced toxicity towards human cells whilst retaining antimicrobial 
activity.212 Structural analysis revealed that, although the introduction of these 
enantiomeric amino acids maintained an amphipathic structure with an equivalent 
number of charged side chains on the hydrophilic face, the hydrophobic surface of the 
peptide was significantly disrupted. This is likely to arise from the D-amino acids 
distorting the alignment of the peptide backbone causing hydrophobic defects in the 
amphipathic structure of the peptide. 
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Analysing the bioactivity profiles of LL-37 and its 118 derivatives in terms of these 
physio-chemical properties not only aids the design and synthesis of new therapeutic 
agents but also provides insights into the molecular mode of action of the natural 
product. Although immunological function can be limked to hydrophobicity and 
antimicrobial activity to charge and helicity there is still considerable difficulty in 
predicting a bioactive peptide with minimal unwanted side effects. Only 15 (3 analogues 
and 12 native fragments) of the reported 118 derivatives have an antimicrobial activity 
higher than the parent natural product. 
 
3.3.6 Molecular mode of action of LL-37 
 The previous section highlighted the effect of amino acid substitutions in, and 
truncations to, the sequence of LL-37 on the observed bioactivity of the peptide. This 
section will focus on the origins of these effects of LL-37 and various derivatives. In the 
simplest classification, the biological profile of LL-37 can be dissected into three groups 
reflecting how LL-37 interacts with membranes; with cellular proteins and with DNA. 
LL-37 is a fascinating diversion from most -helical AMPs because it does not exhibit 
high species specificity with in vitro experiments revealing binding to both microbial 
and mammalian membranes.222,223 In general, antimicrobial peptides have evolved to 
target bacterial rather than mammalian cells due to a fundamental difference in the 
composition of the cell membrane. 224,225  The outer surface of Gram negative bacteria is 
covered in lipopolysaccharides, and Gram positive bacteria present a surface of teichoic 
acids resulting in both classes of bacteria having negatively charged cell surfaces. In 
contrast, most mammalian cell membranes have an outer leaflet comprised of 
zwitterionic phosphotidylcholine (PC) and sphingomyelin phospholipids (SM), whilst 
the inner leaflet is composed of phosphotidylserine (PS) leading to an essentially neutral 
surface. The negative charge associated with bacterial cells means that cationic AMP‟s 
are primarily attracted to the pathogenic membrane rather than that of mammalian cells. 
Consistent with such a model, NMR, epifluorescence and impedance spectroscopic 
studies revealed that LL-37 readily inserts in monolayers derived from anionic DPPG or 
Lipid A whereas little penetration occurred into zwitterionic mono-layers derived from 
DPPC or DOPC.226 One notable exception is human erythrocytes which contain 
negatively charged sialic acid units on external gylcoproteins rendering these cells are 
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vulnerable to lysis by cationic peptides and thus accounting, in part, for the observed 
cytotoxicity of LL-37 derived peptides, e.g. 100, 101 However, in vivo host cell 
cytotoxicity of LL-37 is minimised for two reasons. Firstly, the high concentration of 
sterols, notably cholesterol and spingomyelin, in the outer leaflet of mammalian cell 
membranes decreases the ability for LL-37 to insert into the lipid bilayer227 and, 
secondly, because serum and apolipoprotein-1 binds the antimicrobial peptide with 
Kd = 0.6-2.4 M effectively reducing the concentration of free peptide.,228,229  
Three general mechanisms have been proposed for how antimicrobial peptides such as 
LL-37 disrupt membranes and hence exert their antimicrobial effects. These are the 
barrel-stave model, the carpet model and toroidal mechanism (Figure 51).230 The barrel-
stave model requires that membrane bound peptides recognise each other, oligomerise 
forming structured transmembrane pores through the membrane through which 
essential cellular components can escape. Alternatively, in the „carpet model‟, peptides 
coat the phospholipid membrane surface until a threshold concentration is reached 
when the peptide either permeates the membrane in a detergent like manner or leads to 
the formation of toroidal holes. In the former, the peptides bind parallel to the 
membrane surface such that the positively charged amino acids of the peptide can 
maintain constant contact with the membrane. At this threshold concentration the 
peptide exerts disruptive forces on the membrane leading to curvature in the membrane 
lamellae, causing defects and ultimately disintegration of the lipid bilayer. The toroidal-
pore mechanism follows a similar initial pathway also involving curvature of the 
membrane. In this case, self-association of the membrane associated peptides leads to the 
formation of toroidal (doughnut like) holes in the membrane.231 
For LL-37 the carpet model appears to be more plausible. Recent studies suggest that on 
binding to a lipid surface the peptide adopts a helical conformation with a parallel 
alignment to the membrane surface.232 NMR studies have demonstrated that, whilst the 
peptide can diffuse into the bilayer such that the hydrophobic face of the helix interacts 
with the hydrophobic interior, the orientation to the surface is maintained. Moreover, 
LL-37 does not re-orientate even under conditions that might favour the adoption of the 
aggregates need for a transmembrane spanning mode.233 In addition, LL-37 is suggested 
to associate to membranes in an oligomeric state in which the (relatively unstructured 
and non-helical) N-terminal amino acids form hydrophobic bundles which facilitate the 
insertion into the bilayer.234  
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Figure 51 Postulated mechanisms for insertion of LL-37 into membranes. Peptides adsorb to the 
membrane as either monomers or aggregates (A). Barrel stave mechanism: Peptides insert perpendicular 
to the bilayer forming a large cylinderical pore lined with peptide oligomers (B). Carpet mechanism: 
Peptides coat the membrane surface until a critical concentration when either the membrane is disrupted 
in a detergent like manner (C) or binding to the phospolipid headgroups induces such a high degree of 
membrane curvature that toroidal pores are formed (D) 
 
Consistent with this, the formation of amyloid-type structures has been observed during 
the interaction of peptide 179 with a lipid bilayer surface.224 
Distinguishing between the toroidal-pore and detergent models has proved to be more 
difficult and appears to be highly dependent on the exact nature of the membrane lipids. 
For example in DPC micelles NMR studies revealed that, whilst LL-37 induces 
significant membrane curvature consistent with the peptide maintaining contact with 
the lipid headgroup as the membrane opens, no evidence could be foundfor the 
destruction of the membrane into small fragments indicating a non-pore mechanism. In 
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contrast, in the case of the fungal membrane found in Candida albicans, LL37 induced 
rapid phase separation and ultimately disintegration of membrane into discrete vesicles 
resulting in the formation of large pores or channels in the cytoplasmic membrane that 
allow molecules <40 kDa to diffuse out of the cell. 
3.3.7 Interactions of LL-37 with mammalian cellular proteins 
As discussed above, although LL-37 can cause significant and selective disruption of 
microbial membranes, it is also able to interact with the mammalian cell membrane and 
stimulate a wide range of cell receptors and transcriptional factors. Significantly, it is 
through stimulating such targets that the human natural product exerts its 
immunomodulatory effects.239 For example, DNA array analysis reveals that LL-37 
stimulation caused differential expression of over 450 genes in a complex network of 
signalling pathways.241 However, despite the wide range of responses caused, there is 
still surprisingly little known of the precise molecular basis for these responses and a 
number of potential pathways have been proposed.235  
The simplest models are those most closely related to the antimicrobial mode of action 
and rely on the disruption of the lipid bilayer to modulate the function of a membrane 
bound receptor proteins. Either, AMP binding triggers a chain of events leading to the 
displacement of a signalling molecule which then activates its cognate receptor or 
insertion of the AMP into the lipid structure triggers an allosteric change to the receptor 
structure thus modifying the activity. Evidence for both possibilities have been 
described. The transactivation of the epidermal growth factor receptor (EGFR) is a key 
component in the wound healing activity of LL-37 and transactivation of this receptor is 
an example of the first mode of function.236,237,238 In this, insertion of LL-37 into the 
membrane activates a metalloprotease on the cell membrane. This results in the cleavage 
of the extracellular domain of the membrane bound heparin binding EGF family. The 
resultant soluble growth factor can locate, bind to and initiate phosphorylation of EGFR, 
thus activating signalling pathways which ultimately leads to enhanced keratinocyte 
migration to the wound site and cell proliferation respectively.239,240 Importantly, EFGR 
is upregulated in cancer cells and so stimulation of this receptor by LL-37 can lead to 
cancer cell proliferation.241 In a related model, it has been proposed that insertion of the 
peptide into the membrane increases membrane fluidity resulting in leakage of 
intra cellular signalling components.242, For example, insertion of LL-37 into the 
membrane has been suggested to result in the release of ATP and Ca2+ that can then 
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stimulate the P2X7 receptor, an ATP activated ion channel having an important role in 
inflammation.243,244 However, other studies have shown that the effect of exogenous ATP 
but not LL-37 on P2X7 can be inhibited suggesting that LL-37 has a more direct 
interaction.245 This alternative mode of activation, relying on a direct allosteric effect 
triggered by insertion of LL-37 deep into the membrane bilayer has also been proposed 
to be key to the downregulation of the TLR4 dependent inflammatory response. 
Surprisingly, such membrane perturbations must be quite specific as unlike P2X7 and 
TLR4 the related P2Y and TLR2 receptors are not sensitive to LL-37.246  
In a more classical small molecule receptor interaction model, it has been suggested that 
LL-37 can function as an alternative ligand for certain receptor proteins. In particular, 
this mechanism has been proposed for the interaction of LL-37 with the G protein 
coupled receptor FPRL-1 leading to direct initiation of a signalling cascade, which is 
currently of interest in cancer research.247 In support of this, recent inhibitor studies, 
using simple hydrophobic peptides, WRWWW and WYMV, revealed evidence for direct 
interaction of LL-37 with FPRL1.248 The former peptide successfully inhibits LL-37 
induced kinase induction in fibroblasts.249 Furthermore F2L (Ac-MLGMIKNSLFGSV-
ETWPWQVL; average hydrophilicty = - 0.7, % hydrophilicity = 29 %) inhibits LL-37 
induced chemotactic migration in human vascular epithelial cells suggesting the 
peptides occupy similar binding sites.250 
The final model proposed for LL-37 induced action is an indirect process arising from 
scavenging of other signalling molecules of either host or external origin. For example, 
LL-37 is effective at negating excessive inflammation in wounds as part of the immune 
response by binding bacterial products such as lipopolysaccharide and lipoteichoic acid 
thus preventing activation of the Toll Like Receptors (TLRs). The positive charge 
associated with LL-37 enables the peptide to bind LPS/LTA preventing the bacterial 
saccharides from binding to lipopolysaccharide binding proteins or its receptor. In 
support of this idea, complex formation between the LL-37 and bacterial product can be 
enhanced by truncation of both the N and C termini to produce peptide 79, which has a 
greater positive charge. 251 
More detailed mechanisms at the molecular level for the action of LL-37 are still a matter 
for debate and, as indicated above, remain very much target protein / system specific. In 
all these models, as with antimicrobial activity, it appears likely that it is the -helical 
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and hydrophobic nature of LL-37 that is key. In support of this, analogues which retain 
similar helicity, although not necessarily helical sense e.g. enantiomeric (all D, 101) LL-
37, exhibit similar effects whilst relatively unstructured orthologues do not.84 Such 
concepts are more challenging for the receptor binding model and one suggestion that 
accounts for the hydrophobicity and -helicity of LL-37 and the all D-amino acid 
analogue is that the cell receptors contain a „promiscuous‟ binding domain or 
hydrophobic binding groove that recognises lower order structural features of a 
ligand.252253These structural features are exploited in the design of high affinity, 
engineered small protein ligands for LL-37 responsive receptors.254,255,256 These results are 
consistent with the concept of LL-37 acting as hydrophobic signalling molecule as part of 
an ancient response mechanism.  
3.3.8 Interactions with DNA 
As discussued above, LL-37 achieves membrane selectivity through preferential binding 
to the negatively charged microbial membrane lipids. The other common negatively 
charged biomolecules are nucleic acids and although the association of LL-37 with DNA 
is a relatively unexplored area but there is growing evidence that these interactions can 
influence both transport, immunomodulatory and antimicrobial effects.257 For example, 
psoriasis is an autoimmune disease characterised by an upregulation in the production 
of LL-37 and an overactive immune response. Lande has rationalised these observations 
by showing that, through binding to LL-37, self-DNA can form condensed aggregates 
capable of translocation to plasmacytoid dendritic cells where they stimulate interferon 
production through interactions with the toll like receptor (TLR9). 258 Whilst electrostatic 
attraction is likely to be a key factor, structure remains important as a scrambled 
analogue GL-37 was not able to bind the DNA.  
Similarly through binding to LL-37 plasmid DNA a similar binding of LL-37 to DNA 
(and F-actin) is associated with increased severity of microbial infection in patients with 
cystic fibrosis.259 This binding appears to require poly valency in the anionic component 
as treatment of these LL-37 : DNA bundles with human DNase I or poly-aspartic acid 
releases the antimicrobial peptide and such methods may provide a new regime for 
treatment of chronic airway infections.260,261 
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Figure 52 Web of in vivo LL-37 interactions167  
 
3.3.9 Conclusions 
It is clear from analysing the mode of action of LL-37 that the antimicrobial and 
immunomodulatory effects of the peptide are interlinked and dependent on the key 
properties of charge, helicity and amphithaticity. The interplay between LL-37, 
mammalian and microbial systems, and the complex pathways influenced by this 
natural product are summarised in Figure 52.  
Reflecting the growing challenge of microbial resistance to conventional small molecule 
antibiotics there is a growing number of reports describing attempts to isolate and 
optimise the antimicrobial and other activities from the various responses revealed by 
LL-37 and other AMPs. A major motivation for such an approach is that AMPs, unlike 
conventional antibiotics are less likely to lead to a general resistance process than any 
small molecule class of antibiotic. However a number of challenges remain notably cost, 
in vivo stability and selectivity.130,262 LL-37 has potential roles in many therapeutic areas; 
as an antibacterial agent including the inhibition of biofilm formation, and also in the 
treatment of inflammation, cancer, HIV, and fungal infections.263,264,265 The specific 
challenges in the application of LL-37 in these contexts reside in the need to simplify the 
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structure (reducing production costs) and reduce host-cell toxicity whilst maintaining 
stability to general proteolysis and enhancing activity and selectivity. To this end several 
AMP databases and prediction software programmes have been developed for use by 
chemists and biologists.266  
The multifarious activity profile of LL-37 makes it a fascinating natural product to study. 
Despite intense research into the physiological role of LL-37 since its discovery in 
degranulated granulocytes in 1996 there is still much to understand and investigate. The 
production of derivatives and analogues of the antimicrobial peptide sequence has 
revealed a wealth of knowledge regarding how the structure affects the function of the 
peptide but unravelling the molecular mechanisms that underpin how LL-37 acts 
remains a challenging problem. The ability to tune the physio-chemical properties, 
notably amphipathicity, helicity and charge, of LL-37 so that its activity can be altered 
makes the peptide an ideal foundation for the development of new therapeutic agents.  
With the knowledge gained from the reported structure-activity relationships LL-37, and 
the reports that LL-37 is a substrate for the MtrCDE efflux pump, this chapter presents 
work done to characterise the interaction of LL-37 with MtrR. The following sections 
summarise techniques applied in the course of this research project to analyse how 
LL-37 and chemically synthesised derivatives interact with MtrR and the MtrCDE efflux 
pump.  
3.4 Interaction studies  
In order to investigate how LL-37 and synthetic peptides interact with MtrR, isothermal 
titration calorimetry (ITC) was used. Isothermal titration calorimetry provides a label 
free experiment for the determination of thermodynamic parameters for protein : ligand 
interactions, viz. the association constant (Ka), stoichiometry (n), free energy (ΔG°), 
enthalpy (ΔH°) and entropy (ΔS) of binding267. ITC studies have revealed valuable 
information about the ligand specificity and the strength of interactions for ligand : TetR 
protein interactions as discussed in the introduction. To further characterise peptide : 
MtrR binding a photoactivated binding study strategy was instigated. The principles of 
activity based protein profiling are discussed below. 
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3.4.1 Activity based protein profiling  
ITC gives a wealth of information regarding the thermodynamics of binding but no 
direct structural information about the site of binding. Consequently other methods are 
needed to provide structural information and these can include X-ray crystallography 
and Activity Based Protein Profiling (ABPP). 268 These are complementary techniques as 
a crystal structure is not always available and so ABPP then becomes the method of 
choice for mapping the binding pocket of a protein. ABPP can also supplement other 
structures generated from X-ray studies as ABPP is a solution state technique whereas 
the information gained from the crystal structure represents only the solid state 
structure, in which the protein may adopt a different conformation. Two key processes 
occur in an ABPP experiment – firstly ligand capture and second analysis. There are 
three different methods that have been developed to enable ligand capture are shown in 
Figure 53. 
Typically, the ABPP probes contain a functional group that reacts with the nucleophilic 
residue of the protein (Figure 53). If the probe carries a purification tag, e.g. biotin, the 
protein of interest can be pulled out of the protein pool by affinity chromatography  
 
Figure 53 Different approaches to activity based protein profiling (ABPP): A) Reactive nucleophilic 
amino acid side chain reacts with ligand to form a covalent adduct. The ligand modified protein can then 
be separated from other proteins by using affinity chromatography. B) A reactive cysteine near the ligand 
binding site cross links the ligand trapping the protein in the ligand bound form (Proximity Induced 
Covalent Capture). C) A high affinity ligand bearing a photoactivateable cross linking group is held in 
the ligand binding site by non-covalent interactions until irradiation with UV light causes the 
photoactivated group to react with the protein forming a covalent bond. 
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(streptavidin is used as the binding partner for biotin). During this project experiments 
were carried out on recombinant purified protein so using ABPP probes for use in vivo 
or with mixtures of proteins will not be discussed further. For target proteins that can be 
expressed using recombinant techniques but do not contain an active site nucleophile, a 
reactive cysteine can be engineered into the protein for reaction with an electrophilic 
centre on the ligand (e.g. Michael acceptor B, Figure 53). Once the ligand is located in the 
active site, the reactive amino acid can form a covalent bond with the probe trapping the 
protein in the ligand bound state. This technique is termed Proximity Induced Covalent 
Capture (PICC). The third type of ABPP is affinity controlled, photoreactive ligand 
capture (C, Figure 53).269 In this technique the ligand binds in the ligand binding site and 
then the sample is irradiated with a UV source, activating a reactive group in the probe 
to crosslink the protein.  
MtrR contains a large ligand binding site that is composed of six -helicies, as is seen in 
all members of the TetR family of proteins. In order to probe the binding of peptide 
ligands to MtrR by PICC, several mutations would be required in order to cover the 
large surface area of the ligand binding site. The mutations may affect the stability of the 
protein and the introduction of extra cysteines may alter the structure of the protein as 
there are already four cysteines present in the wild type protein. For these reasons, PICC 
was discounted as an appropriate method to map the ligand binding site of MtrR and 
instead an affinity controlled, photoreactive ligand capture approach was followed. The 
following section details literature reports of photoreactive ligand capture peptide 
probes that influenced the design of photoreactive ligand capture experiments 
implemented in this thesis. 
3.4.1.1 Photoactivated activity based protein profiling 
The aryl azides (189), benzophenone (190) and diazirine (193) moieties have been 
developed as photophores that generate reactive intermediates on irradiation with UV 
light, which can insert into a nearby C-H bond of a protein (Figure 54).270 Both the 
benzophenone and diazirines have the advantage that they are activated with light > 350 
nm, which is not damaging to biomolecules. Aryl azides, however, are activated with 
light < 300 nm, which can effect the integrity of biomolecules. The nitrene (190) 
generated by irradiation of 189 is also highly promiscuous compared to radicals 192 and 
193 therefore aryl azides were discounted as an option in this study. 
100 
 
  
Figure 54 Photophores for protein labelling and the reactive intermediates generated on irradiation with 
UV light specific for each photophore. 
The carbene produced by irradiation of 191 has been shown to insert more selectively 
than 190, but 192 is more prone to side reactions and insertion with solvent molecules 
than the carbonyl diradical of the benzophenone system (194).271 Diazirine carbenes react 
more quickly than carbonyl diradicals and so to increase the likelihood of a specific 
insertion in to an unactivated protein C-H bond the benzophenone moiety (194) was 
chosen as the photophore of choice for this project. The photochemistry and application 
of the benzophenone photolabel will now be described in more detail. 
3.4.1.2 Benzophenone containing photoactivated ABPP  
Absorption of a photon at ~350 nm results in the promotion of an electron from the 
non-bonding sp2-like n orbital on oxygen to an antibonding π* orbital of the carbonyl 
(Figure 55). 272 The oxygen n-orbital thus has electrophilic character and interacts with a 
nearby weak C-H σ-bond resulting in proton abstraction. The resulting ketyl and alkyl 
radicals recombine to give a new C-C bond. The lifetime of the diradical is 100 times 
longer than the singlet state and the excited state will relax to the ground state if no 
suitable proton is available for abstraction. The ability for the excited state to return to 
that stable ground state is one of the main advantages over diazirine and aryl azides in 
photolabelling experiments as the benzophenone moiety can go through several cycles 
of excitation before inserting into a C-H bond, whereas the carbene of the diazirine and 
nitrene of an azide must react immediately when formed. 273,274  
ABPP peptide probes containing a benzophenone moiety have been used to investigate 
several protein families such as metalloproteases,275 RAS,276 and G-coupled protein 
receptors as highlighted in Figure 56.277 The photolabel can be placed in the sequence of 
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the peptide by use of Fmoc-benzoyl phenylalanine as the amino acid building block, or 
on an amino acid side chain or at the N-terminus. The benzophenone peptide probes 
designed in this thesis are described in section 3.5.5.3. 
 
 
Figure 55 Photochemistry of the benzophenone system 
 
 
                                          
      
 
 
Figure 56 Structures of benzophenone containing peptide ABPP probes. Incorporation of benzoyl 
phenylalanine amino acid in metalloprotease probe (199);  RAS peptide probe carrying a benzophenone 
modified farnesyl side chain (200); C) Probe for cholecystokinin receptor (a G-coupled receptor) with a 
modified lysine side chain (201); D) N-terminally modified inflammatory protein-1R (MIP-1R) probe for 
chemokine receptor 1 (a G-coupled receptor) (202).  
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3.4.1.3 Techniques for analysing ABPP experiments 
The ABPP probes bound to the protein were analysed using mass spectrometry. The 
insertion of the peptide into the protein can be confirmed by MALDI or electrospray 
mass spectrometry. The location of the modification can be located by proteolytic 
digestion of the complex, followed by either MALDI or electrospray analysis of the 
peptides. Sample preparation for MALDI analysis is quick and no chromatography is 
necessary enabling rapid determination of modified peptides, by either comparison to 
control samples or database searches. For example, 1 L of the trypsin peptide solution 
containing buffer can be mixed with ~ 1 L of MALDI matrix (for peptides typically this 
is  cyano-4-hydroxycinnamic acid) and provide enough sample for several analyses by 
MALDI. MALDI analysis typically yields singly charged peptides whereas electrospray 
yields doubly charged peptides. Samples analysed by electrospray are subject to HPLC 
to separate out the constituent peptides to facilitate identification. LC-MS analysis 
requires more time than MALDI, but typically a greater mass accuracy can be achieved 
on electrospray systems such as Fourier Transform Ion Cyclotron (FT-ICR) or 
quadrapole devices than on MALDI instruments and so greater confidence can be placed 
in the observed masses.278 
Once novel peptides have been identified, these can be further interrogated by MS / MS 
experiments to locate the position of modification. The LIFT technique can be used on a 
MALDI instrument, whereby the peptide of interest is selected in an ion trap, the laser 
power increased to a sufficient level to fragment the peptide along the peptide backbone 
to give predominantly b and y ions (Figure 57). Several techniques have been developed 
on electrospray instruments for sequence determination and these include collision 
induced dissociation (CID) and electron capture dissociation (ECD). In CID, the selected 
ion is held in a trap with an inert gas and collisions between the peptide and the gas 
molecules induces peptide fragmentation, principally yielding b and y ions (Figure 57).   
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Figure 57 Generation of fragment ions in peptide MS / MS 
 
Analysis using an FT-ICR instrument allows for ECD analyses to be carried out that 
generates C -N cleavages enabling c and z fragments to be generated, with smaller 
amounts of b and y ions. The complementary nature of MALDI and ESI techniques 
allows a vast amount of sequence data to be generated that can locate where an ABPP 
has inserted into a protein. 
3.5 Results and discussion 
3.5.1 Introduction 
The hypothesis of this thesis is that in order for MtrR to dissociate from the operator 
DNA of the MtrCDE genes, ligands bind to MtrR. The substrates for MtrCDE efflux 
pump are putative ligands for MtrR. LL-37 is a candidate ligand for the regulator as it 
has been shown to be transported by MtrCDE and cellular studies have shown the LL-37 
can translocate to the nucleus and target DNA so it is possible for LL-37 to migrate to 
where MtrR is bound to DNA. The following chapter begins with preliminary studies 
that confirm LL-37 as a ligand for MtrR. The design and synthesis of peptide fragments 
of LL-37 is discussed followed by a range of studies used to characterise the function of 
the peptides. 
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3.5.2 LL-37 MtrR ITC study  
In order to probe the nature of the interaction between the human antimicrobial peptide 
LL-37 and MtrR, ITC was used.  Recombinant MtrR was obtained from over-expression 
in E. coli as detailed in chapter 2. The protein was dialysed overnight into the ITC 
analysis buffer (Tris 20 mM, NaCl 300 mM, pH 8.2), and the same buffer was used to 
solubilise LL-37 (gift from Dr Peter Henklein, Institute for Biochemistry, Charité 
University Berlin). 
The ITC trace shows that LL-37 (1 M) binds weakly MtrR (70 M) (Figure 58). The 
initial endothermic reaction is due to the oligomers of LL-37 dissociating in solution, an 
enthalpy that is larger than the binding interaction between the regulator protein and 
the peptide. Attempts to decrease the heat of dilution by altering the injection volume of 
the ligand were unsuccessful. Decreasing the injection volume from 10 L to 4 L did 
not produce enough signal to see a binding isotherm. Analysis of such data can be 
supported by reference to the literature, and particularly to host-guest complexation in 
cavitands as such interactions have been used to model protein ligand interactions. In 
the supramolecular host-guest interaction, an amphiphlic ligand inserts into a 
hydrophobic cavity inside a cyclodextran, mimicking the insertion of amphiphilic 
peptide into a protein.279 Similar binding profiles to the LL-37 MtrR interaction were 
seen for the binding of organic carboxylates to 15-metallocrown-5 complexes.280 With 
confirmation that LL-37 is a ligand for MtrR, we initiated a chemical strategy to 
investigate how LL-37 binds MtrR by dividing the peptide into sections and analysing 
each section for protein binding.  
 
Figure 58 ITC of LL-37 and MtrR. N = 1.1, Ka = 1.1 x 10-5, ΔH = -2577 ± 190 kJ mol-1, ΔS = 14.5 kJ mol-1·K 
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It has been proposed that regulation of TetR protein can function by one of three 
mechanisms: disruption of the dimerisation domain, occupation of the ligand binding 
pocket or competition for operator DNA. Each mechanism arises from a particular 
property of a peptide: -helicity determines the ability to prevent dimersation, 
hydrophobicity governs the ability to insert into hydrophobic pockets and charge is the 
mediating factor in competing for DNA. In order to understand how LL-37 binds MtrR 
and if binding to MtrR affects the function of the transcriptional regular, a range of 
derivatives of LL-37 were designed. The following section details the design, synthesis 
and evaluation of LL-37 derivatives binding to MtrR.  
 
3.5.2 Peptide synthesis plan 
LL-37 is a large molecule (MW > 4000 Da) and the overview of the peptide in section 3.3 
showed that its different functions are due to key motifs within the structure of the 
peptide. We reasoned that the binding to MtrR (Figure 58) may be due to a key binding 
motif that we hoped to access through structure function studies. The ability for only a 
small motif of a large effector molecule to cause activation or repression of protein 
function is exemplified by the activation of nuclear cell receptors. The androgen receptor 
(AR) is a nuclear transcription factor involved in ligand inducible gene regulation of 
male sexual development, prostrate growth and bone metabolisim. The naturally 
occurring cellular coactivators of AR are large ~ 600 amino acid proteins that contain an 
LXXL of FXXLF helix motif that binds to a hydrophobic groove on the AR surface.281 It 
has been shown that activation of the AR can be achieved when the helical motifs (LXXL 
or FXXLF) is contained in much smaller (~ 20 amino acid) peptides. 
In order to probe whether -helicity is important for LL-37 to bind to MtrR, peptides 99 
and 101 were selected. Peptide fragment 101 of LL-37 is known in the literature to be the 
minimum -helicial peptide required to maintain antimicrobial activity (see section 
3.3.5) and as part of this thesis we investigated the correlation between -helicity of the 
ligand and MtrR binding. 
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Figure 59 Regions of LL-37 to be synthesised to probe the different properties that effect binding to MtrR  
Table 8 Physiochemical properties of the planned fragments of LL-37. 
Sequence Hydrophilicity Charge Predicted -helicity 
LL-37 (12) 0.6 6 5.0 
FLRNLVPRTES (203) 0.1 1 0.01 
FKRIVQRIKDFLR(101) 0.7 4 4.29 
IGKEFKRIVQRIKDFLRNLVPRTES 
(99) 
0.5 4 6.96 
LLGDFFRKSK (204) 0.4 3 0.63 
Hydrophilicity is calculated using the Innovagen property calculator (www.innovagen.se) with 
hydrophilicity values taken from Hopp and Woods.282 helicity is predicted using the AGADIR online 
calculator (www.agadir.crg.es) 
 
The peptide sequences to the N and C-terminus of the central peptide (101) display 
different hydrophobicities and charges. To investigate the effect of hydrophobicity on 
binding to MtrR, we designed peptide 203. The low hydrophilicity (0.1, Table 6) suggests 
that this peptide would be suitable for inserting into the hydrophobic binding pocket of 
MtrR. 
In contrast to the C-terminal peptide, the N-terminal 12 residues (204) display a 
hydrophilic profile. The acidic and basic amino acids present in the peptide sequence 
may enable the peptide to bind (via salt bridges) to the DNA binding domain of MtrR 
and thus act as a competitor for DNA thereby enabling a further mechanism for peptide 
binding to MtrR to be investigated. The N-terminal domain 92 has also been shown to be 
necessary for 12 to form oligomers and so peptide 99 was synthesised to investigate 
whether removal of the oligomerisation domain increases binding to MtrR.  
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The peptides synthesised in this thesis were constructed using Fmoc solid phase peptide 
synthesis (SPPS) Figure 60. The principle advantages of Fmoc SPPS over Boc SPPS, are 
the conditions required to remove the N-terminal protecting group and cleave the 
peptide from the resin. The tert-butyloxycarbonyl group requires treatment with 
trifluoroacetic acid, whereas the N -Fluorenylmethoxycarbonyl protecting group is 
removed by mild bases, e.g. piperidine and morpholine, that abstract the acidic fluorenyl 
proton (pKa ~22). Repetitive treatment with TFA during peptide synthesis increases the 
risk of peptide degradation during synthesis, which is avoided during Fmoc SPPS.283  
A further advantage of Fmoc chemistry is that the leaving group has a chromophore 
thus the deprotection reaction can be monitored by UV absorption spectroscopy at 290 
nm. There are two advantages from monitoring the cleavage of the N-terminal blocking 
group, namely the speed of the deprotection gives an indication of the extent of chain 
aggregation during peptide synthesis and secondly the amount of the piperidine-
fluorene adduct can be quantified, thus the resin loading can be determined.  
 
Figure 60 Principles of Fmoc solid phase peptide synthesis; Resin 205 is acylated with side 
chain protected amino acid (207) that is activated by a coupling agent (dentoted R’). The N-
terminal Fmoc group of 207 is removed with 25 % piperidine / DMF to give free amine (208). 
The acylation and deprotection steps are repeated until the peptide with the desired chain 
length is reached (211). Fmoc deprotection followed by acidolysis yields unprotected peptide 
213. 
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Figure 61  Mechanism of Fmoc removal by piperidine 
 
The resins used in the course of this project contained a polymer matrix composed of 
either copoly(styrene - 1 % divinyl benzene) or a polyethylene glycol polsytrene mix. 
Resins composed of 219 swell better in DMF than 220 and have been reported to increase 
the yields of long peptides so resin 219 was used to synthesise peptides > 20 amino acids 
in length. The linkers attached to the resin are shown in Figure 62. Linkers that are 
cleaved in 95% TFA include Wang (221) and Rink amide (222) were used for the most of 
the peptides synthesised. For the preparation of side chain protected peptides 223 was 
used as the peptide is cleaved from the resin using TFE / DCM.  
 
Figure 62 Polymer structures of resins used in this project Tentagel – polyethylenegylcol resin (219) and 
polstryrene-divinylbenzene (220); Linkers attached to resins used were Wang linker (221) Rink amide 
linker (222) and chloro trityl (223). 
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Resins were purchased ready loaded or derivitised at the beginning of each synthesis. 
Attachment to Rink amide resin (222) is carried out using standard amino acid coupling 
protocols described below, whereas attachment to 221 requires special conditions. Three 
methods have been developed for the esterification of alcohol functionalised resin, that 
use either a symmetric anhydride, mixed anhydride or activated carboxylic acid strategy 
(Figure 63). The symmetric anhydride method was applied in this project. Advantages of 
the chosen method are its simplicity, no special agents are required unlike the MSNT 
(217) method. The symmetric anhydride is not as sensitive to water as the MSNT method 
and acylation occurs faster than with the mixed anhydride dichlorobenzoyl chloride 
(218) method. For example to achieve a loading above 70%, an 18 hr reaction time is 
needed for the DCB method, compared to 1 hour for the symmetric anhydride method. 
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Figure 63 Esterification of Wang resis using A) MSNT method, B) DCB C) symmetric anhydride 
 
3.5.3 Results of peptide synthesis 
3.5.3.1 Automated synthesis 
The synthesis of 203 was carried out on an ACT348  synthesiser, using Wang resin 
previously derivitised outside of the machine using the symmetric anhydride method. 
The symmetric anhydride of Fmoc-Ser(tBu)-OH was prepared and after addition to the 
Wang resin (substitution 0.25 mmol /g) the Fmoc loading was determined to be 88%. 
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The unreacted resin –OH groups were capped with N-acetyl-imidazole.286 The resin was 
transferred to an ACT 348 synthesiser but the synthesis failed to yield any product, 
despite each coupling done twice using PyBOP (230), an analogue of BOP (229), that 
unlike its predecessor does not evolve toxic HPMA in the course of the reaction.287 
PyBOP possesses good reactivity and was considerably cheaper than the more reactive 
uronium salts but HBTU (231) and HATU (232). 
A large number of side products were detected in the crude product and several deletion 
peptides could be identified by MALDI mass spectroscopic analysis (Figure 65). The 
truncated peptides that were observed corresponded to [M-V]+ [M-R]+ [M-P]+ [M-2R]+. 
Also present were peptides carrying the Pbf protecting group as a result of the slow 
cleavage of Pbf that can occur in peptides with more than one Pbf protecting group.288  
 
Figure 64 Structures of selected coupling agents: BOP (229), PyBOP (230), HBTU (231) and HATU (232) 
 
Figure 65 HPLC trace for automated synthesis of 203. HPLC gradient: 5-95% MeCN over 40 min 
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Deletion peptides were also encountered in the automated peptide synthesis of 204. The 
purity of the crude product was lowered by the presence of piperidides. Consistent with 
literature reports, the excess treatment with piperidine during Fmoc deprotection may 
lead to the formation of  and  piperidides (235 and 236) at aspartic acid residues 
carrying tBu protection on the side chain.289 Repetition of the synthesis on an ACT357 
synthesiser using deprotection reagent 20% piperdine /0.1 % HOBt in DMF suppressed 
piperidide formation and gave an 8% yield. The peptide synthesis was optimised by 
manual synthesis, as discussed below.  
 
Figure 66 Piperidide formation in conventional SPPS 
 
Similarly, the problems encountered in the synthesis of the short peptides were mirrored 
in the synthesis of fragment 99. Furthermore, the activator solution for the automated 
peptide synthesis experiments was made fresh at the beginning of each experiment, but 
despite efforts to keep the solution in the dark, it is known that PyBOP solutions can 
degrade by over 57% within 48 hours. The degradation of 230 may account for the poor 
yield from the ACT synthesis.290 The yield of the crude product was very low (2%) 
indicating that couplings failed to reach completion and this led to a re-evaluation of the 
conditions used as discussed in the following section. 
 
3.5.3.2 Manual synthesis 
Changing from an automated to a manual synthesis approach enabled each coupling to 
be monitored by the Kaiser or chloranil test. A sample of resin was removed from the 
reaction vessel after 1 hour of coupling and if the test was negative, the coupling was 
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repeated. The synthesis of 195 was repeated manually using the same coupling 
conditions but on a less substituted resin, 0.28 mmol / g vs 0.87 mmol / g with the aim 
of decreasing the steric crowding close to the resin surface. Couplings were performed 
with 230 and each coupling done twice, with each coupling monitored by using the 
Kaiser test. The Kaiser test cannot be performed on proline due to the lack of a primary 
amino group and so the chloranil test was used instead couplings that showed blue 
beads indicative of a free amine and therefore an incomplete coupling reaction were 
identified at the R34 to T35, V32 to P33 and L31 to V32 (Figure 67).291 Coupling to -
branched amino acids is described in the literature as a “difficult” coupling and to 
overcome these slow couplings alternative strategies were sought.292  
The aminium coupling agent HATU (232) has been shown to be more reactive than 
PyBOP (230). The increased reactivity for the aminium agents is due to the ammonium 
ion being a better leaving group than the phosphonium ion.293 This more reactive 
coupling agent (232) was used to facilitate couplings at threonine, valine and proline in a 
repeat of the synthesis of 203. The couplings proceeded quicker (completed in 30 min as 
judged by Kaiser test) and the crude HPLC was cleaner than the ACT synthesis (Figure 
65). After preparative HPLC a single peak was isolated but mass spectrometry showed 
that the isolated peak contained a considerable amount of a side product which was 27 
mass units higher than expected and inseparable by HPLC. Accurate mass in ESI mode 
coupled with ECD experiments indicated that modification occurred at the N- or C-
terminus. The mass adduct corresponds to addition of CHO, possibly during the acid 
cleavage step.  
Application of the combined PyBOP / HATU strategy to the synthesis of 100 increased 
the crude yield from 2 mg to 10 mg but the product still contained piperidide adducts. 
The synthesis of 99 was carried out manually with the PyBOP / HATU strategy and 
although side products were detected, enough material was isolated (2 mg) to supply 
biological studies. 
 
F27L28R29N30L31V32P33R34T35E36S37 
Figure 67 Numbering of residues in peptide 203 is based on the numbering in the parent peptide (12) 
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To further optimise the synthesis of 100, HBTU (231) was also tried as a coupling agent 
based on a recommendation by Dr J Fox (Alta Bioscience). Repeating the synthesis with 
231 as the sole coupling agent, yielded the desired peptide in higher purity than with the 
combined PyBOP/HATU synthesis but still in low yield (15%).  
3.5.3.3 Microwave synthesis 
In an attempt to further increase the yield of the peptide synthesis, we next turned to a 
microwave assisted synthesis. Recent studies have shown that microwave heating not 
only enhances the coupling efficiency by reducing the coupling time from 1 hour to 5 
minutes, but can also overcome problems of chain aggregation in long or hydrophobic 
peptides (higher yield, cleaner HPLC spectrum).294 It has been proposed that the N-
terminal amine and peptide backbone are polar thus they try and align with the 
alternating electric field of the microwave, helping to break up aggregated chains. In a 
comparative study of a 20-mer amino acid (VYWTSPFMKLIHEQCNRADG-NH2) 
synthesised on a conventional and microwave peptide synthesiser, the conventional 
synthesis gave only a 68% crude yield with several deletion products, whereas the 
microwave synthesis gave 84% in an unoptimised system. Recently, Galanis and co 
workers showed that microwave heating is also efficient at facilitating solid phase 
peptide synthesis where water is the solvent.295 The reasons for the improvements in 
yield and purity in microwave peptide synthesis have been challenged by Kappe, who 
has shown that conventional heating is as efficient as microwave heating at improving 
the yield of solid phase peptide synthesis.296 Nevertheless, in our hands we found 
microwave assisted chemistry most advantageous. 
Application of microwave heating to the synthesis of 203 made a huge difference to the 
speed of the synthesis, the yield and the purity. Coupling reactions were conducted for 5 
minutes instead of 1 hour, with the exception of arginine, which was incorporated in 20 
minute coupling. All deprotections and couplings were conducted at 70 °C. Couplings 
were only done once, and the purity of the synthesis was checked periodically by HPLC. 
After the addition of P and V, no deletion or side products were obtained. Similar 
successes were achieved with peptides 100 and 204, where microwave synthesis gave 
the desired product in high crude yield, 35% and 28% respectively. All the peptides 
synthesised are summarised in Table 9. 
114 
 
 
3.5.3.4 Summary  
 
Table 9 Summary of synthesised peptides and yields (NA = not attempted) 
Peptide Sequence Yield (%) 
  ACT Manual Microwave 
203 FLRNLVPRTES 2 15 25 
100 FKRIVQRIKDFLR 0 Mixture 35 
99 IGKEFKRIVQRIKDFLRNLVPRTES 0 4 NA 
204 LLGDFFRKSK 8 10 28 
237 IKDFLRNLVPRTES 0 12 NA 
238 RIVQRIK 7 NA 30 
239 KIGKEKFRIVQR 4 16 NA 
240 KEKIGKEKFRIVQR 4 18 NA 
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3.5.4 ITC binding studies involving synthetic peptide fragments and MtrR 
3.5.4.1 Screening of synthetic peptides by ITC 
With the successful preparation of peptide fragments of LL-37, attention next turned to 
investigating how these peptides interact with MtrR and to compare the results to the 
ITC experiment with LL-37.  
The recombinant MtrR used in the ITC experiments was purified by affinity 
chromatography, gel filtration and anion exchange chromatography, as discussed in 
Chapter 2. In contrast to the penicillin binding studies, the protein was dialysed into 
20 mM Tris, 300 mM NaCl, pH 8.2 prior to the ITC experiment. The ligand was dissolved 
in the same buffer as used for the protein. A typical ITC experiment involved 10 L 
injections of a 1 mM solution of peptide every 2 minutes into 70 M of protein. In each 
case, a control experiment was performed whereby the peptide of interest was injected 
into buffer alone. The data acquired from the buffer only experiment was subtracted 
from the experiment with protein and the modified data was fitted using the One-Site 
Model provided in the Origin software. 
The first synthetic peptide that was checked for binding to MtrR was 99, as the effect of 
the N-terminal region could then be assessed by resulting raw data was fitted with the 
one site model. The 10 M dissociation constant (Kd) and 20 kJ mol-1·K change in entropy 
(ΔS) values are very similar to the Kd and ΔS for LL-37. The major difference between the 
two experiments is observed in the shape of the raw data. The initial endothermic event 
is missing in the truncated peptide indicating that residues 1-10 are responsible for the 
aggregating potential of the peptide. Furthermore, although the observed heat change 
for 99 does not return to the base line at the end of the experiment, literature suggests 
that such data is still sufficient for fitting to a model.297 The increase in entropy suggests 
that interactions are non-specific, and the increased entropy arises from desolvation of 
the hydrophobic surfaces when the peptide associates with the protein.298 Interestingly, 
the N-terminal peptide (204) does not bind at all. 
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IGKEFKRIVQRIKDFLRNLVPRTES (99) 
 
H = -2.5 ± 0.2 kJ mol-1 
S = 20.5 kJ mol-1· K 
Kd = 10 ± 1 M 
N = 2 ± 0.09 
LLGDFFRKSK (204) 
 
Data does not fit One Site Model 
 
FKRIVQRIKDFLR (100) 
 
H = -42 ± 8 kJ mol-1 
S = -12.8 kJ mol-1· K 
Kd = 5 ± 0.7 M 
N = 0.8 ± 0.1 
 
FLRNLVPRTES (203) 
 
H = -69.7 ± 0.2 kJ mol-1 
S = -26.5 kJ mol-1· K 
Kd =30 ± 0.8 nM 
N = 1.3 ± 0.02 
 
Figure 68 Summary of ITC experiments for LL-37 fragments binding to MtrR 
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In contrast to the long peptides, the shorter C-terminal (203) and central peptide (101) 
bind with Kd of 30 nM and 5 M respectively (Figure 68). The binding constants are 
indicative of tight binding and analysis of the H and S values provides further insight 
into the binding event. The enthalpy change ( H) is a measure of the heat change of the 
system thus the more negative the H the more favourable non-covalent interactions 
that are formed. Typically, these involve hydrogen bonds between polar groups and van 
der Waals interactions.299 The negative entropy for 203 and 101 indicates that there is a 
large degree of reordering of the protein when the ligand binds. The central peptide is 
known to adopt an  helical structure whereas the C-terminal peptide 203 has no overall 
structure in solution thus when 203 binds MtrR there is a much larger change in entropy 
than when the 101 binds MtrR. By homology to other TetR proteins, MtrR is predicted to 
have a large binding pocket formed by several -helices. It is known that on ligand 
binding, the ligand binding domain of TetR proteins undergoes a conformational change 
and this is transmitted through the breaking of existing, and the formation of new, salt 
bridges and hydrogen bonds to the DNA binding domain. The observation that the 203 
produces a greater change in S and H than the 99 indicates a tighter binding ligand. 
The ability for a segment of a large peptide to bind stronger than the parent molecule is 
illustrated by the 53 amino acid regulatory peptide ArmR. ArmR binds the regulatory 
protein MexR with H = -60 kJ mol-1 and S = 78 kJ mol-1·K, whereas the C-terminal 
region of ArmR (residues 41 - 53) exhibits H = - 42 kJ mol-1 and S = - 21 kJ mol-1·K.300 
The observed change in the sign of entropy from positive to negative suggests strong 
binding due to a net reorganising of the protein structure to a more stable conformation. 
The dissociation constants of 290 nM for the full peptide and 190 nM for the truncated 
peptide underscore the increased binding affinity that is achieved on truncating the 
regulatory peptide. The regulatory peptide ArmR is a natural molecule produced by 
P. aeruginosa where as LL-37 is an antimicrobial peptide that has previously not been 
shown to bind a regulatory protein before and so the ITC data presented here provides 
new insights into ligands for DNA binding proteins. 
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Figure 69 MexR-ArmR (peptide in green). The peptide binding site extends across the ligand 
binding domain in MexR (a MarR family protein) .Image produced in MOE from PDB file 
3ECH. 
There are three postulated mechanisms for peptide derepression of transcriptional 
regulators. The functional dimer can be disrupted through insertion into the 
dimerisation domain, the peptide can bind to the DNA binding region of the regulator 
or the peptide can insert in the the ligand binding domain.300 The results of the ITC 
suggest that full length LL-37 and the shortened 27 amino acid fragment predominantly 
interact with MtrR via non-specific hydrophobic interactions but the ITC results alone 
are not enough to discount insertion into the ligand binding domain. More conclusive 
thermodynamic evidence was obtained to support the theory that the shorter peptides 
peptides insert into the ligand binding domain. The negative H and S for the 
FLRNLVPRTES (203) peptide is indicative of a high affinity peptide. 
3.5.4.2 Conclusion 
The ITC results show that decreasing the number of residues from 37 in the parent 
peptide to 11 in FLRNLVPRTES substantially increases binding of the peptide to MtrR. 
This result is rationalised by comparison to the literature on peptidic ligands for DNA 
binding proteins. In order to gain more insights into the molecular mechanism of 
peptide binding to MtrR, the site of binding was investigated next and efforts to 
elucidate the ligand binding site in MtrR are discussed in the following section. 
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3.5.5 Photoactivated peptide substrates 
3.5.5.1 Introduction 
With the successful identification of 203 as a high affinity ligand for MtrR, attention 
turned to localising the peptide binding site. At the outset of this research project there 
was no structure information on MtrR and so two strategies were instigated to enable 
insights at the molecular to be gained. This involves X-ray crystallography and affinity 
based protein profiling (ABPP). A brief overview of the X-ray crystal trials attempted in 
this research project will be summarised below. ABPP was described above and results 
presented here provide insights into molecular recognition by MtrR.  
 
3.5.5.2 X-ray crystallographic trials 
As reported in Chapter 1, the 3D structure of TetR proteins has provided valuable 
information regarding DNA and ligand binding mechanisms. Attempts to crystallise 
MtrR in this research project are described herein.  
Crystal screening trials were set up using an Innovadyne Screenmaker robot that enables 
96-well plates to be prepared on a nanolitre scale. The ability to screen a large number of 
conditions for crystal growth is essential as nucleation of a crystal requires the protein to 
be brought to a point of supersaturation, when the concentration of the protein exceeds 
its intrinsic solubility Sº.301 The point of Sº is unique for each protein and dependent on 
temperature, pressure and solvent. Consequently crystallisation screening experiments 
are conducted at room temperature and 4 °C and with a range of buffer conditions. 
Supersaturation can be induced by decreasing the volume of the solvent drop in which 
the protein is dissolved and this is termed the vapour diffusion method. Two different 
ways exist to set up vapour diffusion method experiments (Figure 70) and each method 
was attempted in this study. 
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Figure 70 Vapour diffusion methods for crystallisation. In the hanging drop method, the sample is 
suspended above a reservoir of buffer (R). The lower vapour pressure of the reservoir draws water from 
the sample to reduce its volume and thus the protein concentration increases above S°, resulting in 
precipitation or crystallisation. In the sitting drop, the sample is located in a well next to the reservoir but 
otherwise the method is the same as for hanging drop. 
 
Ten 96-well plate screening trials were set up (using the robot) in the sitting drop format 
and twenty 12 well hanging drop plates were set up (manually) to screen a range of 
commercially available buffer systems (Wizard I and II, Cryo I and II, Crystal Screen 
HT). The concentration of protein used was 10 mg / mL. Attempts to concentrate the 
protein above 10 mg/ mL lead to precipitation of the protein. Disappointingly, only 
precipitated protein or clear droplets were observed in the screening trials after 1 day, 1 
week and 1 month of setting up the plates. 
The observed precipitation of MtrR during buffer exchange processes in the purification 
of the protein and also when concentrated over ~ 10 mg /mL and also in the 
crystallisation trials indicates that the protein is not very stable. Consequently, when the 
concentration of protein increases in the droplets in the crystal screening trials, instead 
of nucleation occurring (a slow process requiring a highly ordered lattice to form), 
numerous tiny nuclei formed and precipitated from the solution. Due to the failure of 
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the crystal screening trials, an alternative approach was sought and the use of 
photoactivated activity based protein profiling is detailed in the next section. 
 
3.5.5.3 Photoaffinity peptides 
As reviewed in section 3.4.1, ABPP can reveal the site of ligand binding and the use of 
peptides as active ligands has been shown to be a useful strategy. The literature on 
benzophenone containing ABPP probes revealed that the photolabel can be placed at 
any point along the peptide sequence. The insertion of the benzophenone moiety can 
affect the affinity of the peptide for the protein, however, the ligand binding domain of 
MtrR is predicted to be large so the effect of adding a benzophenone group to the 
peptide should be tolerated. At the outset of this project, there was no structural 
information regarding the ligand binding domain of MtrR and so as a proof of concept 
experiment, the photolabel was placed at the N-terminus of the peptide. The chemistry 
required to insert the photolabel at the N-terminus is facile and would allow for the 
photolysis and mass spectrometric conditions to be optimised. 
Peptide 203, was synthesised on Rink amide resin using microwave assisted manual 
synthesis using 250 mg of resin was used with a substitution of 0.61 mmol /g. The 
benzophenone label was introduced after deprotection of the N-terminal residue. 
4-carboxyl-benzoyl-benzoic acid (241) was activated with HATU / DIPEA in DMF for 5 
min prior to addition to the N-terminal deprotected peptidyl resin (242). The coupling 
reaction was carried out at 70 °C for 15 minutes, which is 10 minutes longer than for a 
standard coupling reaction as carboxylic acids on aromatic systems are slower to react 
than standard amino acids. The product  
 
Figure 71 Synthesis of benzophenone labelled peptide 
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was cleaved from the resin using TFA /TIS /H2O. LC-MS analysis of the crude material 
revealed two major products, with m/z = 770 [M+H]2+ and m / z = 762 [unknown] 
(Figure 72). The desired product and unknown side product were isolated by 
preparative mass directed HPLC and the identity of the desired product was confirmed 
by accurate mass measurement.  
 
 
Figure 72 HPLC trace of crude 243 (Gradient 595% MeOH, 20 min) 
 
The accurate mass measurement for the unknown side product indicates that structure 244 is present ( 
). Other side products that were considered included Fmoc-peptide 245, that might be 
formed due to incomplete treatment with piperidine and N-terminal guandidated 
peptide 246, which would be due to excess HATU in the coupling mixture but neither of 
these adducts gave the desired mass. The primary sequence of the unknown product 
was solved by sequencing the peptide using an FT-ICR mass spectrometer in ECD mode. 
The z11 fragment confirms that sequence of the peptide is 203 and that the modification 
is at the N-terminus. The difference between the MH+ signal and the z11 signal 
corresponds to the c1 ion and the accurate mass for the c1 ion corresponds to peptide 244. 
Comparison to the peptide sequencing data for 243 shows that the C-terminal data is 
identical for both peptides and the only difference is at the N-terminal region. The origin 
of the impurity is not known. The starting material 4-carboxylic acid benzophenone was 
bought from Sigma Aldrich and its purity as the desired compound was confirmed by 
NMR and LC-MS. 
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Table 10 Side products in the preparation of 243 
Peptide C59H100N19 O16 Composition [M+H]+ [M+H]2+ 
 
C73H108N19O18 1540.8033 770.4017 
 
C73H110N19O17 1524.832711 762.164 
 
C74H111N19O18 1553.835451 776.177 
 
C64H111N21O16 1429.851768 714.925 
 
 
 
Figure 73 Diagram showing fragmentations possible at the N terminus of peptide 244 in MS / MS 
experiments. The colour indicates ion pairs. an, xn ions arise from C-C bond cleavage. bn, yn, ions are due 
to fragmentation at a C-N bond. cn, zn ions are due to breakage of N-C bonds.  
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Figure 74 ECD mass spectrum for the characterisation of the side product from the labelling of 195 
 
The N-terminal labelling of peptide 203 with 4-benzophenone-4-carboxylic acid (241) 
gave a 50 : 50 mixture of the desired product 243 and an unwanted side product 244. 
Using mass directed prep. HPLC, the desired product was isolated in 30 % yield. With 
the photoactive peptide in hand, the photoaffinity binding study with MtrR was 
attempted next. 
A variety of incubation procedures and UV sources are listed in the literature for the 
conversion of benzophenone to the corresponding ketyl diradical.302 Initial experiments 
involved incubating the photoactive peptide with the protein for 2 hours at room 
temperature. Incubation of protein and ligand is normally undertaken at 4 oC but due to 
the low stability of MtrR when stored at 4 °C, incubation of the peptide ligand with the 
protein was conducted on a rotary shaker at room temperature. The solubility of the 
benzophenone peptides in Tris buffer was lower than for the parent peptides and to 
effect dissolution, addition of 5 % MeCN was necessary. Irradiation was conducted at 
355 nm for 30 minutes using a Jobin-Yvon Fluorolog FL-3-22/ Tau-3 Spectrofluorimeter. 
Irradiation was also conducted at room temperature and to prevent localised heating of 
the protein : peptide solution the cuvette was shaken periodically. A 20 L sample was 
removed from the irradiated sample every 15 minutes for one hour to monitor the 
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conversion process. Very low intensity signals were seen that corresponded to modified 
protein peaks after 2 hours, but the absolute identity of the species could not be 
determined. Trypsin digest of the irradiated protein did not yield any modified peptides 
relative to an MtrR only control that was treated in the same way. 
The low yield from the insertion was proposed to arise from insufficient power arising 
from the UV source and so the UV source was changed to an Nd:YAG laser. The 
incubation time was also reduced to 1 hour. Following irradiation at 355 nm using a 
Nd:Yag laser for 15 min at room temperature, an initial analysis of the reaction showed 
the presence of a new peak but the resolution was low. To remove low molecular weight 
contaminants, the reaction mixture was injected onto a 5 mL desalting column and the 
excess peptide was separated from the protein (Figure 75). MALDI mass spectrometry 
analysis of the protein peak, showed the presence of unmodified MtrR (m/z = 25257, 
Figure 76) and modified protein (m/z = 26857, Figure 76) with a mass difference of 
1600 Da. 
  
Figure 75 Separation of excess peptide from protein after photo-irradiation. Injection of 1 mL 
photobinding solution onto 5 mL HITRAP Desalting column, fractions eluted with Tris 20 mM, NaCl 300 
mM, pH 8.  
 
Figure 76 Appearance of modified protein after irradiation of photopeptide with MtrR for 15 min at 
355 nm using an Nd:Yag laser. 
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Analysis of the excess peptide peak confirmed the presence of the benzophenone 
labelled peptide (m /z = 1540. 742) indicating that not all the benzophenone peptide 
reacted with the protein. With firm evidence to show that the benzophenone peptide 
inserts into the peptide, attention next turned to localising where the benzophenone had 
inserted into MtrR. As discussed in the introduction, the site of insertion can be located 
by mass spectrometric analysis of tryptic peptide derived from the modified protein. 
MtrR contains several trypsin cleavage sites (lysine and arginine) and there are well 
developed protocols for the use of trypsin digests in the group so this enzyme was 
chosen for this investigation.  
The modified protein was precipitated in acetone, and subjected to trypsin digest 
overnight. As a control, MtrR that had been incubated and irradiated in the absence of 
photolabelled peptide was also digested. An initial comparison of the tryptic peptide 
data from the MALDI mass spectrometry analysis showed the presence of 5 modified 
peptides (Figure 77). Subsequent analysis by ESI mass spectrometry confirmed the 
presence of the peptides (Table 11). 
 
Figure 77 MALDI mass spectrum for tryptic digest of 243. Modified peptides are indicated with a star. 
 
The identity of the peptides was deduced by comparison of the observed data to an in 
silico digest. The sequence for MtrR containing all potential modifications was inputted 
into SequenceEditor (Bruker) and „digested‟. The peptide ligand used in this experiment 
is also a substrate for trypsin so the different cleavage products of the peptide were also 
considered. The settings applied allowed for 2 missed cleavages, which is important in 
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this experiment because when a peptide is bound in a protein it can be protected from 
cleavage by trypsin.78 The modified sequences from MtrR are highlighted in Figure 78. 
 
Table 11 Tryptic peptides deduced from mass spec data 
m/Z Peptide origin Method 
 MtrR Peptide 6  
1017.53 KTK FLR MALDI , ES+ 
1430.77 TKTEALK FLR MALDI, ES+ 
1452.75 HQAIWR FLR ES+ 
1481.65 EK FLRNLVPR MALDI, ES+ 
1506.82 KTKTEALK FLR (-NH3-2H2O) ES+ 
1805.97 HTLLHFFER FLR (-2H2O) ES+ 
1841.67 HTLLHFFER FLR MALDI 
2620.32 HQAIWR FLRNLVPR (-NH3) MALDI, ES+ 
2720.16 HTLLHFFER FLRNLVPRTES(-H2O) ES+ 
 
 
MRKTKTEALKTKEHLMLAALETFYRKGIARTSLNEIAQAAGVTRGALYWH 
FKNKEDLFDALFQRICDDIENCIAQDAADAEGGSWTVFRHTLLHFFERLQ 
NDIHYFHNILFLKCEHTEQNAAVIAIARKHQAIWREKITAVLTEAVEN 
QDLTEAVENQDLADDLDKETAVIFIKSTLDGLIWRWFSSGESFDLGKTA 
PRIIGIMMDNLENHPLCRRK 
Figure 78 Sequence of MtrR with labelled peptides highlighted 
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To confirm the identity of the modified peptides MS / MS experiments were conducted 
on a Bruker TOF / TOF MALDI spectrometer. Parent ions were isolated and subject to 
increased laser power in order to fragment the peptide. The observed sequence data was 
then compared to an in silico generated fragmentation. The theoretical peptide fragment 
data for the peptides was generated using the MS-Protein software (UCSF Protein 
Prospector).303 Comparison of the experimental data with theoretical peptide fragment 
data enabled the identity of two peptides (HTLLHFFER and KTKEALK) to be 
confirmed, the identity of the third peptide HQAIWR was confirmed by comparison of 
the observed and calculated accurate mass for the peptide. The modified HQAIWR 
peptide was not able to be isolated in the MALDI analysis due to the low abundance of 
the parent ion. 
 
 
 
Figure 79 LIFT spectrum for the characterisation m / Z 1841 (benzophenone-FLR modified HTLLHFFER). 
The observation of y5 and y7 ions either side of the proposed site of modification provide evidence that 
the insertion occurred at the leucine indicated.  The internal fragment peptide L*HFFER (where * 
indicates the benzophenone modification) provides further proof for the proposed sequence. Full mass 
list is given in appendix 7.2 
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Figure 80 LIFT spectrum for m/z 1481 (benzophenone-FLRNLVPRTES modified EK) 
 
The trypsin digest data enabled three peptides of MtrR to be identified that are modified 
by the benzophenone peptide. The peptides HQAIWREK, HTLLHFFER and KTKEALK 
correspond to helices 6, 5 and 1. Figure 78 highlights the modified sequences but does 
not provide an easy way to visualise the relationship in space between the modified 
helices. In order to understand the localisation of the labelling in a 3D format, a 
homology model was constructed using MOE (Chemical Computing Group). The MtrR 
amino acid sequence was searched against the PDB database and MOE identified a 
family of proteins with similar fold / topologies, as described by the „hydrophobic 
fitness score‟ (Z); the higher the value of Z, the greater the accuracy of the alignment. 
The greatest homology was seen with AcrR. MtrR was aligned to the found sequences 
and 10 homology models built using the Amber-99 force field. The 10 models represent 
different energy conformations with different side chain rotomers. The final homology 
model is the lowest energy conformer. The validity of the homology model can be 
checked by analysing the psi and phi bond angles, as displayed in the Ramachandran 
plot in Figure 81. All the angles are within accepted limits and so the homology model 
represents a biologically feasible conformation.  
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Figure 81 Ramachandran plot for the MtrR homology model. No outliers are observed indicating the 
model is reliable. 
 
The model produced by MOE corresponds to a single MtrR protein, not to the biological 
unit (dimeric MtrR). In order to provide a dimeric model of MtrR, the symmetry mate 
for AcrR (homologous to MtrR) was found using the crystallography software Coot (this 
analysis was performed by Dr. Ehmke Pohl).304 MtrR was then mapped to the symmetry 
mate to provide a dimeric model (Figure 82). 
The modified residues are highlighted on an homology model of MtrR (Figure 82). Helix 
1 is at the bottom of the ligand binding domain and helices 5 and 6 are part of the ligand 
binding domain. Labelling of helices 5 and 6 is expected as ligands have been shown to 
have contact with these helices in other TetR proteins. The location of insertion on 
hydrophobic helices is indicative of specific interactions between the peptide and 
protein. In an attempt to gain greater insight into the ligand binding process, the peptide 
was docked into the dimeric homology model using MOE. The aim of this docking 
process was to correlate the observed labelling with a particular mode of peptide 
binding to MtrR. 
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Figure 82 Annotated homology model of MtrR with peptides identified by mass spectrometry studies 
highlighted. Peptides are highlighted on both subunits as it is not possible to determine the origin of the 
peptides in the mass spectrometry experiments undertaken. 
 
Before the peptide can be docked to MtrR, potential binding sites on MtrR must be 
identified using the „Site Finder‟ programme in MOE. The „Site Finder‟ applies geometric 
methods (  spheres) to identify hydrophobic pockets that are not “too exposed” to 
solvent and then ranks the sites found by the number of hydrophobic contacts within an 
 sphere.305 The largest site found corresponded to the tunnel composed of the two 
ligand binding domains in MtrR, consistent with other TetR proteins, eg EthR.306 As a 
control, the site finder programme was run on TetR protein and isolated the site 
occupied by TIP peptide indicating the reliability of the method.  
Peptide 243 was then docked into the found binding site. Ten lowest energy conformers 
were generated and two orientations found that account for the labelling observed in the 
mass spectrometry study. The eight discarded conformers show the peptide bound with 
the benzophenone moiety extending away from the protein so insertion is not possible 
(appendix 7.3). 
132 
 
 
Figure 83 MOE docking result for peptide 243 bound to MtrR. The benzophenone moiety is orientated 
close in space to Ile 135 (shown in purple), contained on the HQAIWR peptide isolated from the trypsin 
digest analysis.  
 
Figure 84 A: MOE docking result for peptide 243 bound to MtrR. The benzophenone is orientated close 
in space to Leu 9 (KTKEALK, helix 1), contained on KTKEALK isolated from the trypsin digest analysis. 
B: Close up of interaction between benzophenone (green) and Leu 9 (orange) 
 
A Gaussian surface representation of the MtrR dimer (Figure 85) highlights the 
hydrophobic Ile135 residue (shown in red) in the peptide binding site. This also 
highlights the accessibility of the residue towards ligand binding. 
 
A B 
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Figure 85 Surface map of MtrR showing the benzophenone labelled Ile 135 in red. 
 
A secondary site found by the site finder function in MOE identified the outer most 
helices as a potential site and this also supports the mass spectrometric data for labelling 
at L 93 of helix HTLLHFFER. The location of this binding on the edge of the protein and 
not in the main ligand binding domain may arise from non-specific labelling of the 
protein due to favourable hydrophobic interactions on the protein surface as the labelled 
at Ile 135 corresponds to an opening in the protein surface enabling ligand entry to the 
ligand binding domain (Figure 85). 
 
3.5.5.4 Summary 
The work described above using an affinity controlled photoactivatable peptide ligand 
of MtrR, can be summarised as follows: 
- The LL-37 C-terminal peptide FLRNLVPRTES (203) was labelled with 
benzophenone – 4 – carboxylic acid (241) in a single step on the solid phase. 
-  Conditions were developed and optimised to facilitate photoactivated insertion 
of the benzophenone labelled peptide (243) into MtrR. 
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-  Trypsin digest of the labelled protein followed by MALDI and ES+ mass 
spectrometric analysis identified five non-native peptides that corresponded to 
insertion of the probe into three helices of MtrR. 
- MS / MS experiments were used to confirm the identity of two of the
 insertion products. 
-  In silico analysis of the peptide binding to MtrR provides evidence to support 
the mass spectrometric results. 
 
3.5.5.5 Conclusion 
The use of benzophenone labelled peptide provides the first characterisation of the 
ligand binding domain from MtrR. The observed insertion products can be rationalised 
by comparison to an in silico modelling study that shows two putative peptide binding 
sites. The central and larger of the two binding sites, is capable of binding the 
benzophenone labelled peptide in two possible conformations. The different orientations 
of the peptide account for the observed labelling of helicies 1 and 6. A secondary binding 
site composed of three parallel helices accounts for labelling of helix 5.  
 
3.5.6 Electrophoretic gel mobility shift assays 
 
3.5.6.1 Introduction 
The ITC and photoaffinity binding studies involving peptide 203 showed that the 
peptide is a ligand for MtrR and so attention next turned to investigating the effect of 
ligand binding on the MtrR : DNA complex. The widely accepted mechanism for the 
activation of genes by a TetR type protein assumes ligand induced dissociation of the 
regulator protein from DNA. The following section details efforts to investigate this 
hypothesis. 
A common in vitro technique used to assess protein : DNA complexes and the effect of a 
ligand on protein : DNA complex is the electrophoretic mobility shift assay (EMSA) as 
discussed in section 1.3.2.2. The results in the literature show that EMSA provides a 
reliable method for investigating the effects of ligand on protein : DNA complexes. The 
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operator region for MtrR has been previously indentified in the literature so the studies 
in this project began by ensuring the MtrR : DNA protein complex could be observed 
before the peptide ligands were screened to probe the effects of the synthetic peptides on 
the MtrR : DNA complex. 
 
3.5.6.2 MtrR:DNA complex 
The DNA sequence that MtrR binds was identified by DNA footprinting assays, as 
discussed in Chapter 1 and biophysical evidence to support the microbiological evidence 
was provided by Hoffmann et al who showed using a fluorescence polarisation assay 
that a 27-mer oligonucleotide (5‟-TTTTTATCCGTGCAATCGTGTATGTAT) bound MtrR 
with a Kd 0.9 nM. The interaction of MtrR with its operator DNA was undertaken by ITC 
to provide greater chemical insight into the nature of the protein : oligonucleotide 
complex. MtrR and dsDNA (sequence see Figure 86) were dialysed into the same buffer 
(Tris 20mM, NaCl 300mM, Glycerol 10%, DTT 1mM, pH 8.0) and dsDNA was injected 
into MtrR. The observed data was fitted using the standard OneSite Model provided in 
the ITC analysis software by Microcal.  
 
 
Figure 86 ITC data for the injection of dsDNA (1 mM) into MtrR (70 M) 
(F: 5’-TTTTTATCCGTGCAATCGTGTATGTATAATG-3’ (247) 
R : 3’-AAAAATAGGCACGTTAGCACATACATATTAC-5’ (248) 
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Table 12 Summary of thermodynamic parameters for the interaction of TetR type proteins MtrR, IacR 
and QacR with their respective DNA operator regions 
Protein : DNA Kd / nM ΔH / kJ mol-1 ΔS / kJ mol-1.K Ref. 
MtrR 56 ± 1 156 ± 11 158 This study 
MtrR 0.9 ND ND 136 
IacR 5 ± 0.1 57 ± 0.8 84 86 
QacR 46 ± 3 64 ± 5.7 359 88 
 
The calculated thermodynamic parameters are compared to the values obtained by 
Hoffmann et al for MtrR and also to 2 other TetR proteins (Table 12). The ten fold 
discrepancy in Kd between the values obtained in this study and by Hoffman is likely to 
be due to the different oligonucleotide sequences used.136 Hoffmann used a 27-mer 
dsDNA sequence that was 4 residues shorter at the 3‟ end than in this study. The large 
H can be attributed to the presence of four more charged residues in the DNA binding 
domain of MtrR relative to IacR and QacR therefore increasing the potential for salt 
bridges and thus increasing H.  
3.5.6.3 Development of EMSA conditions using synthetic peptide as ligands 
Following the ITC binding study between MtrR and DNA, the conditions for the EMSA 
study between MtrR, DNA and peptide were developed. These experiments were 
conducted in collaboration with Dr Ines Borges-Walmsley.  
The strategy of the EMSA assay is outline in Scheme 6. Biotin was chosen as the 
visualisation tag as biotinylated DNA can be detecting using a chemiluminescent 
method and thus avoids the safety issues surrounding the use of 32P labelled DNA. 
Following the labelling reaction, the single stranded DNA is annealed. dsDNA is then 
incubated with protein in the presence or absence of peptide ligand for 10 – 20 minutes. 
It is at this point that the protein : DNA complex may form and so to support complex 
formation the native gel is run in Tris borate buffer (TBE) rather than SDS which can 
disrupt protein : DNA binding. Following gel electrophoresis, the protein and DNA are 
transferred to a nylon membrane and then the DNA can be detected by a 
chemiluminescent assay (Scheme 6). 
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Scheme 6 Work flow for EMSA assay 
 
The oligonucleotide sequences in Figure 87 were labelled at the 3‟ end using the 
commercially available biotin 3‟ end DNA labelling kit (Pierce). The forward and reverse 
strands (1 M) were incubated separately with 0.5 M biotin-11-UDP and 2U/ L 
terminal deoxyribonucleotidyl transferase (TdT). After stopping the reaction with 
EDTA, the labelled DNA was extracted and the single strands annealed using either a 
hotblock or PCR machine. The melting temperature for the DNA sequence is 59.9 ºC (as 
determined by the MWG online calculator) and so equal volumes of forward and reverse 
strand DNA were mixed together, heated to 90 ºC in a hot block and slowly cooled to 
room temperature. Alternatively, the DNA was annealed in a PCR machine. The labelled 
DNA was not purified at any stage prior to the EMSA as literature states that 
purification is not necessary.  
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Figure 87: Concentration screen to determine concentration of MtrR required to observe a gel 
shift. Lanes 1-7: 3’labelled dsDNA (1 nM) incubated with 0, 0.0125, 0.25, 0.375, 0.62, 0.75 and 
1 M MtrR. Lanes 8-10: 3’-labelled forward DNA, 3’-labelled reverse DNA, 3’-labelled 
annealed DNA. 
DNA sequence used: 
Forward: 5’-TTT TTA TCG GTG CAA TCG TGT ATG TAT AAT (249) 
Reverse: 3’-AAA AAT AGC CAC GTT AGC ACA TACATA TTA (250) 
 
The annealing was not 100% successful in forming double stranded DNA as can be seen 
in Figure 87. The absence of a lower band in lane 7 together with the retarded band is 
indicative of the MtrR : DNA complex. 
With evidence that 1 M MtrR causes a gel shift of labelled ds DNA (5 nM), an 
experiment was designed to assess the effect of peptide 203 on the complex. If the 
peptide acts as an inducer of MtrR, the protein should be released from the DNA. A 
screen of different concentrations of 203 was undertaken (Figure 88). The peptide did not 
appear to dissociate MtrR from the operator DNA. In experiments using 1 M MtrR two 
shifts were observed, whereas when 0.5 M MtrR was used only one shift (a faint band) 
was observed. The high shift may be due to a 4:1 MtrR : DNA complex and the lower 
shift due to a 2:1 MtrR : DNA complex, although this is only speculation. At high 
concentrations of peptide, the peptide : DNA : protein complex does not enter the gel, as 
no dsDNA is observed in lane 9, 10, 11 or 12. 
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Figure 88 Result of EMSA using peptide 203 (0 – 1mM) , biotin-labelled mtrDNA (5 nM) and MtrR (0.5 or 
1 M) and table detailing reagents used. 
 
3.5.6.4 Conclusions 
The synthetic peptide 203 did not displace MtrR from its operator DNA. Despite ITC 
evidence showing that this peptide binds MtrR it appears not to act in the hypothesised 
manner as a ligand that causes derepression of the gene. Furthermore, EMSA 
experiments using the natural product LL-37 (personal communication Dr Ines Borges-
Walmsley) also indicate that LL-37 does not cause the protein to dissociate from the 
DNA. These results indicate that either the peptides function via an unexpected 
mechanism, possibly binding to MtrR not complexed to the DNA thus preventing MtrR 
from locating on the operator DNA. More studies are necessary to determine the role of 
peptides in the activation of the mtrCDE genes via MtrR depression of the mtrCDE 
operon. Unfortunately there was no time to explore other techniques such as NMR, cell 
and in vitro methods to assess the ability of ligands to induce protein based depression of 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
MtrR ( M) - - 0.5 1 0.5 1 0.5 1 0.5 1 0.5 1 1 1 
DNA (nM) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
Peptide ( M) - - 0 0 1 1 25 25 50 50 1000 1000 - - 
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genes are reported in the literature. A cell based assay was used to show that a TetR 
ligand peptide isolated from a PHAGE display library could induce derepression of the 
lacZ gene by binding to TetR.307 Expression of the inducer peptide was as a thioredoxin 
fusion and rather than attempting to express the C-terminal section in vivo as a fusion 
protein, a chemical biology solution was sought.  
 
3.5.7 Investigating antimicrobial properties of LL-37 and derivatives 
 
3.5.7.1 Introduction 
Undeterred by the negative result from the EMSA assays, two further questions 
remained regarding the bioactivities of the synthetic derivatives of LL-37, viz. 
antimicrobial activity and the ability for MtrCDE to export the peptides. The following 
section outlines microbiological methods to determine the antibacterial effects of 
peptides and then the results from this study are discussed. 
An experiment was designed that allowed the antibacterial effects and substrate 
specificity for the MtrCDE pump to be screened in the same experiment. It was not 
possible to work with strains of N. gonorrhoeae (a Catagory II pathogen) during this 
research project, so an E. coli system was used that contained the genes for the MtrCDE 
efflux pump. Precedent exists in the literature for using an antibiotic susceptible strain of 
E. coli (KAM3 strain) to probe the effects of -lactamase and efflux pump genes on 
antimicrobial susceptibility.308 It was envisaged that the inclusion of the mtrC, mtrD, 
mtrE and genes into KAM3 E. coli cells would create a system to test whether the 
synthesised peptides are substrates for the MtrCDE efflux pump. The antibacterial effect 
of the peptides would be tested at the same time, as control cells with no gonoccocal 
gene inserts would show whether the peptides are capable of killing susceptible bacteria. 
The KAM3 E. coli cell strains containing the mtrC, mtrD and mtrE and genes were 
constructed by Li Zhang from the Walmsley research group.309 The genes for the inner 
membrane protein, MtrD, the outer membrane protein MtrE and the membrane fusion 
protein, MtrC, were cloned into the pACYC-duet expression vector that allows for 
simultaneous expression more than one protein. Four KAM3 strains were prepared that 
contained 0, 1, 2, or 3 membrane protein genes: mtrD, mtrCD, mtrCDE and plasmid only 
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(strain previously described in Chapter 2).310 The strains are designed to reveal the 
importance of the different components of the tripartite efflux pump and analogue 
systems have been reported in the literature for testing the resistance conferred by the 
efflux pump to a variety of antimicrobial compounds. Expression of MtrD alone does 
not lead to increased resistance without the membrane fusion protein MtrC. The 
expression of mtrCD can increase resistance towards antimicrobial agents as the toxic 
compounds can be removed from the cytoplasm to the periplasm. High levels of 
resistance can be achieved by expression of mtrCDE as the toxic compound can be 
transported across the outer membrane. Previous studies by the Walmsley group using 
pACYC containing strains have shown that the mtrCDE expressing E. coli gave results 
comparable to growth curve monitoring in N. gonorrhoae cultures indicating the utility 
the model E. coli system.309 Glycerol stocks of the four pACYC strains were kept at -80 °C 
and colonies grown on agar plates as required for culturing of cells for growth assays. 
3.4.2 Antimicrobial assays using synthetic peptides as probes 
Screening of the peptide antibiotics against the various strains of mtrCDE expressing 
bacteria requires multiple readings to obtain repeats of the data in order to validate it. 
Whilst this can be achieved manually this requires considerable time and resources. For 
example, if four strains of E.coli are to be screened against one antimicrobial agent using 
a manual growth curve assay, three test tubes are required per concentration, which is 
18 tubes per strain and a total of 72 test tubes are required. Consequently, an automated 
method was sought to simplify and expedite data collection. In the literature, several 
methods to assess antimicrobial susceptibility have been reported that use 96-well plates 
and UV-vis spectrophotometric plate readers.311 For example, bacterial susceptibility to 
small molecule antibiotics and antimicrobial peptides has been evaluated using 96-well 
plate technologies since Brewster reported a reliable 96-well plate method for bacterial 
enumeration.312,313 Brewster showed that there is a direct correlation between optical 
density as measured at 600 nm and bacterial cell survival so that observing a decrease in 
the optical density indicates a decrease in the number of viable bacteria. The optical 
density can then be used instead of the traditional plate assays to count the number of 
bacteria present, as measured in colony forming units (cfu). It was also shown, that the 
length of time for the culture to reach an O.D of 600 nm, set as the threshold value for 
survival, is indicative of the number of viable cells present. These methods have been 
developed by other researchers and applied to peptide antibiotics. For example Ericksen 
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et al used the length of time for the threshold value to be reached to determine the MIC‟s 
of a range of defensin peptides.314 Otvos used the relationship between O.D and cell 
viability to generate a general method for the determining the antimicrobial effects of 
cationic peptides by monitoring growth at 600 nm, then taking the final O.D value at 
600 nm at the end of the growth curve monitoring (16 hrs) and plotting O.D. versus 
peptide concentration to determine cell MIC values.315 IC50 values can also be 
determined using the Otvos method and an IC50 is defined as the antibiotic 
concentration where the activity crosses the half-line between uninhibited growth and 
medium only at λ = 600 nm.316 
Application of the 96-well method in this project enabled the four test strains (pACYC-
mtrD KAM3, pACYC-mtrCD KAM3, pAYCY-mtrCDE, pACYC-only KAM3) to be grown 
on the same microwell plate and at a range of concentrations (Figure 89). The outermost 
wells are prone to evaporation so these contained only 100 L of media. Each well in the 
microplate has a capacity of 400 L and so using only 200 L per well ensures that when 
the microplate is shaken in the spectrophotometer there is no cross contamination 
between wells. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B   0 0 0 25 25 25 50 50 50 100   
C   100 100 150 150 150 0 0 0 25 25   
D   25 50 50 50 100 100 100 150 150 150   
E   0 0 0 25 25 25 50 50 50 100   
F   100 100 150 150 150 0 0 0 25 25   
G   25 50 50 50 100 100 100 150 150 150   
H                         
 
Total volume 200 uL 
 
  MtrD 
 
  MtrCD 
 
100 uL Culture 
  
  MtrCDE   
pACYC 
only 
 
100 uL peptide + buffer 
       
Figure 89 Preparation of microwell plate for peptide bioactivity studies 
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Growth was monitored for 16 hours using a UV-Vis spectrophotometer thermostated at 
37 °C. The data was exported and analysed in EXCEL. To construct the survival curves, 
the end points of each concentration were averaged and the mean O.D. values were 
changed to percent survival using the equation ([mean O.D, x M peptide] / [mean O.D. 
0 M) peptide] and the data plotted on a graph with concentration vs O.D. 
Initial experiments with peptide 203 used LB broth as the media for the growth curve 
monitoring but the lowest survival rate observed was 40%. It is known that 
antimicrobial peptides can be inhibited by salts and this effect may contribute to the low 
activity so Müller Hinton broth was used in the repeat of the experiment and a larger 
antibacterial profile was observed.317 The difference between mtrCDE expressing cells 
and control cells (pACYC only) was ~ 30% compared to ~ 20% for the experiment 
carried out using LB. Consequently, all subsequent experiments were carried out with 
MH broth. 
Using the conditions optimised with the C-terminal peptide the other synthesised 
peptides were assessed for antimicrobial activity. The addition of the benzophenone 
moiety to the N-terminus of peptide 203 decreases the susceptibility of pACYC control 
and MtrD expressing KAM3 cells towards the peptide (40% survival relative to 20% 
survival with the native peptide), but the survival of MtrCD and MtrCDE expressing 
cells is not affected (~ 50% in both experiments). This suggests that the aromatic group 
does not affect the ability for the efflux pump to transport the peptide. The MtrCDE 
pump is also capable of recognising peptides, as shown by the survival curve for the N-
terminal peptide (Figure 92). 
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Figure 90 Survival curves for FLRNLVPRTES (203) in either Luria Broth (LB, upper panel) or Müller 
Hinton Broth (MHB, lower panel) 
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Figure 91 Survival curve for peptide 243 
 
 
 
Figure 92 Survival curve for N-terminal peptide of LL-37 (204) 
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Figure 93 Growth curve data for pACYC and MtrCDE expressing KAM3 cells in the presence of peptide 
204 (200 M) 
 
There is only a small change in strain susceptibility to the N-terminal peptide 196, even 
at high concentrations, which suggests that the peptide is not very effective at 
penetrating the cell membrane. Greater insight into the observation that the MtrCDE 
expressing strain and the pACYC control strains exhibit the same level of survival at 
200 M is provided by looking at the optical densities with respect to time (Figure 93). 
The MtrCDE expressing cells are not affected at all by the peptide and grow at the same 
rate over the course of the experiment. The pACYC strain shows a lag time of 
250 minutes when the cell density is not increasing but thereafter the strain grows at 
exponential rate to reach a final O.D similar to MtrCDE strain.  
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Figure 94 Survival curve for core peptide 100 
 
The core peptide 100 is also hydrophilic but in contrast to the NT peptide 204, the core 
peptide is helical.214 As a result of the defined structure the core peptide displays a 
potent antimicrobial effect against each of the test strains (Figure 94). A 50% increase in 
susceptibility is seen for each strain on increasing peptide concentration from 
0  50 M.  
Further truncation of the core peptide to RIVQRIK (238) decreases activity to a level 
comparable to the N-terminal region (Figure 95).  
 
Figure 95 RIVQRIK 238 
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Figure 96 Survival curves for LL-37 (12) in at various concentrations and different strains of mtrCDE 
 
These results together with the observation that the 203 peptide has an MIC against the 
pACYC strain comparable to the core peptide indicate that helicity and 
hydrophobicity are more important structural factors that contribute to antibacterial 
activity than charge. 
The natural product LL-37 is the most active antibacterial peptide, and due to the high 
activity the concentration range was lowered to 0 – 10.0 M range (Figure 96). The 
MtrCDE pump provides some resistance to the peptide, raising the MIC four fold. 
The effects of the tested peptides against the pACYC strain are summarised in graph G. 
The only peptides to have an MIC of 200 M or less were the natural product and the 
core and C-terminal peptides. The addition of the benzophenone moiety to the C-
terminal peptide reduced the antibacterial effect by a factor of 2. This can be rationalised 
by the addition of the hydrophobic photolabel to the peptide increases the overall 
hydrophobicity of the peptide significantly, causing the peptide to lodge in the 
membrane but not to cause structural defects sufficent to cause bacterial cell wall lysis.  
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Figure 97 Comparison of MtrCDE expressing KAM3 cells grown in the presence of different peptides 
 
Previous studies in the Walmsley group using the pACYC strains showed that the MIC 
for nafcillin against the pACYC strain was 153 M (64 g / mL). The observed MIC for 
LL-37 in this study is 50 M (43 g /mL) the two synthetic peptides 203 and 100 are 
~ 200 M indicating that despite exhibiting much MIC higher values than LL-37, they 
still maintain antibacterial activity.  
Differences are observed in MIC values between MtrCDE expressing bacteria and 
pACYC stains indicating that the synthesised peptides are substrates for the MtrCDE 
efflux pump. In order to investigate the protective effect of expressing mtrC, mtrD and 
mtrE genes, growth curve monitoring was performed for the MtrCDE expressing strain 
in the presence of 203 (100 M) and varying concentrations of CCCP (Figure 98), which 
uncouples proton motive force across the bacterial membrane, removing the energy 
source for the efflux pump.318 If the MtrCDE efflux pump is capable of exporting the 
peptide, then the presence of CCCP should effect the efflux of the antibacterial peptide 
from the cell and hence compromise the growth rate and survival of the bacteria. It has 
been shown that the concenration of CCCP necessary to block efflux is strain dependent  
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Figure 98 Effect of peptide (203, 100 M) in the presence of CCCP at different concentrations on the 
growth of KAM3 E. coli cells expressing proteins for the MtrCDE efflux pump. Blue circles = 0 M 
CCCP, red squares 100 M CCCP, green triangles 1000 M. 
consequently E. coli were grown at two concentrations of CCCP, 100 and 1000 M.319 
200 M peptide concentration was chosen because Figure 98 shows MtrCDE to confer a 
dinstinct protective effect to the bacteria compared to the control strain. The effect of 
100 M CCCP is clearly seen , with growth considerably slowed and the presence of 
1000 M CCCP is fatal for the bacteria.  
As a control to analyse the effect of CCCP, the concentration of CCCP was held constant 
at 100 M and the concentration of peptide varied. The aim of this analysis was to check 
that the decrease in survival of bacteria seen in Figure 98 was due to the peptide and not 
due to the CCCP. Figure 99 indicates that the change in susceptibility towards peptide 
203 is due to the removal of the proton motive force and not due to a toxic concentration 
of CCCP. The general reduction in survival across all stains suggests that CCCP may 
compromise the viability of cells, however, only a small change in survival of the 
pACYC only strain relative to the strains is seen at 200 uM concentration peptide. It 
would be expected that the pACYC only strain not to be greatly affected by CCCP due to 
the lack of active efflux in the membrane and, as expected, the percent survial at 200 M 
peptide is comparable to that in Figure 98. A considerable change is seen for MtrCDE 
and MtrCD expressing strains. The percent survival for the MtrCDE expressing strain is 
lower at 200 M peptide than the control strain. The presence of protein channels in the 
bacterial membrane may compromise the stability of the inner and outer membrane, and 
possibly enable more peptide to enter the cell thus decreasing cell survival to a level 
lower than that of the control strain. 
 
 
151 
 
 
Figure 99 Effect of 100 mM CCCP on the survival of MtrD, MtrCD, MtrCDE and pACYC strains of E. coli 
in varying concentrations of peptide 203 
 
3.4.4 Summary 
The studies using E. coli cells expressing gonococcal membrane transport proteins show 
that the peptides synthesised in this project are susbstrates for the MtrCDE efflux pump. 
Peptides 203 and 100 were shown to have MIC values of 200 M towards E. coli cells not 
expressing membrane transport proteins and this concentration is comparable to the 
known antibiotic naficillin (MIC 153 M for KAM3 E. coli). 
 
3.4.5 Conclusions 
In conclusion, the growth curve studies show that the synthesised peptides are 
substrates for the MtrCDE efflux pump and have weak antimicrobial effects at high 
concentrations. 
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4. Conclusions and further work  
This chapter details work carried out alongside the research project described and 
provides suggestions for the development of the work described. 
4.1 Conclusions 
Key findings from this thesis are: 
1. Tetracycline (11), spectinomycin (10), penicillin G (2) and LL-37 (12) were shown 
to be ligands for MtrR. 
2. MtrR is capable of hydrolysing penicillin G (2) and this was shown to provide a 
survival benefit to E. coli cells. 
3. The binding of LL-37 was analysed by synthesising fragments of the natural 
product and assessing each peptide individually for binding to MtrR by ITC. 
This approach confirmed that the N-terminal peptide (204) does not interact with 
the protein whereas the C-terminal peptide (203) binds MtrR with high affinity. 
The known antibacterial peptide 100 was shown to bind the peptide weakly. 
4. Using a photoactivated analogue of 203 insights into the molecular interactions 
between the peptide ligand and MtrR were determined. A large peptide binding 
domain and a secondary peptide binding domain were isolated through a mass 
spectrometric assay and confirmed by homology modelling. 
5. Peptide 203 was shown not to dissociate MtrR from its operator DNA. This 
contradicts the hypothesis that ligands for the MtrR and MtrCDE efflux pump 
induce derepression of the efflux pump genes. It is possible that the charged 
peptide associates with the DNA in the EMSA assay, stabilising rather than 
destabilising the interaction.  
6. A microwell plate assay was developed to assess the antimicrobial effects of the 
synthesised peptides and also whether the peptides are susbtrates for the 
MtrCDE pump. Hydrophobic or -helical peptides are more active than 
hydrophilic and charged peptides. 
The following section details suggestions for future elaboration of the results of this 
project, together with a summary of some initial studies conducted alongside the 
discussed research.  
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4.2 Future work 
4.2.1 Introduction 
4.2.2 Development of cathelicidin peptide screening 
At the beginning of section 3.2 it was shown that not only was LL-37 a substrate for the 
MtrCDE efflux pump, but also porcine antimicrobial peptide PG-1 (71) and its synthetic 
analogue PC-8 (72). PG-1 belongs to the cathelicidin family due to the way in which it is 
produced and stored in vivo. In contrast to LL-37, PG-1 adopts a -hairpin structure 
constrained by two disulphide bonds. Initial experiments to assess the viability of PG-1 
and PC-8 to act as ligands for MtrR began with the synthesis of PC-8. This proceeded 
well using PyBOP double coupling. Although some deletion peptides were identified 
arising from incomplete couplings of arginine to arginine, subsequent prep HPLC 
yielded the desired product in 18% yield. 
 
Figure 100 HPLC PC-8 
Encouraged by the successful synthesis of PC-8, attention next turned to the preparation 
of the parent natural product PG-1. The preparation of cysteine containing peptides 
requires special consideration due to the number of potential side products due to the 
unique reactivity of the sulphur containing side chain. Preparation of multiple 
disulphide bonds requires prudent use of protecting groups.320 Reflecting this, it was 
envisaged that the disulphide bond between Cys8 and Cys13 would be installed by 
selectively deprotecting Cys8 and Cys13 on the solid phase. TFA / TIS /H2O cleavage 
would then yield the side chain deprotected peptide in a -turn conformation, 
constrained by the Cys8-Cys13 disulphide bond. This would bring Cys6 and Cys15 in 
close proximity to allow formation of the second disulphide bond by air oxidation. The  
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Figure 101 Organisation of cysteine protecting groups for regioselective disulphide bond formation (252); 
Fmoc-Cys(tBuS)-OPfp (253);  Fmoc-Cys(Mmt)-OH (254) 
 
protecting groups chosen to establish the disulphide bond on the solid phase were tert-
butyl-S ether and monomethoxytrityl (mmt). The tBuS ether can be removed by 
treatment with mecaptoethanol and mmt is removed in 1% TFA.321 HPLC purification 
of the mono-disulphide peptide provides the substrate for the second disulphide bridge 
formation that occurs in 100 mM Tris buffer, pH 7 over a period of hours, the reaction 
can be monitored by HPLC. Protection of sulphur with tBuS has been shown to activate 
the  proton to base removal and so to avoid racemisation at the  chiral centre, the 
amino acid is introduced as the highly reactive OPfp ester, that does not require 
activation with a phosphonium or urononium coupling agent.322 
Unfortunately, in two attempts at the synthesis the machine completed its cycles but 
HPLC analysis (Figure 102) revealed multiple products and the MALDI analysis showed 
that contained only trace amounts of the desired peptide were present.  
Following the failure of the initial syntheses, and owing to the high cost of the Fmoc-
Cys(tBuS)-OPfp and Fmoc-Cys(Mmt)-OH, an alternative strategy was sought. 
Reviewing the literature revealed the possibility of constructing both disulphide bonds 
by air oxidation, as the conformation of the desired product represents the most 
thermodynamically stable arrangement of disulphide bonds.323 
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Figure 102 HPLC trace of failed PG-1 synthesis 
 
Building on the success of the microwave synthesis of LL-37 peptides, a manual 
microwave assisted synthesis of 71 was attempted. Standard HBTU couplings were 
used, with no preactivation of Cys in the HBTU solution. The synthesis proceeded 
without problems and the desired product linear peptide was obtained in a crude yield 
of 35%. The peptide was dissolved in 100 mM Tris-HCl, pH 8.2 and stirred in an open 
vial for 24 hours. Mass spectrometry indicated full conversion to the disulphide product. 
With both peptides in hand, ITC binding studies with MtrR were carried out. 
Dissappointingly, neither PC-8 nor PG-1 were observed to bind MtrR by ITC. To confirm 
that these peptides are substrates for the MtrCDE efflux pump, growth curve 
experiments were performed that confirmed literature reports of PC-8 and PG-1 as 
substrates for MtrCDE and that PG-1 was more active than PC-8. Further investigation 
with these peptides was not undertaken.  Future avenues for investigation include the 
use of florescence assays or NMR (isotopically labelled or fluorine labelled peptides) to 
monitor protein : peptide binding and to correlate the results with the ITC studies. 
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Figure 103 Bioactivity of PG-1 (upper panel) and PC-8 (lower panel) Each of the KAM3 strains was more 
susceptible to PG-1 than to PC-8 and this is consistent with literature that suggests the structure of PG-1 
being more able to insert into membranes than the random coil PC-8. In both sets of experiments, it is 
clear the  MtrCDE efflux pump provides a survival advantage indicating that the peptides are 
transported by the efflux pump. 
 
4.2.3 Conclusion 
The porcine antimicrobial peptide and its linear analogue were synthesised and shown 
not to bind to MtrR by ITC. Antimicrobial assays showed that PG-1 (71) is more active 
than PC-8 (72) and both are substrates for the MtrCDE efflux pump. Further experiments 
are required to investigate the ligand binding capabilities of PG-1 and PC-8 to MtrR. 
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4.3 Cyclic peptides 
The C-terminal peptide fragment (203) reported here as a ligand for MtrR and 
antimicrobial peptide is an interesting lead peptide for further investigation. Linear 
peptides are not stable in vivo for a long time and the predicted in vivo persistence of 203 
is only 2 minutes.324 In order to improve the lifetime and antimicrobial effects of the 
peptide it would be interesting to look at cyclic analogues. To this end, an initial study 
on the synthesis of cyclic peptides as ligands for MtrR was undertaken. Two strategies 
will be discussed briefly a) the solution cyclisation using a protected peptide precursor 
and b) the synthesis of a solid phase linker to aid peptide cyclisation on the solid phase.  
 
4.3.1 Solution phase synthesis 
In order to develop the chemistry to produce cyclic analogues of peptide 203, the 
sequence was simplified. The peptide was shortened to seven residues and the glutamic 
acid residue changed to alanine. Scheme 7 outlines the synthesis of cyclic LVPRTAS 
(262). The synthesis began with the acylation of chloro trityl resin (223) with Boc-Ser-OH 
(256). The side chain OH was then acylated, with Fmoc-Ala anhydride (258), and at this 
point the loading was determined by Fmoc number to be 80%. The remaining OH were 
capped with acetic anhydride and the remaining amino acids added using standard 
microwave assisted peptide couplings. The linear peptide was removed from the resin 
(260) using TFE / DCM (2:8) to maintain the side chain protecting groups (261). 
Cyclisation with PyBOP and HBTU were attempted but no product were seen. Due to 
time constraints, the synthesis was not optimised further but represents the foundation 
for future studies in the group. 
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Scheme 7 Synthesis of cyclic analogue of FLRNLVPRTES 
 
4.3 Initial studies on the synthesis of a pseudo-proline linker for solid phase peptide 
synthesis 
In order to aid the solid phase synthesis of cyclic peptides, preorgisation of the linear 
peptide in a conformation that aids cyclisation is desirable. One possible way to achieve 
this is to introduce a bend at the C-terminus by construction of the peptide on a pseudo-
proline linker (263). The orthogonal protecting groups allow Fmoc chemistry to be 
followed by Pd catalysed removal of the allyl protecting group to enable on-resin N- to 
C-terminus cyclisation. On TFA cleavage of the cyclic peptide from the resin, the 
pseudo-proline is cleaved to give native amino acids in the peptide product. 
The synthesis began with the allyl protection of the carboxylic acid of threonine and this 
proceeded in 96% yield. Protection of the side chain alcohol was followed by an EDCI 
mediated peptide coupling to Fmoc-Gly-OH. Removal of the TBDMS protecting group 
was initially attempted with TBAF but this led to removal of the Fmoc protecting group 
so the milder Et3N-HF was used and this gave 268 in 76% yield. Disappointingly, 
attempts to couple the dipeptide to the linker 269 were unsuccessful. Future 
development of this work is necessary and a screen of the conditions for forming the 
oxazolidine ring (acid catalyst and temperature) is needed to identify the optimum 
conditions for forming 263. 
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Scheme 8 Initial synthesis route to pseudo proline linker 
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5. EXPERIMENTAL 
5.1 Chemistry 
5.1.2 General procedures 
Dried solvents were prepared using the Innovative Technology Solvent Purification 
System, as per standard procedures within the department.  
Melting point 
Melting points were determined using a Thermo Scientific 9100 machine. 
NMR spectroscopy 
1H-NMR experiments were recorded in CDCl3, DMSO or d6-MeOH at 200, 300, 400 or 
500 MHz on Varian Mercury 200, Varian unity 300, Varian 400, Bruker Avance 400 or 
Varian Ionva 500 and reported as follows: chemical shift δ (ppm) (number of protons, 
multiplicity, coupling constant J (Hz), assignment). Residual protic solvent CHCl3 
(δH = 7.26) was used as the internal reference. 13C NMR were recorded at 126 MHz on a 
Varian Ionva 500 or at 101 MHz on a Bruker Avance 400 using the NMR solvent peak as 
the internal reference. 19F NMR was recorded on a Varian 400. 
Mass spectrometry 
Electrospray mass spectra (ES) were recorded at the University of Durham on a either a 
Micromass LCT, Thermo Finningan LTQ FT or Micromass LCT, Q-TOF Premier. MALDI 
spectra were recorded on either an Applied Biosystems Voyager-DE STR, Micromass 
MALDI TOF MS or Bruker Autoflex TOF/TOF.  
Preparation of MALDI target (Synthetic peptides) 
A saturated solution of -cyano hydroxyl cinnamic acid (~ 50 mg) in 3:7 H2O containing 
0.1 % TFA (1 mL) was prepared. 2 L of this matrix solution was mixed with 2 L 
analyte and each target well of the 96-well plate was spotted with three drops (each ~ 1 
L) of analyte. The matrix : analyte drops were air dried before analysis. 
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Chromatography 
Thin layer chromatography was carried out on Merck aluminium backed silica gel 60 F254 
plates and visulilised under UV light at 254 nm; phosphomolybdic acid in ethanol and 
potassium permanganate in water were used as stains.  
Flash chromatography was carried out manually using 40 – 63 m 60 Å silica gel, or using 
pre-loaded cartridges on a Combiflash® Rf (Teledyne Isco) system. 
HPLC was carried out at either Cambridge Research Biochemicals using Waters system 
with a Jupiter column (C18, 250 x 25 mm, 5 m particle size)  or at Durham University 
on either a Perkin-Elmer Series 200  HPLC with a ACE semi-prep column (C18, 250 x 10 
mm, 5 m particle size), or on a Waters Mass Directed Prep instrument using an Xbridge 
analytical column (C18, 100 x 4.6 mm, 3 m particle size) or a preparative column (C18, 
100 x 19 mm, 5 m particle size). Peptides were eluted in either H2O / MeCN + 0.1 % 
TFA or H2O / MeOH + 0.1 % formic acid.  
 
IR spectroscopy 
Infra red spectra were recorded either as a solution in chloroform via transmission IR 
cells or as KBr discs on a Perkin Elmer Series 1600 FT-IR spectrometer. 
 
Optical rotation 
Optical rotations were acquired on a Jasco P-1020 polarimeter in solution (solvent stated 
per experiment). 
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5.1.3 Peptide synthesis 
5.1.3.1 General procedures 
Fmoc-amino acids and Boc-amino acids were purchased from Novabiochem 
(Nottingham, UK), Pepceuticals (Nottingham, UK) or CEM (Buckingham, UK). 
Coupling agents were purchased from Novabiochem. HPLC grade DMF was used for 
coupling reactions and was purchased from Fisher Scientific or Rathburn (Walkerburn, 
UK). Resins were purchased from Novabiochem. 
Method Coupling Deprotection T / oC 
 Activator t / min Eq. Composition t /min  
ACT 348  HOBt  
PyBOP 
60  4.9  25% Piperidine  i) I) 3 
ii) II) 10 
~ 25 
ACT 578 PyBOP 2 x 60  4.9  25% Piperidine  i) 3 
ii) 10 
~ 25 
Pioneer PyBOP, 60 4.9 20 % piperidine 
/3% DBU 
5 ~ 25 
HATU Arg, 
Val, Ile) 
60 4.9  
CEM 
Microwave 
HBTU 5 4.9  25% Piperidine  5 70 
HBTU Arg  15 4.9  
Manual PyBOP 60  7 25% Piperidine  i) 3 
ii) 15 
~ 25 
HBTU 30  5 
HATU 30  5 
 
Table 13 Peptide synthesis cycles 
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Method Resin Cleavage mixturei Time / min Temp. / °C 
Manual and 
after 
automated 
synthesis 
Rink amide, Wang TFA / TIS / H2O 120 – 300 ~ 25 
Microwave Rink amide, Wang TFA / TIS / H2O 
TFA / TES / H2O 
15 – 30 38  
Trityl TFE / DCM 15 38 
iVolume of cleavage solution was 5 x resin volume  
Table 14 Peptide cleavage conditions 
Process Temperature /oC Microwave power / W Time  / min 
Deprotection 70 ± 5 20 3 
Coupling (not Arg) 70 ± 5 20 5 
Coupling (Arg) 25 ± 5 0 5 
70 ± 5 20 15 
Coupling (benzoyl 
benzoic acid) 
70 ± 5 20 10 
Cleavage 38 ± 5 20 18 
 
Table 15 Settings used in the CEM microwave for peptide synthesis 
Fmoc loading test 
5 mg resin was removed for the Fmoc loading test. The resin was agitated in 3 mL 
piperidine / DMF solution for 15 min and the resin allowed was to settle prior to 
measuring the absorption of the solution at 304 nm. 
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5.1.3.2 Synthesis of LL-37 and derivatives 
FLRNLVPRTES (203) 
ACT 348 synthesis: Wang resin was (300 mg, 0.87 mmol /g) derivitised with Fmoc-
Ser(tBu)-OH using the symmetric anhydride method.336 Fmoc-Ser(tBu)-OH (1 g, 2.61 
mmol) and DIC (163 mg, 1.3 mmol) were dissolved in dry DCM (10 mL) at 0 °C and the 
reaction stirred for 30 min. The reaction was concentrated and the resulting white foam 
dissolved in DMF (2 mL) and added to pre-swollen Wang resin contained in an SPPS 
tube. DMAP (3 mg, 0.03 mmol) was added and the reaction was shaken for 2 hours at 
room temperature. The resin was drained, washed with DMF (3 x resin volume) and 
5 mg resin removed for Fmoc loading test. The resin was agitated in 3 mL piperidine / 
DMF solution for 15 min and the resin allowed to settle prior to measuring the 
absorbance of the solution at 304 nm. Resin loading was calculated to be 0.55 mmol /g. 
Unreacted OH functionality of the resin was blocked by reaction of 10% acetic anhydride 
with the resin for 60 min. The resin was washed with DMF (3 x resin volume) before 
being transferred to the peptide synthesiser. Standard Fmoc / tBu chemistry used as 
described in Table 13. The final Fmoc protecting group was removed in the synthesiser 
and the peptide cleaved using the standard protocol. Although the desired product was 
detected, separation from the side products was not possible. MS m/z (MALDI) 1330.7 
[M+H]+, 1231.6 [M-V]+, 1216.6 [M-L]+, 1174.6 [M-R]+, 1017.5 [M-2R]+; HPLC (595% 
MeCN) 
 
Figure 104 HPLC trace for the crude product from the ACT348 synthesis of 203 
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Manual synthesis: Pre-loaded Fmoc-Ser(tBu)-Wang resin (750 mg, 0.28 mmol / g) was 
swollen in DMF for 15 min in a SPPS reaction vessel. Couplings were conducted with 
PyBOP as described in Table 13 and all couplings monitored by Kaiser test. 250 mg resin 
was cleaved and isolated using standard protocols. Purification gave FLRNLVPRTES 
(203) as a white powder (3 mg, 15%). MS C59H98N18O17: m/z (MALDI) 1331.1 HRMS: 
Calculated for C59H98N18O17 1331.521 found 1331.743. HPLC (595% MeCN) 
Microwave synthesis: Rink amide resin (500 mg, 0.61 mmol / g) was swollen in DMF 
(8 mL) and all deprotections and couplings conducted in a CEM microwave as per Table 
13, 15 and 16. The peptide was cleaved and isolated using standard protocols. 250 mg of 
resin was used for the cleavage step. Purification gave 203 as a white powder (8 mg, 
25 %). MS C59H98N18O17: m/z (MALDI) 1331.1 HRMS: Calculated for C59H98N18O17 
1331.521 found 1331.621; HPLC (595% MeOH) 
 
Figure 105 HPLC trace for the purified product from the microwave synthesis of 203 
 
IKDFLRNLVPRTES (237) 
ACT 348 synthesis: Wang resin (300 mg, 0.87 mmol /g) was derivitised with Fmoc-
Ser(tBu)-OH using the symmetric anhydride method as detailed above before being 
transferred to the peptide synthesiser (final loading 0.55 mmol /g). Standard Fmoc / tBu 
chemistry used as described in Table 1. The final Fmoc protecting group was removed in 
the synthesiser and the peptide cleaved using the standard protocol product. No desired 
product was detected.MS: m/z (MALDI) 1905.9, 1790.9. 
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Manual synthesis: The resin was prepared as above (resin substitution 0.28 mmol /g). The 
peptide chain was assembled in an SPPS tube and all couplings were facilitated by 
HBTU, as per conditions listed in Table 13. 50 mg of resin was transferred to a SPPS 
vessel and the peptide was cleaved and isolated using standard procedures to yield 237 
as a white powder  (2.8 mg, 12%). MS C75H127N22O22: m/z (MALDI) 1686.9 [M+H]+; HPLC 
(595% MeCN) 
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Figure 106 HPLC trace for the purified product from the manual synthesis of 237 
 
FKRIVQRIKDFLR (101) 
Manual synthesis: Rink amide resin (500 mg, 0.60 mmol /g) was swollen in DMF in a 
SPPS tube. The peptide was prepared manually using PyBOP as the coupling reagent 
and the conditions listed in table. The peptide was cleaved and isolated using standard 
procedures. Crude yield not determined due to many side products, inseparable by 
HPLC; MS (MALDI) m/z 1719.0 [M+H]+, 1786.2 [M+piperidine]+ , 1562.2 [M+H-R]+, 1406 
[M+H-2R]+ ; HPLC (595% MeCN) 
 
Figure 107 HPLC trace for crude product from the manual synthesis of 101 
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Microwave synthesis: Rink amide resin (500 mg, 0.60 mmol /g) was swollen in DMF in a 
SPPS tube. All deprotection and coupling reactions were carried out using a CEM 
microwave adapted for peptide synthesis. The conditions and settings are listed in 
Tables 14, 15 and 16. 250 mg of resin was used for cleavage, using standard protocols to 
give 12 mg, 4% of the final product after HPLC purification. MS C74H124N24O16: m/z 
M+H+ (MALDI) 1619.1; (ES+) 573.99 [M+3H]3+ HRMS: Calculated for C80H136N25O17 
1719.054 found 1719.064; HPLC (595% MeOH)  
 
Figure 108 HPLC trace for the purified product from the microwave synthesis of 101 
 
RIVQRIK (238) 
Manual synthesis: The resin was prepared as above for FKRIVQRIKDFLR. The peptide 
chain was assembled in an SPPS tube and all couplings were facilitated by HBTU, as per 
conditions listed in Table 14. The peptide was cleaved and isolated using standard 
procedures to yield 238 as a white powder. MS C68H120N22O16: m/z (MALDI) 
911.9[M+H]+; HPLC (595% MeCN) 
 
Figure 109 HPLC trace for the final product 238 
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LLGDFFRKSK (204) 
ACT 578 synthesis: Rink amide resin (250 mg, 0.67 mmol / g) was swollen in the peptide 
synthesiser and all couplings conducted as described in Table 1. The N-terminal Fmoc 
protecting group was removed on the synthesiser and the resin was transferred to a 
sintered glass funnel. The resin was washed with of DMF (3 x resin volume) and DCM (3 
x resin volume) before addition of the cleavage solution. The resin was submerged in 
cleavage solution for 2 hours, before the resin was drained and the filtrate evaporated to 
give thick oil. The crude peptide was precipitated in cold diethyl ether, decanted and air 
dried yielding white platelets; MS: C57H91N15O14 m/z (MALDI) 1210.9 [M+H]+; HPLC 
(595% MeOH). 
 
Figure 110 HPLC trace for the final product 204 
KIGKEFKRIVQRIKDFLRNLVPRTES (99) 
Manual synthesis: Wang resin loaded with Fmoc-FLRNLVPRTES (500 mg, 0.28 mmol /g) 
was swollen in DMF for 15 min in a SPPS reaction vessel. Couplings were conducted 
with PyBOP as described in Table 14 and all couplings monitored by Kaiser test. 50 mg 
of resin was cleaved and the peptide isolated using standard protocols. Purification gave 
99 as a white powder (2 mg, 4.5 %); MS: C143H244N44O37 m/z (MALDI) 3171.1 [M+H]+ ; 
HPLC (595% MeCN) 
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Figure 111 HPLC analysis for the final product 99 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (12) 
Pioneer synthesis: Wang resin pre-loaded with Fmoc-Ser(tBuOH) was loaded dry into the 
synthesiser. Couplings were carried out as described in Table 1. Synthesis was aborted 
after addtition of R18 due to many side products, inseparable by HPLC. HPLC (595% 
MeCN) 
Manual synthesis: Wang resin loaded with Fmoc- KIGKEFKRIVQRIKDFLRNLVPRTES 
(450 mg) was swollen in DMF for 15 min in a SPPS reaction vessel. At the end of the 
synthesis the final Fmoc group was removed by treatment with 25% piperidine /DMF/3 
% DBU before cleavage from the resin using TFA/TIS/H2O. After cleavage of the 
peptide from the resin, mass spec showed no desired product to be present. HPLC 
(595% MeCN) 
 
Figure 112 HPLC trace for the failed synthesis of LL-37 
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5.1.4. Synthesis of benzophenone labelled peptides 
5.1.4.1 Benzophenone-FLRNLVPRTES (243) 
Microwave synthesis: Rink amide resin carrying Fmoc-FLRNLVPRTES (200 mg) was 
swollen in DMF for 15 min. The N-terminal Phe residue was deblocked using 20% 
piperidine / DMF using the standard microwave programme. Benzophenone-4-
carboxylic acid (280 mg, 1.1 mmol) was dissolved in activator solution of HATU 
(380 mg, 0.62 mmol) and DIPEA (2M) for 5 min before being added to the deblocked 
resin. The coupling was conducted in the microwave for 10 min at 70 °C. The resin was 
drained, washed with DMF (3 x resin volume) and fresh reagents added and the 
coupling repeated. The resin was drained, washed with DMF (3 x resin volume), DCM (3 
x resin volume) and then the resin was cleaved using standard protocols. The crude 
peptide was precipitated in cold Et2O, decanted and dried (30 mg, 12%, 59% pure by 
HPLC). A small sample was removed for HPLC and mass spectrometric analyses. The 
crude material was purified using mass directed HPLC to yield a fluffy white solid (3 
mg, 1.2%) m/z 770 (M+H)2+ HRMS (1540.4584) HPLC (595% MeOH)  
 
 
5.1.5 Photoactivated binding studies 
General method: Benzophenone labelled or unlabelled (control) peptide (64 M) was 
incubated with purified MtrR (64 M) for 15 min at 4 °C. The reaction was transferred to 
a quartz cuvette and the photo conversion was performed using a Q-switched third 
harmonic YAG (Elforlight UVFQ series) operating at 355 nm for 15 min. The temporal 
width of the optical pulses was 5 ns and the repetition rate was 1 kHz. Typical pulse 
energies are 100 micro J per pulse. Immediately after irradiation, the cuvette was placed 
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on ice. In order to remove unreacted peptide, the solution was injected onto a 5 mL 
Hitrap desalting column (30 mM Tris, 300 mM NaCl, pH 8.2). The first peak eluted 
contained modified protein and the second peak contained only peptide. The buffer 
used was. The solution was analysed by SDS-PAGE, MALDI and ES+ mass 
spectrometry. 
5.1.6 Synthesis of PC-8 
RGGRLAYARRRFAVAVGR (72) 
ACT 348 synthesis: Fmoc-Arg(Pbf)-Wang resin (0.43 mmol/g substitution) was placed in 
the synthesiser and all deprotections and couplings carried out a per Tables 1, 2 and 3. 
No desired product was synthesised. HPLC (595% MeCN) 
ACT 578 synthesis: PC-8 was synthesised on a 0.2 mmol scale using Fmoc-Arg(Pbf)-Wang 
resin, (0.43 mmol/g substitution). Fmoc deprotection step was performed with 30% 
piperidine in DMF. and all deprotections and couplings carried out a per tables 1, 2 and 
3. The crude peptide was purified by RP-HPLC to yield # as a fluffy white solid 70 mg 
after freeze drying (18%, 100% pure by HPLC). MS C88H150N36O20 (MALDI) 2032.31 
HRMS: Calculated for C88H150N36O20 found ESI- 508.80349 [M+H]4+ 
 
 
Figure 113 HPLC trace for final product 72 
 
 
 
172 
 
5.1.7 Synthesis of PG-1 
RGGLCYCRRRFCVCVGR (71) 
ACT348 synthesis: Rink amide resin (100 mg, 0.62 mmol /g) was swollen in DMF (8 mL). 
All couplings were conducted as described in Tables 14, 15 and 16. After addition of the 
final R residues, the resin was removed from the synthesiser, N-deblocked using 25 % 
piperidine / DMF solution and the resin washed with DCM (3 x resin vol.) No desired 
product seen. 
Microwave synthesis: Fmoc-Arg(Pbf)-Novasyn TGA® resin (300 mg, 0.32 mmol/g) was 
swollen in DMF in a SPPS tube suitable for a CEM microwave. All couplings used 
standard conditions detailed. 100 mg resin was cleaved to give the product as a white 
powder (32 mg, 50%); (MS (MALDI) 2003.5, 1901.99 C88H150N36O20S4 1901.98589 (ES+) 476 
[M+H]4+; HPLC (595% MeOH). 
5.1.8 Cyclic analogue of 203 
Chlorotrityl resin (500 g, 1.3 mmol / g substitution) was swollen in DCM (8 mL) in a 
SPPS tube. The resin was drain and then Boc-Ser-OH (220 mg, 2 mmol) and DIPEA (0.39 
mL) were added to the resin in DCM (8 mL) and shaken at room temperature for 30 
minutes. The resin was drained, washed with DCM and the procedure repeated. 
Unreacted resin was capped using DCM / MeOH / DIPEA (8 : 15 : 5). The free OH of 
serine was esterified with Fmoc-Ala-O-Ala-Fmoc, preformed by stirring Fmoc-Ala-OH 
(2.4 g, 7.8 mmol), DIC (0.49 g, 3.3 mmol) and DMAP (10 mol %) in dry DCM for 30 min 
at 0 °C. The acylation with anhydride was repeated once with fresh reagents to yield 259. 
The resin was transferred to a CEM microwave adapted for peptide synthesis and 
standard coupling procedures applied to prepare 260.  The resin was treated with 
TFE /DCM (8 : 2) for 45 minutes to cleave the peptide from the resin to yield 261. m/z 
(ES+) 965.5 [M-Ser]+  Cyclisation using in solution was attempted using PyBOP but no 
desired product was seen. 
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5.1.9 Pseudo proline synthesis 
 
L-Threonine Allyl Ester325 (265) 
 
Threonine (10g, 84 mmol) was dissolved in CCl4, allyl alcohol (7.32g, 126 mmol) and 
para toluene sulphonic acid (126 mmol) were added and heated under reflux using 
Dean-Stark apparatus. When no more water was collected (15 mL), the reaction mixture 
was concentrated in vacuo. The crude product was washed with water, the organic layers 
collected, dried over MgSO4 and the solvent removed under reduced pressure to yield # 
as a viscous yellow oil (24.1 g, 91 %). [α]D= 4.4, c=1.5 mg/mL, MeOH,; νmax(film) 3154 
(NH2), 2979, 1748, 1215 cm-1; δH (200 MHz; CDCl3) 7.91 (3H, brd, NH3+) 7.73 (2H, d, J 8, 
Ar-H) 7.11 (2H, d, J 8, Ar-H) 6.34 (1H, brd, OH) 5.90 (1H, m, 2-H) 5.30 (1H, d, J 18, 1, 1-
HH), 5.14 (1H, d, J 10, 1, 1-HH) 4.52 (2H, t, J 6, 3-H2), 4.18 (1H, dd, J 13, 6, 4-H) 3.94 (1H, 
dd, J 8, 5-H) 1.24 (3H, d, J 7, CH3); δc (125 MHz; CDCl3) 21(CH3) 22 (Ar-CH3) 54 (CH) 59 
(NCH) 67 (CH) 69 (CH2) 119 (C=CH2) 126 (Ar-C) 128 (Ar-C) 131 (Ar-C) 140 (Ar-C) 141 
(Ar-C) 142 (Ar-C) 172 (OC=O); m/z (ES+) 160.1 (M+H+); HRMS (ES+) found MH+ 160.123, 
C7H13O3N requires M+ 160.125. 
L-Threonine (OTBS)OAlloc (266) 
 
Crude 265 (4g, 12 mmol) was dissolved in dry DCM (50 cm3) and tert-butyl dimethyl 
silyl chloride (3.6g, 23 mmol) and imidazole (4.1g, 53 mmol) were added and the 
reaction stirred at room temperature overnight. The reaction was diluted with ethyl 
acetate (50 cm3), washed with sodium hydroxide (50 cm3) and saturated brine solution 
(50 cm3). The organic layers were combined dried over magnesium sulphate and the 
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solvent removed in vacuo to yield a yellow oil (3.12g, 95%) [α]D= +16.7,c=1.0mg/mL, 
MeOH; νmax(film) 3429, 2955, 2858, 1731 (C=O) 1216 cm-1; δH (400 MHz; CDCl3;) 5.86 (1H, 
m, 2-H), 5.34 (1H, dd, J 16, 1, 1-HH), 5.25 (1H, d, J 9, 1, 1-HH), 4.71 (2H, d, J 5, 3-H2), 4.64 
(1H, dd, J 13, 6, 4-H), 4.42 (1H, dd, J 17, 6, 5-H), 4.25 (1H, m, 4-H), 1.24 (3H, d, J 7, CH3) 0.9 
(9H, s, tBu), 0.01 (6H, d, J 7 Hz, 2 x Si-CH3); δc (101 MHz; CDCl3) 19.7 (HCCH3), 37 
(C(CH3)3), 61 (H2NC), 65 (OCH2), 71 (OCHCH3), 119 (C=CH2) 148 (CH2C=CH2) 174 
(OC=O); m/z (ES+) 273.2 [M+H]+; HRMS (ES+) found MH+ 273.1831, C7H13O3N requires 
M+ 273.1825. 
 
Fmoc-Gly-Thr(OTBS)-OAlloc (267) 
 
Fmoc-Gly-OH (216, 0.73 mmol) was dissolved in dry DCM at 0 °C. EDCI (140 mg, 0.73 
mmol) and DMAP (17 mg, 0.15 mmol) were added. After 10 minutes, a solution of 2 (200 
mg, 0.73) in dichloromethane was added and the reaction stirred for a further 2 hours at 
0oC. The solvent was evaporated and the crude mixture purified by column 
chromatography (1:1 Et2O: Hexane) to give 3 as a colourless oil (320 mg, 79%) Rf 0.2 
[α]D= 4.4, c = 1.5 mg/mL, CHCl3; νmax(film) 3494, 3019, 2955, 2930, 1731 (C=O), 1687, 
1504, 1216, 897 cm-1; δH (500 MHz; CDCl3) 7.78 (2H, d, J 8, Ar-H) 7.61 (2H, d, J 8, Ar-H) 
7.32 (2H, t, J 8, Ar-H), 7.28 (2H, t, J 8, Ar-H), 6.6 (1H, d, J 10, NH), 5.95 (1H, m, 2-H), 5.35 
(1H, d, J 17, 1-HH), 5.27 (1H, d, J 10, 1-HH), 4.61 (2H, m, 3-H2) 4.5 (2H, t, J 8, 6-H), 4.01 
(2H, d, J 6, 7-H2 ), 1.23 (3H, d, J 6, CH3), 0.9 (9H, s, tBu),  0.05 (3H, s, Si-CH3), 0.01 (3H, s, 
Si-CH3); δc (126 MHz; CDCl3) 20 (C-CH3) 28 (C-(CH3)3) 42.5 (6-CH2) 48 (C-(CH3)3) 58 (5-C) 
61.5 (3-O) 63.5 (7-C), 70 (4-C) 119.6 (1-C) 120.1 (2-C) 128-136 (ArFmoc) 140 (OCONH); m/z 
(ES+) 552.73 [M]+ 553.2 [M+H]+ 575.4 [M + Na]+,489.4 [M-C3H5]+ HRMS (ES+) found MH+ 
553.2725, C30H40O6N2Si requires M+ 553.2715. 
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Fmoc-Gly-Thr-OAlloc (268) 
 
267 (200mg, 0.36 mmol) was dissolved in dry THF (5 cm3) and triethylamine 
trihydrofluoride (0.41 cm3, 2.3 mol) was added dropwise. After stirring overnight the 
reaction was complete by TLC analysis. The reaction was filtered through silica to 
remove excess triethylamine trihydrofluoride and the solvent removed in vacuo. 
Purification by flash chromatography (Ethyl acetate: Hexane 2:1) gave 268 as an off 
white oil that crystallised on standing (157 mg, 76%); Rf 0.8 [α]D= 10.0,); νmax(film) 3250, 
2954, 2930, 1728, 1665, 1216 cm-1; δH (500 MHz; CDCl3) 7.78 (2H, d, J 10, Ar-H), 7.59 (2H, 
d, J 10, Ar-H), 7.39 (2H, m, Ar-H), 7.31 (2H, m, Ar-H) 6.87 (1H, d, NH) 5.88 (1H, m, NH) 
5.45 (1H, m, 2-H) 5.27 (1H, d, J 17, 1-HH) 5.21 (1H, d, J 8, 1-H) 4.65 (1H, m, NH) 4.41 (2H, 
t, J 9, 3-H2) 4.21 (1H, t, J 6, 8-H2), 4.11 (1H, m, 5-H), 4.0 (2H, 6-H2) 1.24 (3H, m, CH3); δc 
(126 MHz; CDCl3) 21 (CH3) 43 (Gly-CH2) 58 (NHCH) 62 (OCH2CH) 63 (OCH2CH) 119 
(C=CH2) 120 (H2C-CH=CH2) 128-136 (ArFmoc) 142 (C=O) 172 (C=O) 175 (C=O); m/z (ES+) 
461 [M+Na]+; Found C, 65.21; H, 5.80 C24H25N2O6 requires C, 65.74; H, 5.98% 
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5.2 Biology 
5.2.1 General Procedures 
Bacterial culture 
The following media were used for the culturing of bacteria: 
LB broth: 10.0 g /L Tryptone, 5.0 g / L yeast extract, 5.0 g / L NaCl 
LB agar: 10.0 g /L Tryptone, 5.0 g / L yeast extract, 5.0 g / L NaCl, 15.0 g agar 
YT broth: 16.0 g /L Tryptone 10.0 g / L yeast extract, 5.0 g / L NaCl 
SOC media: 2.0 g Tryptone, 0.5 yeast extract, 2.0 mL NaCl (5M), 1.0 mL KCl (1M), 1.0 mL 
MgCl2 (1M), 1.0 mL MgSO4, 2.0 mL glucose (1M) in 100 mL H2O 
MH broth: Purchased from Fluka and used at 23 g / L 
All media were prepared using MilliQ H2O and autoclaved at 121oC for 15 min. prior to 
use. 
SDS-PAGE 
Preparation of gel: Typically a 10% acrylamide gel was prepared: The resolving gel 
consisted of 2.75 mL resolving buffer (1.5M Tris-HCl, 0.4% (v / v) TEMED, 0.4% (w/v) 
SDS, pH 9.0), 2.58 mL 40% bis-acrylamide, 4.82 mL H2O and 10% APS. The stacking gel 
was composed of 4.5 mL stacking buffer (0.14M Tris-HCl, 0.11% (v/v) TEMED, 0.11 
(w /v) SDS, pH 6.8), 0.5 mL 40% bis-acrylamide, 50 L 10% APS. 
Running of gel: Electrophoresis was carried out at 180V for 1 hour in 124 mM Tris, 1M 
glycine, 17 mM SDS. 
Molecular mass markers: Biorad low molecular mass markers were used. 
Gel stain: Protein bands were stained using 20 mL of Comassie blue colloidal stain 
(prepared by filtering a suspension of 70 mg Comassie G-250 in 250 mL EtOH into 
phosphoric acid solution) 
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Agarose gel (for DNA) 
Preparation of 1.0% gel: 0.5 g agarose was dissolved in 50 mL TAE buffer (50 x TAE, 242 g 
Tris, 57.1 mL glacial acetic acid, 100 mL 0.5M EDTA, pH 8.0) by microwave heating. On 
cooling to 60 °C,  1 L ethidium bromide was added and the gel poured into the gel 
tank. 
Sample loading: 20 L digest DNA was mixed with 4 L 6x loading buffer (0.25 % 
bromophenol blue, 0.25 % xylene cyanol FF, 15 % Ficoll in H2O) and loaded into the gel. 
Running of gel: 120 V were applied for 30 min. 
5.2.2 Overexpression and purification of MtrR 
An L Agar plate was poured containing 5 µL carbenicillin or kanamycin (stock 
solution 100mM) and when solid was streaked with stock cells (BL21-AI containing gene 
for MtrR in pET21a vector or pET28). The plate was placed in 37 °C room overnight. In 
the morning, the plate was removed from the 37 °C room and placed in the fridge for 
storage. In the afternoon a colony picked and transferred to 10mL L overnight culture 
(containing 5 µL carbenicillin) and left on a flat bed shaker set at 180 rpm in the 37 °C 
room overnight. 1 mL of culture transferred to 250 mL of YT broth containing 
carbenicillin (250 µL). The flasks were shaken using a flat bed shaker set to 220 rpm at 
37 °C for 3 hours. The O.D. at 600 nm was measured using a spectrophotomer 
previously blanked using YT broth. If the O.D. was less than 0.5 the flasks were shaken 
for 20 minutes longer before the O.D. was remeasured. When the desired optical density 
had been reached, the cells were induced with 1mM IPTG and 0.4% L-arabinose. The 
flasks were shaken for a further four hours at 180 rpm, at 37 °C. 
The cell suspensions were transferred to centrifuge bottles and centrifuged using a 
JL 10.5 rotor at 7,500 rpm for 20 minutes at 4 °C. The broth was decanted and the cell 
pellet dissolved in a small volume (2 mL) of lyses buffer (Tris 20 mM, NaCl 300 mM, 
10% glycerol). Lysozyme was added to a final concentation of 1mM. The cell suspension 
was then sonicated for a total of 2 minutes (4 x 30 second bursts of sonar energy) at a 
power output of 12%. All sonication were carried out whilst the protein was on ice. 
The lysed cells were centrifuged in a J 25.5 rotor at 20,000 rpm for 20 minutes at 4 °C. 
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A HITRAP 1mL or HITRAP 5 mL FF column was washed with water (10 column 
volumes) and equilibrated with 5 volumes of loading buffer (10mM Tris, 300 mM NaCl, 
pH8.2). The cell lysate / crude protein solution was filtered through a 0.4 uM filter and 
loaded onto the HITRAP column using a peristaltic pump running at 0.5 mL / min. The 
flow through was collected and analysed by SDS-PAGE to ascertain if all the His-tagged 
protein had been loaded onto the column. 
The HISTRAP column was transferred to a GE healthcare AKTA Explorer FPLC. The 
column was washed with 2 column volumes of loading buffer and the flow through 
collected. A gradient of increasing buffer B (Tris 20mM, NaCl 300mM, Imidazole 500 
mM, pH 8.0) from 0-100% was run over 10 column volumes and 1 mL fractions collected. 
The fractions were analysed by SDS-PAGE, MALDI mass spectrometry. 
The elution buffer was exchanged for a non-imidazole containing buffer using either a 
PD-10 column (Pierce), HITRAP 5 mL desalting column or dialysis overnight. 
The second purification was carried out on a MonoQ column. Protein was dialysed into 
Tris 20mM, NaCl 100 mM and prior to injection onto column. Buffer a = Tris 20 mM, 
buffer B = Tris 20 mM, NaCl 1 M, pH 8.2. Protein eluted at approximately 50% B. 
The protein was purified on a gel filtration column (15/60 superdex, GE Healthcare). 
The purification buffer was (tris 20 mM, NaCl 300 mM, pH 8.2). The gel column was 
equilibrated in water (1 column volume) and buffer (2 column volumes) before the 
sample was injected. The sample was eluted after 50 minutes with a flow rate of 
1 ml/min.  
5.2.3 MtrR mutant proteins 
Primers for H105A, H105Y and H105F were designed using online Stratagene software. 
Site directed mutagenesis was undertaken by Bing Zhang. Proteins were overexpressed 
and purified as per MtrR above. 
5.2.4 Construction of BL21AI and KAM3 E. coli containing pET28a-MtrR plasmid 
5.2.4.1 Plasmid prep from BL21-AI (pET21a mtrR) 
A single colony of BL21AI E. coli carrying pET21a MtrR was picked from an agar plate 
and transferred to 10 mL LB media containing carbenicillin (1 mmol) an incubated 
overnight at 37 °C with shaking at 180 rpm. The pET21a MtrR plasmid was isolated 
179 
 
from the overnight culture using a Wizard mini-prep kit. Plasmid DNA sequenced by  
DBS Genomics.  
5.2.4.2 Transformation of XL-10 with pET21a mtrR 
100 L XL-10 ultracompetent (Stratagene) were incubated on ice with 4 L of -
mercaptoethanol for 2 min. 50 ng of plasmid DNA was added and the tube swirled 
gently. Incubated on ice for 30 min., heat shocked at 42 °C for precisely 30 sec., incubated 
on ice for 2 min., 0.9 mL SOC medium added and incubated at 37 °C for 1 hour. Cells 
were spread on L agar plates containing carbenicillin and plates incubated overnight 
at 37 °C. 
5.2.4.3 Excision of mtrR gene from pET21a and purification of the mtrR gene  
Buffer D (Promega) was placed in an autoclaved eppendorf. 1 L of XbaI and 16 L of 
MtrR plasmid were added. The eppendorfs were incubated at 37 °C overnight. Digest 
was analysed by running the sample on a 1.0% agarose gel. The bands containing MtrR 
at ~ 750 kBp and the pET 28a blank vector were visualised on a UV-transilluminator and 
cut from the gel using a scalpel. The gel pieces were transferred to autoclaved 
eppenddorfs and the DNA extracted using the „Prep- Gene‟ system (Biorad). 
100 L DNA purification buffer (sodium perchlorate 6M, Tris 50 mM, EDTA 10 mM, 
pH 8) was added per 100 mg of gel. 20 L of Prep- Gene matrix (slurry of 
diatomaceous earth) was added to each eppendorf and vortexed briefly. The eppendorfs 
were incubated at 40 °C for 5 min, vortexed briefly and the process repeated until the gel 
pieces had dissolved. The matrix bound DNA was pelleted by centrifugation (1 min, 
16,000 rpm). The supernatant was removed carefully with a pipette. The pellet was 
washed with DNA purification buffer (NaCl 400 mM, Tris 20 mM, EDTA 2mM, 50% 
EtOH) and vortexed to mix thoroughly. The DN matrix was pelleted by centrifugation 
(1 min, 16,000 rpm). The wash process was repeated with a further 750 L purification 
buffer. After removal of the liquid the pellet was air dried. The DNA was removed from 
the matrix by addition of 30 L of autoclaved H2O to the pellet followed by vortexing 
and incubation at 40 °C to solubilise the DNA. The eppendorf was centrifuged at 16,000 
rpm for 1 min to pellet the matrix. The supernatant (DNA) was transferred to a clean 
eppendorf and stored at -20 °C.  
180 
 
5.2.4.4 Ligation of mtrR gene into pET 28a  
1 L of ligase buffer, 1 L ligase (T4 DNA) and 4 L mtrR DNA were placed in an 
eppendorf and 4 L of autoclaved H2O was added. Simultaneously a control sample was 
prepared in which 4 L H2O was added instead of mtrR DNA. Both samples were 
incubated at room temperature for 2 hours. 
2 L of ligase each reaction was used to transform XL10 competent cells (2 aliquots, each 
25 L). The cells were spread on L plates containing kanamycin and incubated at 37 
oC overnight. Successful ligation and transformation was indicated by more colonies on 
the MtrR positive plate compared to the negative control and this was confirmed by 
DNA sequencing of plasmid DNA acquired by plasmid prep of 1 mL overnight cultures 
from two colonies (one colony from each plate).  
5.2.4.5 Transformation of Kam3 (DE3) cells with pET28-mtrR 
 An overnight culture (10 mL) of KAM3 cells (empty, no plasmid) was centrifuged at 
4,500 rpm for 15 min at 4 °C. The cells were resuspended in 10 mM CaCl2 (1 mL) and 
kept on ice for 5 min. The suspension was centrifuged for 2 min at 5,000 rpm. The 
supernatant was discarded and the cells resuspended in 10 mM MgCl2 (1 mL) and 
incubated on ice for 5 min. The cells were pelleted by centrifugation (2 min, 5000 rpm) 
and resuspened in 10 mM CaCl2 (1 mL). 150 L of cells were transferred to an ice cold 
eppendorf and incubated with 2 L plasmid DNA for 30 min. The cells were heat 
shocked at 42 °C for 2 min, then incubated on ice for 2 min. 250 L SOC medium was 
added and the cells incubated at 37 °C for 1.5 hours. The recovered cells were spread on 
kanamycin containing LB plates, incubated at 37 °C overnight and the plates stored at 
4 °C. 
5.4.5 Analysis of covalent modification of MtrR by small molecule probes using 
trypsin digests and mass spectrometry 
Gel method 
SDS-PAGE gel prepared and run as normal. Gel stained for minimum time necessary to 
reveal protein bands. The desired bands were removed from the gel using a scalpel and 
the gel pieces transferred to a clean eppendorf tube. Rapid destain solution (50 L, 40% 
MeOH, 25 mM NH4HCO3) was added and incubated at room temperature, with 
occasional vortexing, until the blue colour had faded. The decolourised gel was mashed 
into several pieces, washed with MeCN and dried in a stream of N2. Trypsin solution (2 
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L in 40 L 25mM NH4HCO3 per sample) was added and the eppendorf incubated at 
37oC overnight, with shaking at 120 rpm. Peptides were extracted from the gel using 3:7 
H2O : MeCN +0.1% TFA. The peptide solutions were lyopholised and stored at -20 °C 
until analysed by MALDI mass spectrometry. 
Solution method 
The protein of interest was precipitated by addition of acetone (4 x sample volume) and 
incubated at -20 °C for 1 hour. The precipitate was isolated by centrifugation, the 
solution decanted and the pellet dried in a stream of N2. Trypsin solution (2 L in 40 L 
25 mM NH4HCO3 per sample) was added and the eppendorf incubated at 37 °C 
overnight, with shaking at 120 rpm. The solution was lyopholised and stored at -20 °C 
until analysed by MALDI mass spectrometry 
5.2.6 -lactamase activity of MtrR as determined by growth curve analysis using Kam3 
E. coli expressing MtrR 
Agar plate containing kanamycin streaked with stock KAM 3 cells containing pET28a 
vector carrying the gene for mtrR, or no insert, were incubated overnight at 37 °C. 
One colony from each plate was used to inoculate 3 x 25 mL YT media containing 
kanamycin. Cultures grown at 37 °C with shaking at 150 rpm until an optical density of 
0.6 was reached at which point the cultures were induced with IPTG (1 or 10 mM) and 
the cultures were incubated for a further two hours. 
Cultures were transferred to sterile Falcon tubes and centrifuged at 45,000 rpm for 15 
min at 4 °C. The supernatant was decanted and the cell pellet washed in fresh LB media. 
Cells were resuspended in 20 mL YT media (devoid of antibiotic) and the optical density 
at 600 nm was measured. 1 mL was removed from the stock cell solution and diluted 
n-fold until an optical density of 0.1 was reached. 100 L of cell solution was transferred 
to a prepared 96 well plate containing appropriate volumes of media and penicillin G 
(2). The 96-well plate was placed in FLASHSCAN and cell growth monitored for 720 
minutes. Data exported and analysed using EXCEL. 
FLASHSCAN settings: Microwell plate: NuncF; Cyclic measurement, 3 point reading, 1 
reading every x 5 minutes. 
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5.2.7 Analysis of bacterial cultures by Flow Cytometry 
Propidium iodide and thiazole orange where purchased from Sigma Aldrich. 
Fluorescein diactate was a gift from Aileen Congreve. 
The contents of selected wells from the 96-well plate used for overnight monitoring of 
bacterial growth in the presence of a test compound, were transferred to eppdendorf 
tubes and centrifuged using a bench top centrifuge set at maximum speed. The 
supernatant was decanted and the pellets washed in PBS solution. The cell pellet was 
resuspended in analysis buffer (PBS, 1 mM, EDTA, 0.1% sodium azide, 0.01 % TWEEN 
20, pH 7.4). For dead control samples, cells were resuspended in 70% EtOH, kept on ice 
for 5 min, then centrifuged and washed with PBS prior to being resuspended in analysis 
buffer. 
50 L of PI (17  and 50 L of FDA 240 or TO (17  were added to the cell 
suspensions and incubated at room temperature for 5 min. Stained cell solutions were 
kept on ice until analysis. 
Cells were analysed on a MoFlo (Beckman Coulter) cell sorter. Cells were interrogated 
with 488 nm laser and fluorescence collected through FL1 (530 / 30) and FL4 (630 / 30) 
band filters. Data analysed with Summit software. 
5.2.8 Isothermal Titration Calorimetry 
ITC experiments were carried out using a VP-ITC (Microcal) Protein was dialysed 
overnight into the appropriate buffer. Dialysis buffer was retained for preparation of 
ligand solution. Standard settings used were: 70 injections (1 x 2 L, 69 x 10 L, spacing 
between injections = 150 sec) stirring speed of 307 rpm, T = 25oC. initial delay = 60 sec, 
reference power = 10. Data was analysed using OriginTM. Experimental data was fitted 
using standard models. 
5.2.9 Subcellular localisation of MtrR by Western blot 
2 x 10 mL cultures of pET28 KAM cells harbouring the plasmid for MtrR were 
centrifuged (4500 rpm, 20 min, 4 °C) 2 hours after induction with IPTG. The cells were 
washed with Tris 20 mM, NaCl 300 mM, glycerol 10% supplemented with 1 M Gd3+ for 
the control, the cells were centrifuged and resuspended in ice cold hypertonic solution 
(20% sucrose, 30 mM Tris) in the presence or absence of 1 mM Gd3+. The cells were 
incubated for 10 min at 4 °C. The cells were centrifuged, supernatant collected and the 
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process repeated once. 15 L of each sample was loaded in 12% acrylamide gels for SDS-
PAGE (1 gel prepared for MtrR and GroEL). After electrophoresis, the gel was 
transferred onto a Hybond P membrane (Amersham), blotting occurred for 1 hour at 100 
V using cooled, circulating transfer buffer (15 mM Tris, 125 mM glycine). The 
membranes were washed in Tris-buffered saline and blocked by incubation with 1% 
BSA in tris buffered saline for one hour. The primary antibody was added (1:1000 
dilution for MtrR, 1:16000 dilution for GroEL) and the membranes incubated at room 
temperature for 1 hour. The membranes were washed well with TBS solution, and the 
secondary antibody (anti-rabbit alkaline phosphatase, 1:10000 dilution) were added and 
the membranes gently shaken overnight. The membranes were washed well with final 
buffer (Tris 100 mM, pH 9.5). Proteins were visualised by addition of colourmetric 
reagents NBT and BCIP. After 30-45 seconds strong bands could be seen and the reaction 
was stopped by addition of 100 mL MilliQ water. Membranes were air dried and 
scanned. 
Antibodies used in this study: 
Protein Primary antibody Dilution Secondary antibody 
MtrR Anti-mtrR produced in 
rabbit 
1:1 000 Alkaline phosphatise produced in 
goat 
GroEL Anti-GroEL produced 
in rabbit 
1:10000 Alkaline phosphatise produced in 
goat 
MBP Anti-MBP produced in 
mouse 
1:16000 Antimouse Fab alkaline phosphatase 
 
5.2.10. Electrophoresis gel mobility shift assays 
Oligonucleotides were purchased from MWG and used without further purification.  
5.2.10.1 Concentration of oligonucleotides 
The concentration of oligonucleotides used in these experiments was determined by UV 
method: 
Concentration / mM = (Abs260 x dilution factor x 33,000) / MW oligonucleotide 
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5.2.10.2 Biotin 3’ end labelling of DNA 
General procedure: 5 x TdT reaction buffer (10 L), unlabelled oligonucleotide (5 L), 
Biotin-11-UdP, Tdt enzyme (2U / L) 5 L and DNAase free water ( 5 L) were gently 
mixed in an eppendorf and incubated in a water bath at 37 °C for 30 min. EDTA (2.5 L) 
was added to stop the reaction. Chloroform : isoamylalcohol (50 L) was added, the 
mixture vortexed and centrifuged (2 min, 16,000 rpm). The supernatant was removed 
and stored at -20 °C until required. 
Oligonucleotides used in this study: 
(Forward-1) 5‟-TTT TTA TCG GTG CAA TCG TGT ATG-3‟ 
(Reverse-1) 3‟-CAT ACA CGA TTG CAC CGA AAC 5‟ 
(Forward-2) 5‟-TTT TTA TCG GTG CAA TCG TGT ATG TAT AAT-3‟ 
(Reverse-2) 5‟-CAT ACA CGA TTG CAC CGA AAC 3‟ 
5.2.10.3 Annealing of labelled oligonucleotides 
Hot block method: Forward (10 L) and reverse (10 L) oligonucleotides labelled at the 3‟ 
position were annealed by heating at 90 oC (hot block) for 5 min, then cooling slowly to 
room temperature 
PCR machine method: Equal volumes of forward and reverse labelled oligonucleotides 
were placed in a PCR tube. The PCR machine was programmed to maintain 94 oC for 5 
min and then cool 1 oC per min until 27 oC was reached. 
5.2.10.4 Preparation of 4 % bis-acrylamide gels 
Biorad mini-gel glass plates and gel cassettes were used for setting of the gels. 
Distilled water (9 mL), 10 x TBE (1.2 mL), 30% bis-acrylamide (1.6 mL), 10% APS 
(120 L) and TEMED (10 L) were mixed and pipetted into the prepared glass plates. 
The gel was allowed to set for 5 hours at room temperature and stored overnight at 4 °C 
prior to use. 
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5.2.10.5 DNA / Protein / ligand binding reactions 
Table 16 Volumes of reagents used in EMSA reaction 
 Component Volume / L 
 DNAase free H2O 10 - n  
1 10 x reaction buffer 5 
2 Poly (dI.dC) 0.5 
3 MtrR 0.5 
4 Peptide  0.5 
5 Biotin-DNA 0.5 
6 80 % glycerol 1.5 
7 Loading buffer 1 
n = total volume of components 1+2+3+4+5 
Components 1, 2, 3, 4, 5 were added in that order to a sterile eppendorf and incubated at 
room temperature for 30 min. Components 6 and 7 were added immediately prior to 
loading of acrylamide gel. 
5.2.10.6 Gel electrophoresis 
Prior to loading the gel with the samples the gel was prerun for 2 minutes at 100 V. 
Loading buffer (0.5 L) was added to each lane and the gel run at 100 V for a further 3 
minutes. This step enables easy visualisation of the wells to aid the loading of the gel. 
Samples were loaded into the gel and electrophoresis occurred for 45 min at 100 V until 
the bromophenol blue dye had migrated ~ 2/3 down the gel. The tank was surrounded 
by ice for the duration of the electrophoresis. 
5.2.10.7 Electrophoretic transfer of binding reaction to membrane 
Positively charged nylon membrane (Amersham) was soaked in 0.5 x TBE for 10 min. 
The gel was carefully removed from the glass plates and sandwiched between the nylon 
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membrane, filter paper and transfer sponges. The gel sandwich was placed in a transfer 
unit and the transfer cassette filled with cold 0.5 x TBE. The outer tank was filled with 
600 mL cold H2O. The tank was placed on ice and the transfer proceeded at 380 mA (~30 
to ~50 V) for 60 minutes. The membrane was removed from the transfer unit, drained on 
paper towel and the DNA fixed to the membrane by exposure to UV light at 312 nm on a 
transilluminator for 15 minutes.  
5.2.10.8 Detection of Biotin-labelled mtrR DNA by chemiluminescence 
The membrane was blocked in blocking buffer (20 mL, Pierce) for 15 min with gentle 
shaking. The buffer was drained and replaced with blocking buffer (20 mL) containing 
streptavidin-horseradish peroxidise conjugate (66.67 L). The membrane was incubated 
with the antibody for 15 min with gentle shaking. The solution was decanted and the 
membrane washed with washing buffer (4 x 20 mL). The membrane was soaked in 
equilibration buffer (30 mL, 5 min) prior to addition of the substrate developer solution 
(2 mL luminal and 2 mL enhancer solution). The membrane was incubated with the 
developer solution for 5 min, without shaking. The membrane was drained on paper 
towel before being placed in a film cassette. The film was exposed to the membrane for 2 
-10 minutes and developed using a Xenograph cartridge machine. 
 
5.2.11 Antibacterial activity of synthetic peptides as determined by growth curve 
analysis using Kam3 E. coli expressing full, or elements of, MtrCDE 
5.2.11.1 FLASHSCAN method 
Agar plates containing chloramphenicol were streaked with stock KAM 3 cells 
containing pACYC vector carrying either mtrD, mtrCD, mtrCDE or no insert – as 
prepared by Li Zhang (PhD thesis, Durham, UK, 2009). The plates were incubated 
overnight at 37 °C. 
One colony from each plate was used to inoculate 4 x 25 mL YT media containing 
kanamycin. Cultures grown at 37 °C with shaking at 150 rpm until an optical density of 
0.6 was reached at which point the cultures were induced with IPTG to a final 
concentration of 1mM. Cultures were incubated for a further two hours. 
Cultures were transferred to sterile Falcon tubes and centrifuged at 45000 rpm for 15 min 
at 4 °C. The supernatant was decanted and the cell pellet washed in fresh LB media. 
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Cells were resuspended in 20 mL YT media (devoid of antibiotic) and the optical density 
at 600 nm was measured. 1 mL was removed from the stock cell solution and diluted n-
fold until an optical density of 0.1 was reached. 100 L of cell solution was transferred to 
a prepared 96 well plate containing appropriate volumes of media and test compound 
(peptide or antibiotic). 96-well plate was placed in FLASHSCAN and cell growth 
monitored for 720 minutes. Data exported and analysed using EXCEL. 
FLASHSCAN settings: Microwell plate: NuncF; Cyclic measurement, 3 point reading, 1 
reading every x 5 minutes. 
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7 Appendix 
7.1 Data for mass spectrometric analysis of inhibitors 37 and 38 binding to MtrR 
Characterisation of peak at 1269 by MS / MS using MALDI-LIFT 
 
Observed m/z Calculated m/z Identity 
86.065 86.096 L 
87.028 87.0917 R 
110.079 110.071 H 
112.090 112.069 R 
120.088 120.081 F 
138.075 138.0662 H 
175.079 175.119 y1 
199.084 199.181 LL-28 
223.086 223.155 LH-28 
251.103 251.153 LH 
257.092 257.140 TL+C3H3O2-28 
259.105 259.101 FE-H2O 
285.941 285.135 HF 
364.091 364.234 LLH 
369.073 369.223 TLL+C3H3O2 
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7.2 Data for MS /MS analysis of tryptic peptides after photo-insertion of peptide 243 
into MtrR 
 
7.2.1 Insertion into HTLLHFFER 
 
H - T - L - L - H - F - F - E - R
OH
N
H
O
F - L - R
y7y8 y6 y5 y4 y3 y2 y1
y9
y10y11y12
 
 
m/z (obsserved) m/z (calculated) Identity 
158.673 158.094 y1-NH3 
175.678 175.112 y1 
257.7345 257.1397 HF-28 
285.7405 285.1346 HF 
288.264 287.114 y2- NH3 
581.287 581.272 y4- NH3 
717.632 717.337 y5-H2O 
972.098 970.049 LFLR+C14H10O2-28 
1085.224 1081.525 TLHFLR+ C14H10O2 
1703.156 1702.8740 y11 
1776.591 1777.9373 M-CH2N2 
1824.667 1823.9380 MH-H2O 
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7.2.2 Insertion into EK 
 
F - L - R - N - L - V - P - R
OH
N
H
O
y7y8 y6 y5 y4 y3 y2 y1
b6
b2
b3 b4 b5 b9b7 b8
E - K
y10
b1
y9
b10
 
Observed m /z Calculated m /z Identity 
158.9853 158.094 y1-NH3 
175.0191 175.119 y1 
186.9693 185.164 LV-28 
243.0303 243.156 LR-28 
257.9954 255.125 y2-NH3 
358.0883 357.24 y3-NH3 
373.0315 372.240 y3 
450.1774 450.189 b2-NH3 
470.1358 469.325 LRNL-28 
487.15 487.106 F+C19H17NO5 
563.2789 563.362 RNLVP-28 
600.3719 600.019 FL+C19H17NO5 
629.3973 627.361 FLRNL-NH3 
1009.606 1011.621 y8 
1109.157 1111.597 b7 
1481.644 1481.287 M 
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7.3 Models generated for docking peptide 243 into MtrR 
 
 
 
 
